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BCRP Breast cancer resistance protein 
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NSAID Non-steroidal anti-inflammatory drug 
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SNPs Single nucleotide polymorphisms 
Tac Tacrolimus 
TM Transmembrane helices 
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UGT Uridine diphospho-glucuronosyl transferase  
URAT1 Urate transporter 1 
WH Wistar Hannover 
  
 
 
 
 
 
 
General Introduction 
  
 
 
 
Chapter 1 
 
 
12 
 
Over the past decade, the wide expansion of selective immunosuppressant drugs has 
contributed dramatically to the success of organ transplantation. Due to their ability to 
inhibit the immune system, immunosuppressants are also useful in the treatment of 
autoimmune diseases (Mayer and Kushwaha, 2003). In addition, some of these agents have 
cytotoxic effects and are used for cancer chemotherapy (Guba et al., 2004). 
Immunosuppressants include antimetabolites (azathioprine, 6-mercaptopurine, cytarabine, 
and methotrexate), alkylating agents (cyclophosphamide), plant alkaloids (vinblastine and 
vincristine), drugs acting on immunophilins (calcineurin inhibitors as cyclosporine and 
tacrolimus) (McPartland and Pomposelli, 2007), as well as relatively newer compounds like 
the anti-proliferative drug, mycophenolate mofetil (Schieppati and Remuzzi, 2008). 
Unfortunately, this group of drugs possesses a narrow therapeutic index and a wide range 
of inter-individual variability that affects their immunosuppressive efficacy as well as their 
potential toxic effects (Cattaneo et al., 2008). In addition to being often used concomitantly 
as part of multidrug regimens, patients treated with immunosuppressants may require co-
medications to treat associated conditions as hypertension, hyperuricemia or pain. Thus, the 
chance of pharmacokinetic drug-drug interaction is high, which may result in either 
elevated serum levels of those agents exacerbating drug-related toxicity, or sub-therapeutic 
serum levels associated with increased risk of transplant rejection. Elimination of a number 
of immunosuppressants and their metabolites depends largely on renal transport function. 
For example, renal impairment was reported to significantly affect the pharmacokinetics of 
mycophenolate mofetil (Gonzalez-Roncero et al., 2005) and methotrexate (Boey et al., 
2006). On the other hand, some immunosuppressants may aggravate renal function by their 
nephrotoxic side effects (Goncalves et al., 2007). Understanding renal pharmacokinetic 
drug interactions allows rational individualized dosing of immunosuppressants thereby 
optimizing their therapeutic actions while minimizing adverse effects.  
Renal clearance of a drug is the sum of the rates of glomerular filtration and tubular 
secretion minus the rate of tubular reabsorption. Because the transport of drugs is often 
against their concentration gradient, renal secretion is mostly an active process involving a 
variety of transporter mechanisms. Active proximal tubule basolateral and apical 
transporters involved in uptake, efflux, and reabsorption determine the overall net-secretion 
or -reabsorption of a compound. Recently, the role of active transport in 
immunosuppressant pharmacokinetics has been reviewed (Christians et al., 2006;Mourad et 
al., 2008). Nevertheless, knowledge about the role of each specific renal transporter in the 
elimination of individual immunosuppressants, and the various possible drug-drug 
interactions is still, by far, incomplete.  
Post-transplant hyperuricemia is a common complication which is frequently associated 
with immunosuppressant treatment, especially with cyclosporine (Mazzali, 2005). 
Hyperuricemia may contribute to the progressive deterioration of graft function and 
ultimately graft loss. The specific mechanisms of hyperuricemia are not yet fully 
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elucidated. Serum urate levels are the result of the balance between urate production and 
elimination. In this aspect, the kidney plays a pivotal role by excreting 70% of daily urate 
production (Anzai et al., 2007). More than 90% of serum urate is glomerularly filtered, 
from which less than 10% is excreted in urine. Urate, in its anionic hydrophilic form, is 
almost completely reabsorbed by proximal tubule cells, depending on active renal anionic 
transporters participating in maintaining renal urate homeostasis. Several groups of drugs 
may alter serum urate levels (Daskalopoulou et al., 2005), and this may represent a 
challenge in treating hyperuricemia in transplant patients (Baroletti et al., 2004). 
Understanding drug interactions with transporters mediating urate uptake and efflux may 
enhance our understanding of renal hyperuricemic mechanisms. 
The aim of this thesis was to investigate the role of renal transporters in 
immunosuppressant drug interactions and their hyperuricemic complications. For this 
purpose, a system was used to transduce mammalian cells to over-express the renal 
transporter proteins of interest (Figure 1). This system allowed us to measure transport 
activity at the molecular level in transporter over-expressing cells or in membrane vesicles 
isolated from these cells. In addition, new technical tools were designed during this study: a 
membrane vesicular exchange system suitable for investigating the mechanisms of 
transport and drug interactions of bidirectional transporters, and a mammalian double-
transfected cell expressing two renal transport proteins simultaneously that can be used to 
investigate interactions at renal transporters sharing similar substrates. The assessment of 
transport activities was performed by radio-labelled liquid scintillation counting or by high 
performance liquid chromatography. Kinetic analysis of transporter-mediated 
substrate/inhibitor interactions was performed. To test our molecular findings at the organ 
level, the isolated perfused rat kidney was used as an experimental model.  
In Chapter 2, an update of the current knowledge on the mechanisms of different renal 
anionic transporters in drug elimination is overviewed. Chapter 3 describes the interaction 
of the immunosuppressant drug methotrexate, with different non-steroidal anti-
inflammatory drugs (NSAIDs) at the level of apical multidrug resistance proteins (MRP) 2 
and 4. In chapter 4, various immunosuppressants are studied for their interaction with renal 
basolateral organic anion transporter (OAT1), as well as apical MRP2 and MRP4. Chapter 
5 explores the role of renal transporters in urinary excretion of mycophenolic acid (MPA) 
and its inactive glucuronide metabolite in the perfused kidneys isolated from rats deficient 
in Mrp2, and in cells over-expressing human apical renal transporters MRP2 and MRP4. 
This chapter also addresses the role of the kidney in metabolizing MPA and drug-drug 
interactions of MPA with cyclosporine and tacrolimus. In chapter 6, using the 
immunosuppressant drug methotrexate as a model substrate, a first attempt is made to 
identify the binding pocket of the renal apical efflux transporter MRP4. In this chapter, the 
functional role of the amino acid arginine 375 of transmembrane helix 6 in MRP4 substrate 
transport activity is described. In chapter 7, the interaction of a number of drugs that  
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modulate urate homeostasis with MRP4-mediated urate efflux is investigated. Chapter 8 
describes a newly designed membrane vesicular exchange system and a double-transfected 
cellular model as tools to study transport mechanisms of renal exchangers and complex 
renal multi-transporter conditions. In this chapter, a comparative study between the effects 
of hyper- and hypo-uricemic drugs on URAT1-mediated urate transport is conducted. 
Chapter 9 concludes the thesis with a general discussion and summary. 
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Summary 
By utilizing filtration, active secretion and reabsorption processes, the kidney can 
conserve essential nutrients, and eliminate drugs and potentially toxic compounds. Active 
uptake of organic anions and cations across the basolateral membrane, and their extrusion 
into the urine across the brush border membrane mainly takes place in the renal proximal 
tubule cells, and is facilitated via a range of substrate-specific tubular transporters. Many 
drugs and their phase II conjugates are anionic compounds, and therefore renal organic 
anion transporters are important determinants of their distribution and elimination. 
Competition for renal excretory transporters may cause drugs to accumulate in the body 
leading to toxicity, which is a potential hazard of concomitant drug administration. Here, 
we present a brief update on the most prominent human proximal tubule organic anion 
transporters, which either belong to the ATP-binding cassette (ABC) or the solute carrier 
transporter (SLC) families. We focus on the participation of the individual transporters in 
renal anionic drug elimination, in an attempt to understand their overall biological and 
pharmacological significance, hoping to inspire further studies in the renal transporters 
field. 
1. Introduction  
The kidney plays a critical role in conserving essential nutrients and eliminating natural 
end products, toxins, drugs and drug metabolites. It consists of approximately 1 million 
functional units, which are called nephrons. The sum of the processes of glomerular 
filtration, active tubular secretion and reabsorption that a compound can undergo in each of 
the nephrons, determines its net renal excretion rate. Active drug secretion and reabsorption 
mainly take place in the proximal tubule cells, which are equipped with separate transport 
systems for organic anions and cations, each consisting of multiple transporters localised in 
the plasma membrane at both sides of the cell and with overlapping substrate specificities. 
Both systems are characterized by a high clearance capacity and broad diversity of 
substances accepted.  
This review is devoted to the transporters that drive renal organic anion excretion. 
Recent research has provided much insight into their molecular characteristics. Because the 
renal organic anion transport system also accepts many phase II metabolites in addition to 
unconjugated anionic compounds, they play a critical role in the elimination of a large 
number of xenobiotics.  The renal organic cation transporters have been recently reviewed 
by others (Koepsell et al., 2007;Terada and Inui, 2007). Several groups of organic anion 
transporters in the proximal tubule cell mediate the uptake of compounds from blood across 
the basolateral membrane (BLM), followed by their secretion into the urine through the 
brush border membrane (BBM, also known as apical or luminal membrane) (Fig. 1). It has 
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been suggested that the rate-limiting step for excretion of organic anions is the uptake step 
at the BLM, although their concentration inside the proximal tubule cells is higher than 
outside, either at the BLM or BBM side (Wright and Dantzler, 2004). This suggests that net 
transport across both membranes facilitates the intracellular accumulation of organic 
anions, and that the BBM controls the final exit into the urine via ATP-powered 
transporters and bidirectional exchangers. Furthermore, reabsorption processes may also 
contribute to intracellular organic anion accumulation, which in turn can affect BLM 
gradient-sensitive processes. 
 
 
Fig. 1: Schematic presentation of a human renal proximal tubule cell, showing the most important 
renal organic anion transporters. BCRP: breast cancer resistance protein; DC: dicarboxylates; MC: 
monocarboxylates; MRP2/4/6: multidrug resistance protein 2/4/6; OA: organic anion; OAT1/3/4: 
organic anion transporter 1/3/4; OATP4C1: organic anion transporting polypeptide 4C1; URAT1: 
urate transporter 1. 
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Several methods have been employed to study carrier-mediated organic anion transport. 
The recent use of knockout animals provides a powerful tool, yet one that is not devoid of 
limitations. In addition to possible up- or down-regulation of compensatory transporters and 
the possible inter-species variations (Johnson et al., 2006;Chu et al., 2006), other feedback 
mechanisms, as for example the saturation of metabolic pathways, can restrain the use of 
such models. Investigations using the isolated perfused kidney from transporter deficient 
animals (Masereeuw et al., 2003) aimed at circumventing some of these factors. Yet, the 
actual transport across the cell membrane may be the most solid proof to characterize a 
compound as a substrate of a certain transporter protein. With the recent advances in 
molecular cloning methodologies, several cellular models have evolved that are transfected 
to over-express one or more transporters, including Xenopus laevis oocytes, Spodoptera 
frugiperda insect (Sf9) cells, and mammalian cell lines of animal and human origin 
(Masereeuw and Russel, 2004). These different cell types have been used for transport 
studies in the form of cellular monolayers, transwell transport studies or transport in 
isolated inside-out membrane vesicles. Ultimately, combining the results of diverse 
molecular, cellular and in vivo studies are required to identify the role of individual 
transporters in the overall renal handling of drugs. In this review, we present an updated 
overview of the major human organic anion transporter proteins involved in renal proximal 
tubular drug handling, focusing on members of the ATP-binding cassette (ABC) C and 
solute carrier (SLC) 22A subfamilies. 
2. ATP Binding Cassette Proteins 
ATP-binding cassette (ABC) proteins are members of the largest and most important 
superfamily of membrane transport proteins, which are named after their highly conserved 
ATP-binding motif. About 100 putative ABC transporters have been identified throughout 
nature, 49 of which in humans. The ABC superfamily is further divided into 7 subfamilies: 
ABCA to ABCG (see for more details the ABC protein links at 
http://emb1.bcc.univie.ac.at/cgi-bin/ABC-DB/Welcome.cgi). The ABCC subfamily 
members encode a number of organic anion transporter proteins expressed in renal 
proximal tubule cells, which will be discussed in detail below. Another ABC family 
member that may have a role in renal organic anion excretion is the ABCG2 gene product, 
Breast Cancer Resistance Protein (BCRP), which is a half-transporter that forms a 
homodimer to acquire transport activity. BCRP is expressed in the BBM of proximal tubule 
cells of mouse and rat, and was recently also identified in human kidney (Huls et al., 2007). 
In addition, the transporter is expressed in human liver, intestine, brain capillaries, placenta, 
mammary gland and the heart (van Herwaarden and Schinkel, 2006). Its substrate 
specificity includes mitoxantrone, as well as several sulphate conjugates, like edaravone 
sulphate and steroid sulphates. The role of BCRP in renal organic anion elimination needs 
further investigation. 
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2.1. General Features of ATP Binding Cassette Proteins 
Despite the large number of ABC transporters and their wide substrate specificity, they 
share a common architectural organization (Fig. 2), comprising of two cytoplasmic 
hydrophilic nucleotide-binding domains (NBDs), and two hydrophobic multi-spanning 
transmembrane domains (TMD). Each of the two NBDs can bind and hydrolyse an ATP 
molecule, thereby coupling the energy produced to actual transport activity (Higgins, 
2007). The TMDs are thought to contain the substrate and modulator binding sites and to 
form a channel through which substrates can translocate across the cell membrane (Higgins, 
2007). NBDs show 30 to 40% identity among different ABC subfamilies in a region 
spanning 200 amino acids (Hoffmann and Kroemer, 2004). This homology is irrespective 
of the transporters substrate specificity or phylogenetic origin. Each NBD has two sequence 
motifs, the Walker A domain, which is essential for ATP β-phosphate binding, and the 
Walker B domain, which binds magnesium. In between these two domains exists a highly 
conserved sequence of 14 amino acids, known as the active transporter signature or C 
domain (Higgins, 2007). All ABC transporters have extracellular N-glycosylation branches 
to a variable extent. The TMDs are composed of six α-helices that anchor the protein to the 
membrane. Unlike the NBDs, the TMD helices vary largely from one ABC transporter to 
another, and may represent the basic building units that can be arranged in diverse flexible 
fashions to accommodate the tremendous diversity of substrates.  
2.2. Multidrug Resistance Proteins 
ABC subfamily C contains the most important human renal ABC transporters involved 
in organic anion transport, the multidrug resistance proteins (MRPs). As their name 
implies, these transporters can confer multidrug resistance by expelling several anticancer 
agents out of tumour cells in which they are expressed, comprising a major obstacle to 
successful cancer chemotherapy (Huang, 2007). Some of these MRPs are considered 
structurally “long”, as they have an extra N-terminal extension representing an additional 
TMD (TMD0) of 5 α-helices, whose function is still unknown (Altenberg, 2003). These 
include MRPs 1, 2, 3, 6, and 7. As a result, the N-terminus of these transporter proteins is 
located extracellularly. Short MRPs lacking TMD0, include MRPs 4, 5, 8, and 9 (Kruh and 
Belinsky, 2003). Attempts have been made to identify the amino acids that make up the 
substrate binding sites of MRP transporters (Deeley et al., 2006). In our lab, the first trials 
to identify the amino acids of MRP4 involved in substrate binding have been performed 
successfully using mutagenesis studies. Our results suggest that several amino acids in the 
sixth and twelfth transmembrane α-helices determine the binding of substrates (El Sheikh et 
al., unpublished). Nevertheless, similar to other MRPs, the wide variety of compounds 
recognized by this transporter and its allosteric interactions makes the characterization of 
the complete binding pocket quite complicated and in need of further investigation (van 
Aubel et al., 2005).  
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Fig. 2: Topology of the human multidrug resistance proteins (MRPs) and organic anion transporters 
(OATs). NBD: nucleotide binding domain; TMD: transmembrane domain. 
MRP2/ABCC2 and MRP4/ABCC4 are highly expressed in the apical membrane of 
proximal tubular cells, where they determine the renal excretion of anionic drugs. Other 
MRPs are either very modestly or not expressed in the human proximal tubule. 
MRP1/ABCC1 does not appear to be present in the human proximal tubule and its renal 
expression is restricted to the BLM of the loop of Henle and collecting duct cells in mice 
(van de Water et al., 2005). In rat, no renal expression of Mrp1 was found, and only after 
experimental bile duct ligation, expression was detected in the BLM of distal tubules (Pei et 
al., 2002).  
MRP3/ABCC3 shows low levels of expression in the kidney and is also expressed in 
other tissues, like the liver and intestine (Borst et al., 2007) where it is localized in the 
BLM. In human kidney, MRP3 is expressed in the BLM of distal convoluted tubule and 
thick ascending loop of Henle (Borst et al., 2007). In rat kidney, Mrp3 was also found to be 
present in the BLM of proximal tubule cells (Kuroda et al., 2004). 
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MRP5/ABCC5 is expressed in several tissues, including human (Kool et al., 1997) and 
mouse kidney (Maher et al., 2005), and in rat renal cell lines (van de Water et al., 2007). In 
human, it is expressed luminally in brain endothelial cells (Nies et al., 2004), and both 
apically and basolaterally in amniotic epithelium (Aye et al., 2007). MRP5, together with 
MRP4 (van Aubel et al., 2002) and MRP8, are considered as efflux transport systems of the 
cyclic nucleotides, cGMP and cAMP (Borst et al., 2007). 
MRP6/ABCC6 expression seems to be restricted to the kidney and liver, where it 
localizes to the BLM (van de Water et al., 2005). MRP6 has a limited substrate specificity, 
which includes the endothelin antagonist BQ123 (cyclo [Trp-Asp-Pro-Val-Leu]), S-
(dinitrophenyl)-glutathione and leukotriene C4 (Belinsky et al., 2002). Mutations in MRP6 
were noticed in patients suffering from pseudoxanthoma elasticum, which is a rare inherited 
connective tissue disorder, characterized by impaired vision, skin lesions, and 
cardiovascular complications (Bergen et al., 2000). Nevertheless, MRP6 is not expressed in 
these tissues, implying that the absence of functional MRP6 from kidney and liver may be 
the reason for the disorder seen in these patients. Studies using mrp6 knockout mice 
emphasized the exclusiveness of the abcc6 gene in ectopic mineralization (Li et al., 2007b).  
The cystic fibrosis transmembrane conductance regulator (CFTR/ABCC7) is a cAMP-
activated chloride channel. It is localised to almost all nephron segments, including the 
renal proximal tubule BBM (Jouret et al., 2007). The precise role of CFTR in organic anion 
transport still needs to be unravelled. ABCC8 and ABCC9 encode for two sulfonylurea 
receptors, SUR1 and SUR2, respectively, that regulate potassium channels and have no 
intrinsic transport activity (Bryan et al., 2007). ABCC10, 11 and 12 encode for MRP7, 8, 
and 9, respectively, that are widely expressed in various tissues (Kruh et al., 2007), but their 
localisation in the kidney is not yet confirmed. 
2.2.1. Multidrug Resistance Protein 2 
MRP2 is expressed apically in renal proximal tubule and enterocytes, and in the 
canalicular membrane of hepatocytes. Low expression levels have been found in other 
tissues, like the blood brain barrier and placental syncytiotrophoblasts (Nies and Keppler, 
2007). MRP2 protein is comprised of 1545 amino acids, and the gene is located on 
chromosome 10 at 10q24. Normal subjects show inter-individual variability in hepatic 
(Hinoshita et al., 2001) and intestinal (Fromm et al., 2000) MRP2 expression levels. It is 
proposed that tissue expression may vary age- and sex-dependently (Sabolic et al., 2007). 
Various other factors can regulate MRP2 gene expression levels, e.g. endogenous 
compounds, drugs, and disease conditions (van de Water et al., 2005), as well as genetic 
polymorphisms (Choi et al., 2007). Furthermore, MRP2 can be up-regulated by the nuclear 
receptors pregnane X receptor (PXR), constitutive androstane receptor (CAR), and 
farnesoid X receptor (FXR) (Urquhart et al., 2007).  
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Mutations in MRP2 gene cause a lack of functional protein, resulting in an autosomal 
recessive condition called Dubin Johnson syndrome, manifested mainly by defective 
hepatocyte canalicular secretion of bilirubin glucuronide leading to conjugated 
hyperbilirubinemia (Nies and Keppler, 2007). The mutations causing this disorder range 
from point mutations to small deletions, which can cause defective MRP2 protein 
maturation and impaired transport activity (Keitel et al., 2003). Complete absence of 
immunochemically detectable MRP2 is seen in patients with homozygous mutations 
(Huang, 2007). Nephrotoxicity due to reduced methotrexate elimination was reported in a 
patient with a heterozygous MRP2 mutation (Hulot et al., 2005). Furthermore, patients with 
MRP2 polymorphisms had higher plasma levels of mycophenolic acid (Naesens et al., 
2006), possibly due to a decreased renal clearance.  
Given the evident role of MRP2 in renal secretion, it is conceivable that not only 
genetic impairment, but also drug-drug interactions may have drastic pharmacological and 
toxicological consequences. Human MRP2 has wide substrate specificity, including 
conjugates, as well as endogenous compounds (Table 1). Expression levels in tumour cells 
correlated with cellular resistance against various cytotoxic drugs, e.g. vincristine, cisplatin, 
etoposide, doxorubicin and epirubicin (Cui et al., 1999), which could be reversed via 
expression of an MRP2 antisense construct (Folmer et al., 2007). Compounds shown to be 
substrates for murine Mrp2 include pravastatin (Kivisto et al., 2005), doxorubicin (Vlaming 
et al., 2006), mycophenolic acid (Westley et al., 2006) and morphine glucuronides (van de 
Wetering et al., 2007). Furthermore, diverse non-substrates can inhibit MRP2 transport, 
ranging from pharmaceutical drugs and their metabolites (Table 1) to everyday food 
components, like green tea extract (Netsch et al., 2005), grapefruit and orange juice (Honda 
et al., 2004). Other drugs can allosterically stimulate MRP2-mediated transport, like 
benzylpenicillin (Ito et al., 2004), low concentrations of sulfinpyrazone (Evers et al., 2000) 
or phenylbutazone (El Sheikh et al., 2007).  
2.2.2. Multidrug Resistance Protein 4 
The gene encoding MRP4 (ABCC4 gene) is localised to chromosome 13q32, spanning 
over 350 kb, and has 31 exons. MRP4 is the smallest human MRP protein, composed of 
only 1325 amino acids. Initially, MRP4 expression was thought to be limited to a few 
tissues (Kool et al., 1997), but subsequent investigations showed that it is more widely 
expressed in liver, intestine, urogenital tract, brain, adrenal, pancreas, erythrocytes, 
macrophages, and platelets (Borst et al., 2007). High levels of MRP4 expression can be 
found in the prostate (Rius et al., 2005) and kidney (van Aubel et al., 2002). Interestingly, 
MRP4 has a dual cellular localisation, as it is located apically in the kidney (van Aubel et 
al., 2002) and basolaterally in the liver (Rius et al., 2005). Furthermore, in the brain, MRP4 
is present basolaterally in the choroid plexus epithelium and at the luminal side of capillary 
endothelium (Nies et al., 2004), contributing to the barrier function of the blood-
  
 
 
 
 
 
 
 
Table 1: Selected in vitro substrates and inhibitors of human MRP2, MRP4, OAT1, OAT3, and OAT4. A selection of substrates (S) and 
inhibitors (I) of indicated human transporters, investigated via direct transport studies. S/I: groups of compounds with some members acting as 
substrates and others only tested as inhibitors. *Transport in presence of glutathione. #Transport in presence of bile salts. 
 MRP2 MRP4 OAT1 OAT3 OAT4 References 
Antibiotics       
    Amoxicillin   S   (Hill et al., 2002) 
    Benzylpenicillin   I I I (Cha et al., 2000;Cha et al., 2001;Hosoyamada et al., 1999) 
    Cephalosporins   S S/I S/I I (Takeda et al., 2002a;Ueo et al., 2005;Ci et al., 2007) 
    Meropenem   S S  (Shibayama et al., 2007) 
    Tetracycline   S S S (Babu et al., 2002) 
Antiviral drugs       
    Acyclovir   S   (Takeda et al., 2002c) 
    Adefovir, cidofovir  S S S  (Uwai et al., 2007;Imaoka et al., 2007) 
    Azidothymidine  S    (Schuetz et al., 1999) 
    Ganciclovir  S S   (Adachi et al., 2002;Takeda et al., 2002c) 
    Indinavir, ritonavir, saquinavir S     (Huisman et al., 2002) 
    Lopinavir S     (Agarwal et al., 2007) 
    Tenofovir  S  S  (Ray et al., 2006;Uwai et al., 2007) 
    Valacyclovir     S  (Takeda et al., 2002c) 
    Zalcitabine   S   (Jin and Han, 2006) 
    Zidovudine    S S (Takeda et al., 2002c) 
Chemotherapeutics       
    6-Mercaptopurine   S    (Chen et al., 2001) 
    Cisplatin S     (Kawabe et al., 1999) 
    Cyclosporine S/I     (Chen et al., 1999;Karla et al., 2007) 
    Irinotecan  S    (Tian et al., 2006) 
    Methotrexate S S S S S (Hooijberg et al., 1999;Chen et al., 2002;Takeda et al., 2002b) 
    Mycophenolic acid   S S  (Wolff et al., 2007) 
    Topotecan  S  S  (Tian et al., 2006;Matsumoto et al., 2007) 
    Vinblastine   S*     (Honda et al., 2004;van Aubel et al., 1999) 
Diuretics       
    Bumetanide  S I S S (Race et al., 1999;Hasannejad et al., 2004;Uchida et al., 2007) 
    Chlorothiazide   S I I (Hasannejad et al., 2004) 
    Furosemide I S I S I 
(Hosoyamada et al., 1999;Bakos et al., 2000;Hasannejad et al., 2004;Hasegawa et al., 2007;Chu et al., 
2007) 
    Hydrochlorothiazide  S S I I (Hasannejad et al., 2004;Hasegawa et al., 2007) 
    Torasemide    I I (Hagos et al., 2007a) 
Endogenous compounds       
    Adenosine diphosphate  S    (Jedlitschky et al., 2004) 
    Bilirubin S     (Kamisako et al., 1999) 
    Bile salts S/I S*/I  S/I I (Cha et al., 2000;Cha et al., 2001;Rius et al., 2003;Gerk et al., 2007;Zelcer et al., 2003) 
    Catecholamine metabolites   S/I S/I  (Alebouyeh et al., 2003) 
    cAMP  S  S  (Cha et al., 2001;van Aubel et al., 2002) 
  
 
 
 
 
 
 
 
    cGMP  S    (van Aubel et al., 2002) 
    Folate  S    (Chen et al., 2002) 
    Leukotriene B4    S*    (Rius et al., 2007) 
    Leukotriene C4 S S    (Rius et al., 2007;Cui et al., 1999) 
    Prostaglandin A1 S     (Evers et al., 1998) 
    Prostaglandin E1  S    (Reid et al., 2003b) 
    Prostaglandin E2 S S S S S (Kimura et al., 2002;Reid et al., 2003b;de Waart et al., 2006) 
    Prostaglandin F2α   S S S (Kimura et al., 2002) 
    Reduced glutathione S S#    (Rius et al., 2003;Evers et al., 2000) 
    Serotonin metabolites   I I  (Alebouyeh et al., 2003) 
    Urate 
 S S S S 
(Bakhiya et al., 2003;Ichida et al., 2003;Enomoto et al., 2002a;Hagos et al., 2007b;van Aubel et al., 
2005) 
Hormones       
    Cholecystokinin S     (Letschert et al., 2005) 
    Dehydroepiandrosterone sulphate  S  S S (Cha et al., 2000;Cha et al., 2001;Zelcer et al., 2003) 
    Estradiol conjugates S I  S  (Zelcer et al., 2003;Cui et al., 1999;Chu et al., 2004) 
    Estrone sulphate S   S S (Cha et al., 2000;Cha et al., 2001;Kopplow et al., 2005) 
Nonsteroidal anti-inflammatory drugs       
   Celecoxib, sulindac, tolmetin I I    (El Sheikh et al., 2007) 
   Diclofenac I I I  I (Cha et al., 2000;Mulato et al., 2000;El Sheikh et al., 2007) 
   Diflunisal, flurbiprofen, phenacetin   I   (Mulato et al., 2000) 
   Etodolac I I I   (Mulato et al., 2000;El Sheikh et al., 2007) 
   Ibuprofen, indomethacin, ketoprofen I I S S S (El Sheikh et al., 2007;Khamdang et al., 2002) 
   Naproxen I I I   (Mulato et al., 2000;El Sheikh et al., 2007) 
   Piroxicam I I I I I (Takeda et al., 2002b;Jung et al., 2001;El Sheikh et al., 2007) 
   Salicylate I I S S S (El Sheikh et al., 2007;Apiwattanakul et al., 1999;Khamdang et al., 2002) 
Urate-lowering drugs       
    Benzbromarone I I I  I (Iwanaga et al., 2005;Bakos et al., 2000;Bai et al., 2004;Ichida et al., 2003) 
    Probenecid I I I I I (Cha et al., 2000;Takeda et al., 2001;Horikawa et al., 2002;van Aubel et al., 2002) 
    Sulfinpyrazone I I    (Evers et al., 2000;Smeets et al., 2004) 
Miscellaneous       
    Angiotensin II receptor antagonists S S/I S/I S S (Race et al., 1999;Yamashiro et al., 2006;Yamashita et al., 2006;Yamada et al., 2007;Sato et al., 2007) 
    Bosentan I     (Mano et al., 2007) 
    Captopril   S S  (Ueo et al., 2005) 
    Cimetidine   S/I S/I I (Khamdang et al., 2004;Cha et al., 2001;Tahara et al., 2005) 
    Curcumin I     (Wortelboer et al., 2003) 
    Dipyridamole  I    (van Aubel et al., 2002) 
    Glyburide I     (Gedeon et al., 2006) 
    Ochratoxin A S  S S S (Cha et al., 2000;Jung et al., 2001;Leier et al., 2000) 
    para-Aminohippurate S S S S  (Cha et al., 2001;Race et al., 1999;Smeets et al., 2004;Leier et al., 2000) 
    Sildenafil  I    (Reid et al., 2003a) 
    Statins S S I S/I I (Windass et al., 2007;Khamdang et al., 2004;Uchida et al., 2007;Kivisto et al., 2005) 
    Verapamil  I    (Bai et al., 2004) 
    Xanthines as theophylline, caffeine   I   (Sugawara et al., 2005) 
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cerebrospinal and blood-brain barriers, respectively. MRP4 is also present in human cancer 
cell lines (Kool et al., 1997), as well as in various tumour tissues where expression 
correlated with the level of chemosensitivity to pemetrexed (Hanauske et al., 2007). 
Furthermore, MRP4 levels have been correlated with disease prognosis of patients suffering 
from primary neuroblastoma treated with irinotecan (Norris et al., 2005).  
Human MRP4 protein expression levels show nearly 45-fold variability among normal 
subjects (Gradhand et al., 2007). Gender differences in renal expression have been implied 
from animal studies, where Mrp4 protein levels were higher in male than in female rats, 
while mice showed the opposite gender difference (Sabolic et al., 2007). Interestingly, in 
humans, male sex hormones can highly up-regulate MRP4 (Cai et al., 2007). It has been 
reported that hepatic expression levels can be altered as a possible compensatory response 
to pathological conditions, like cholestasis (Gradhand et al., 2007) and biliary cirrhosis 
(Zollner et al., 2007). In rats, obstructive cholestasis up-regulated Mrp4 in the liver and 
down-regulated it in the kidney (Denk et al., 2004). Furthermore, mrp4 mRNA increased 6- 
and 2-fold in the kidney and liver, respectively, in mice lacking mrp2 (Chu et al., 2006). 
This was in contrast with Dubin Johnson syndrome patients, where hepatic MRP3, rather 
than MRP4 was up-regulated (Konig et al., 1999;Corpechot et al., 2006). Numerous genetic 
variants of MRP4 have been identified (Saito et al., 2002), but none were related to a 
specific pathological phenotype. Nevertheless, few cases of MRP4 genetic variations 
showed alterations in lamivudine-and zidovudine-triphosphate levels (Anderson et al., 
2006), although the number of patients was too low to draw a meaningful conclusion. 
A number of detailed reviews addressed the substrate specificity of MRP4 (Russel et al., 
2002;van de Water et al., 2005;Ritter et al., 2005;Russel et al., 2008), which is somewhat 
distinct from, yet overlapping with, other MRPs (Table 1). MRP4 is involved in the cellular 
efflux of eicosanoids, like prostaglandins and leukotrienes. In addition, to date, MRP4 is 
the only renal urate efflux transporter identified (van Aubel et al., 2005). MRP4 is also 
involved in the cellular secretion of the cyclic nucleotides, cAMP and cGMP (van Aubel et 
al., 2002), which are important physiological second messenger molecules. For example, by 
regulating cAMP transport in subcellular microdomains, MRP4 alters CFTR-mediated 
chloride transport in gut epithelial cells where both proteins appear also to be coupled 
physically (Li et al., 2007a). A similar coupling of MRP4 and CFTR in the kidney is 
conceivable, as both proteins are localized apically in proximal tubular cells. The 
possibility that CFTR can, in turn, regulate MRP4-mediated transport has not been 
investigated yet. Interestingly, despite that CFTR does not possess anionic drug transport 
activities (Deeley et al., 2006), studies with anionic drugs, like penicillin, showed higher 
renal elimination in case of defective CFTR.  
It has been suggested that nucleoside and nucleotide drug analogues may be transported 
by MRP4 as monophosphate conjugates (Borst et al., 2007), which may be the possible 
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mechanism by which this transporter confers cellular resistance to anticancer drugs not 
proven to be MRP4 substrates (Tian et al., 2005). MRP4 has also been reported to transport 
other conjugates, preferentially sulphated compounds (Zelcer et al., 2003). Despite the wide 
range of inhibitors (Table 1), to date, none of them have been proven to be specific for 
MRP4. Even the protease inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF) that was suggested as a specific inhibitor of erythrocyte MRP4 (de 
Wolf et al., 2007), may not exhibit the same specificity in proximal tubule cells, because of 
possible interactions with other renal organic anion transporters.  Scanning a cocktail of 
chemically-unrelated drugs in combination with liquid chromatography-mass spectrometry 
may provide a rapid approach to identify new substrates and/or inhibitors of MRP4, but the 
results appear to be difficult to interpret (Uchida et al., 2007).   
3. Solute Carrier Proteins 
The solute carrier (SLC) family consists of 46 gene subfamilies, with a total of 360 
family members. These genes encode for a large number of uniporter, symporter and 
antiporter protein transporters (see http://www.bioparadigms.org/slc/menu.asp). The 
SLC22A gene subfamily encodes the organic anion transporters (OATs) that are critical in 
the transport of anionic drugs throughout the body, but particularly in the kidney. Another 
SLC subfamily that may have an additional role in renal drug transport is the organic anion 
transporting polypeptide subfamily (SLCO/OATP). Several Oatps have been identified in 
rat proximal tubule cells, but only a few human orthologues are present in the kidney 
(Konig et al., 2006). One example is OATP4C1 encoded by the SLCO4C1 gene (also 
known as OATP-H) that facilitates the uptake of methotrexate, cAMP, digoxin, ouabain, 
and thyroid hormones across renal BLM as a first step in their renal excretion (Mikkaichi et 
al., 2004). In general, OATPs are assumed to be bidirectional exchangers. Yet, the exact 
transport mechanism of OATP4C1 and the counter ion it exchanges its substrates for are 
not yet identified. In addition to the OATPs, the SLC17A1 gene encodes for the human type 
I sodium-phosphate cotransporter (NPT1, also called NaPi-1), which is localised to the 
BBM and shows 80% identity to the rabbit Npt1 and 60-70% to the pig voltage-driven 
organic anion transporter OATv1 (Jutabha et al., 2003). In addition to its role in tubular 
phosphate reabsorption, it may mediate efflux of anionic compounds across the BBM 
driven by the inside negative cell membrane potential. In vitro transport studies showed that 
NPT1 transports uric acid, para-aminohippurate (PAH), benzylpenicillin, faropenem, and 
estradiol-17--glucuronide via a voltage-dependent chloride-sensitive mechanism (Anzai et 
al., 2007). Nevertheless, the exact role of NPT1 in renal organic anionic transport is not yet 
fully clarified. SLC15A2 is another member that encodes for the peptide transporter 2 
(PEPT2), which is mainly expressed in the proximal tubule BBM where it mediates the 
reabsorption of di- and tripeptides, as well as some anionic drugs (Li et al., 2006). In 
addition, PEPT2 is also expressed in the lungs, mammary gland and choroid plexus (Terada 
and Inui, 2007). Studies performed in mice lacking pept2 suggested that it is one of the 
  
 
 
 
Chapter 2 
 
 
29 
 
most important oligopeptide transporters in the kidney (Ocheltree et al., 2005). Another 
SLC member that has been implicated in renal organic anion transport is the sulphate anion 
transporter (SAT1/SLC26A1), which is a sodium-dependent antiporter that transports 
sulphate, oxalate and chloride anions, and is inhibited by selenate, thiosulfate and 
probenecid (Lee et al., 2003). This transporter was identified in mouse kidney and localised 
to the proximal tubule BLM. Human SAT1 is also expressed in the kidney (Regeer et al., 
2003), but its localisation and role in renal organic anion transport is not yet characterized.  
3.1. General Features of SLC22A Transporters 
The SLC22A subfamily consists of organic cation/anion/zwitterion transporters 
(Koepsell and Endou, 2004). To date, 18 different members have been identified, including 
the renal organic anion transporters OAT1-4 and URAT1. Structurally, all human OATs are 
comprised of 526-568 amino acids and have 12 TMDs with both their carboxyl and amino 
termini located intracellularly (Fig. 3). Multiple phosphorylation sites are present between 
TMDs 6 and 7, and on the carboxyl terminus. These sites may be involved in 
phosphorylation-induced functional regulation. Furthermore, characteristic multiple N-
glycosylation sites are present within the extracellular loop between the TMDs 1 and 2. The 
removal of these sites at OAT1/SLC22A6 (Tanaka et al., 2004) and OAT4/SLC22A11 
(Zhou et al., 2005) caused cessation of functional maturation and the retention of these 
transporters in intracellular compartments due to their inability to be targeted to the cell 
surface. The glycosylation sites are also thought to play an important role in providing 
ligand recognition sites. In addition, several positively-charged amino acids, hydrophobic 
amino acids and amino acids with small side chains, e.g. cysteine and glycine, have been 
proposed to be crucial for OAT binding and/or transporting capabilities (You, 2004). 
Regarding the assembly of the OATs, it has been hypothesised that they may form 
oligomers. Homo-oligomerisation was suggested for OAT1, possibly forming a trimer 
(Hong et al., 2005), which may not be crucial for the protein transporting capacity, yet it 
may have a role in membrane targeting. The possibility that different OATs can form 
hetero-oligomers has been postulated (Zhou and You, 2007), but not proven yet. 
Mechanistically, OAT1 and OAT3/SLC22A8 can mediate the active uptake of organic 
anions across the BLM by exchanging them for intracellular anions. Several transport 
proteins can secondarily affect OAT1/3 transport activity by controlling the intracellular 
content of counter anions, as -ketoglutarate, lactate, and nicotinate. The primary driving 
force is provided by Na
+
K
+
-ATPase, which maintains an inwardly directed sodium 
gradient. This gradient drives the sodium dicarboxylate cotransporter (NaDC) to sustain an 
outwardly directed dicarboxylate gradient needed for OAT1/3 to exchange their anionic 
substrates (Sweet et al., 2003). A similar mechanism is utilised by the apical transporter, 
OAT4 (Ekaratanawong et al., 2004). These transport processes show the indirect 
dependency of the renal OATs on metabolic energy and the cellular sodium gradient. The 
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sodium-coupled mono-carboxylate transporters SMCT1/SLCA8 and SMCT2/SLC5A12 
(Gopal et al., 2007), respectively, which are expressed in the renal BBM, maintain an 
outwardly-directed monocarboxylate gradient that may drive URAT1/SLC22A12-mediated 
uric acid transport (Anzai et al., 2007). PDZ proteins could be indirectly involved in 
regulating renal organic anion transport. These proteins mediate protein-protein interactions 
by binding to the C-terminus of their target protein in a sequence-specific fashion, and the 
formation of such a complex is often required for efficient cell-surface routing and 
cooperative stimulation of substrate transport. This crucial role of PDZ adaptors has been 
shown for URAT1, OAT4 and PEPT2 (Kato, 2007)  
3.2. Organic Anion Transporters 
OAT1, 3, 4 and URAT1 are the main SLC22A members determining renal anionic drug 
transport. Other OATs are either expressed at low level or not fully characterized. For 
example, OAT2/SLC22A7, originally cloned from rat liver, is lowly expressed in the 
human kidney (Rizwan and Burckhardt, 2007), indicating a modest role in renal organic 
anion elimination. The gene encoding for OAT2 is located at chromosome 6, distinct from 
other renal OATs clustering at chromosome 11. Mechanistically, OAT2 distinguishes itself 
also from other OATs, as it is considered a sodium-independent multi-specific organic 
anion/dimethyldicarboxylate exchanger (Kobayashi et al., 2005). Substrates of human 
OAT2 include tetracycline (Babu et al., 2002), prostaglandin F2α (PGF2) (Khamdang et 
al., 2003), bumetanide, glutarate, estrone sulphate, dehydroepiandrosterone sulphate, 
allopurinol, 5-fluorouracil, paclitaxel and L-ascorbic acid (Kobayashi et al., 2005). 
Inhibitors include probenecid (Enomoto et al., 2002b) and cephalosporins (Khamdang et 
al., 2003). Interestingly, while OAT2 is localised to the BLM of proximal tubular cells in 
humans (Enomoto et al., 2002b), in rats it is expressed at the proximal tubule BBM 
(Ljubojevic et al., 2007). Furthermore, salicylate, which is considered a model substrate for 
rat Oat2, is not transported by human OAT2 (Rizwan and Burckhardt, 2007), emphasizing 
the inter-species dissimilarity. 
Oat5/Slc22a19 has been cloned and characterised in rat (Anzai et al., 2005) and mouse 
(Kwak et al., 2005), and was found to be only expressed in renal BBM. This transporter is 
not related to the non-functional 541-amino acid human OAT5 protein, which is 
exclusively expressed in liver (Rizwan and Burckhardt, 2007). Other OATs, like 
oat6/slc22a20, predominantly expressed in mouse olfactory mucosa (Monte et al., 2004), 
and OAT7/SLC22A9, expressed in human liver (Shin et al., 2007), have been cloned, but 
their role, if any, in human renal organic anion transport is still to be investigated. 
The most prominent renal OATs are OAT1, OAT3, OAT4 (Hosoyamada et al., 
1999;Cha et al., 2001), and URAT1 (Enomoto et al., 2002a). Genes encoding for OAT1, 3, 
4 and URAT1 are clustered on chromosome 11 at 11q12.3-11q13.1, where OAT1 pairs 
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with OAT3, and OAT4 with URAT1 (Nigam et al., 2007). This genetic pairing may 
facilitate coordinated transcription of each couple by sharing a common regulatory DNA 
sequence. In addition, each pair is phylogenetically closely related. This is reflected not 
only in their similarities in tissue distribution, renal membrane localization, and mechanism 
of transport, but also in the overlapping and complementary substrate specificity. 
3.2.1. Organic Anion Transporters 1 and 3 
OAT1 was originally cloned in rat, followed by cloning of its human orthologue 
(Nigam et al., 2007). In addition to its localisation in renal BLM, human OAT1 is also 
expressed basolaterally in the choroid plexus (Alebouyeh et al., 2003). Similarly, human 
OAT3 is expressed in the kidney and, to a lesser extent, in the brain (Cha et al., 2001) and 
the BLM of choroid plexus (Alebouyeh et al., 2003). Four human OAT1 splice variants 
have been identified, designated OAT1-1 till 4, which consist of 563, 550, 506, and 529 
amino acids, respectively (Bahn et al., 2000). OAT1-2 lacks 13 amino acids within its 
intracellular COOH-terminus and is considered the main human orthologue of OAT1. 
These variants have different substrate affinities, as OAT1-1 and OAT1-2 have the same 
PAH transport rate, while variants OAT1-3 and OAT1-4 do not show any transport activity 
(Wright and Dantzler, 2004).  
Several OAT1 amino acid residues, located in TMD1 (Hong et al., 2004) and TMD11 
(Rizwan and Burckhardt, 2007), have been suggested to be involved in the OAT1 substrate 
binding site. Furthermore, a theoretical three-dimensional model revealed that human 
OAT1 TMDs 5, 7, 8, 10 and 11 surround an electronegative putative active site, and that 
TMDs 5 and 10 may contribute to the substrate binding site (Perry et al., 2006). On the 
other hand, TMD3 and TMD6 of OAT3 are suggested to have a role in the activity of this 
transporter, as mutations in these regions led to a loss of transport function (Erdman et al., 
2006). 
Few polymorphisms have been identified for OAT1 (Bleasby et al., 2005;Xu et al., 
2005) and OAT3 (Erdman et al., 2006), some of which resulted in a complete loss of 
transport function of some substrates in vitro. The presence of such polymorphisms in 
apparently healthy individuals suggests a compensatory mechanism by other renal 
transporters sharing overlapping substrate specificities. However, upon treatment with 
drugs, polymorphisms may lead to genetic variability in pharmacokinetics. This was also 
noted in both oat1(Eraly et al., 2006) and oat3 (Sweet et al., 2002) knockout mice, where 
mice lacking oat1 showed profound loss of organic anion transport, manifested by the 
retention of PAH and impaired diuretic responsiveness to furosemide, whereas loss of oat3 
caused reduced taurocholate and estrone sulphate uptake in renal slices. Nevertheless, both 
knockout animals appeared healthy and had no major organ abnormalities or manifestations 
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of toxicity. OAT1/3 double knockouts may further clarify their role in renal basolateral 
organic anion transport. 
OAT1 and OAT3 accept a variety of structurally unrelated compounds as substrates, 
with distinct, yet overlapping substrate specificities (Table 1). Nevertheless, it has been 
suggested that OAT3 exhibits a broader substrate specificity than OAT1 (Nozaki et al., 
2007). OAT1 has a higher affinity for hydrophilic organic anions with small molecular 
weights, like PAH, whereas OAT3 also transports amphipathic organic anions and some 
organic cations. The broader specificity, as well as the relatively higher renal expression 
levels of OAT3 compared to OAT1 (Motohashi et al., 2002), may suggest a more 
pronounced role of OAT3 in human renal organic anion transport. 
3.2.2. Organic Anion Transporter 4 and Urate Transporter 1 
OAT4 was originally cloned from human placenta (Cha et al., 2000), and URAT1 was 
identified by searching the human genome sequence for OAT-related genes (Enomoto et 
al., 2002a). OAT4 and URAT1 are human apical renal urate-anion exchangers that 
contribute to the regulation of serum urate levels. Unlike rabbit and pig, human kidney 
actively reabsorbs urate, thus attaining a relatively higher serum urate level. This 
accumulation of urate is considered an evolutionary advantage, as urate has been suggested 
to be a factor contributing to the relatively increased lifespan of humans. After glomerular 
filtration of almost 100% of serum urate, only 10% is excreted in urine. Intracellular 
organic anions serve as an outwardly directed driving force that facilitates the uphill urate 
reabsorption via URAT1 and OAT4. In addition to urate, chloride can drive URAT1 
(Enomoto et al., 2002a), and possibly OAT4 (Hagos et al., 2007b). OAT4 has several 
substrates and inhibitors (Table 1). On the other hand, aside from urate and chloride, few 
substrates have been identified for URAT1, including nicotinate (Enomoto et al., 2002a) 
and oxypurinol (Iwanaga et al., 2005). The majority of URAT1 inhibitors are drugs that 
may affect serum levels of urate (Enomoto et al., 2002a), at least in part via altering 
URAT1-mediated urate reabsorption. 
To date, 10 URAT1 mutations have been identified, mostly in Japanese patients, with 
idiopathic renal hypouricemia (Komatsuda et al., 2006), which is an autosomal recessive 
hereditary disease characterised by exercise-induced acute renal failure and chronic renal 
dysfunction. Interestingly, no mutations in URAT1 were detected in Greek patients 
suffering from the same disorder (Tzovaras et al., 2007). On the other hand, a single 
nucleotide polymorphism and frame shift mutation in URAT1 has been identified in 
patients with hyperuricemia and gout (Shima et al., 2006;Vazquez-Mellado et al., 2007). 
These genetic correlations imply the importance of URAT1 in urate homeostasis, which 
could not be compensated for by the presence of OAT4. The possibility of the presence of a 
concomitant defect in OAT4 in these patients was not investigated. It is not yet known by 
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which mechanism urate crosses the BLM in its final step of reabsorption. Indeed, OAT1 
(Ichida et al., 2003) and OAT3 (Bakhiya et al., 2003) accept urate as a substrate, 
nevertheless, whether they can act as efflux transporters is still questionable. 
4. Conclusions and Future Perspectives 
The renal excretion of organic anions is handled by a well-organised sophisticated 
system that can excrete xenobiotics and their metabolites, while preserving essential 
molecules. During excretion, transporters in the proximal tubule BLM control the blood-to-
cell transport, and in the BBM the cell-to-urine transport, mediating the final exit of organic 
anions from the body. On the other hand, the route of organic anions is reversed in case of 
reabsorption, where BBM transporters selectively take up essential organic anions. These 
reabsorbed compounds can in turn affect the concentration gradients that provide the main 
driving forces for most BLM transporters. To understand the machinery of the renal anionic 
drug transport system, it is necessary to unravel the structure, mechanism of transport, 
range of substrates and inhibitors, as well as the factors regulating the expression of each 
single transporter. Hence, other factors, like metabolism, inter-individual genetic variations, 
and disease conditions may govern their activity and the interplay with other transporters. 
Thanks to the recent advances in the field of molecular physiology and pharmacology, our 
knowledge on renal organic anion transporters has been enhanced considerably. 
Nevertheless, further investigations are still needed to elucidate the transporter-mediated 
mechanisms involved in renal anionic drug clearance, owing to the overlapping transport 
capabilities and the large number of potential interactions. The real challenge is to integrate 
such basic information and interpret from it the physiological and pharmacological 
consequences at the organ level, finally aiming at safer use of anionic drugs and more 
adequate therapeutic combination regimens.  
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Summary 
Methotrexate (MTX) has been used in combination with nonsteroidal
 
anti-inflammatory 
drugs (NSAIDs) in the treatment of inflammatory
 
diseases as well as malignancies. 
Especially at high MTX dosages,
 
severe adverse effects with this combination may occur, 
usually
 
resulting from an impaired renal elimination. It has been shown
 
that the mechanism 
of this interaction cannot be fully attributed
 
to inhibition of basolateral MTX uptake in renal 
proximal tubules.
 
Here, we studied the effect of various NSAIDs on MTX transport
 
in 
membrane vesicles isolated from cells overexpressing the
 
proximal tubular apical efflux 
transporters human multidrug
 
resistance protein (MRP) 2/ABCC2 and MRP4/ABCC4. 
MTX was transported
 
by MRP2 and MRP4 with Km values of 480 ± 90 and 220 ±
 
70 µM, 
respectively. The inhibitory potency of the NSAIDs
 
was generally higher against MRP4- 
than MRP2-mediated MTX transport,
 
with therapeutically relevant IC50 values, ranging 
from approximately
 
2 µM to 1.8 mM. Salicylate, piroxicam, ibuprofen, naproxen,
 
sulindac, 
tolmetin, and etodolac inhibited MRP2- and MRP4-mediated
 
MTX transport according to a 
one-site competition model. In
 
some cases, more complex interaction patterns were 
observed.
 
Inhibition of MRP4 by diclofenac and MRP2 by indomethacin and
 
ketoprofen 
followed a two-site competition model. Phenylbutazone
 
stimulated MRP2 and celecoxib 
MRP4 transport at low concentrations
 
and inhibited both transporters at high concentration. 
Our data
 
suggest that the inhibition by NSAIDs of renal MTX efflux via
 
MRP2 and MRP4 
is a potential new site and mechanism contributing
 
to the overall interaction between these 
drugs. 
Introduction 
Methotrexate (MTX) has been successfully used for more than
 
three decades in treating 
various malignant tumors and autoimmune
 
disorders. Although MTX is generally well 
tolerated, unpredictable
 
life-threatening toxicity still occurs at high dosages or concomitant
 
use with other drugs, resulting in persistently high plasma
 
concentrations. Of the drugs 
causing such interactions with
 
MTX, nonsteroidal anti-inflammatory drugs (NSAIDs) have 
been
 
well known (Kremer and Hamilton, 1995). Numerous clinical case
 
reports have 
documented that NSAIDs can cause a reduction in
 
the MTX clearance, even at relatively 
low maintenance dosages
 
used to treat rheumatoid arthritis. Ketoprofen, indomethacin,
 
and 
diclofenac caused different levels of toxicities in patients
 
receiving MTX, ending fatally in 
three of four patients receiving
 
ketoprofen (Thyss et al., 1986), two of which had 
approximately
 
12-fold higher MTX serum levels. Similar toxicities were found
 
with 
salicylate (Stewart et al., 1991), ibuprofen (Cassano, 1989), and naproxen (Singh et al., 
1986). 
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MTX is primarily excreted into urine in the unchanged form,
 
and renal handling 
involves tubular secretion and reabsorption,
 
in addition to glomerular filtration. Renal 
tubular secretion
 
of MTX has been thought to be a major site of interaction with
 
other drugs 
(Takeda et al., 2002). The first step is active
 
uptake from the blood across the basolateral 
membrane into the
 
proximal tubular cells via the organic anion transporters (OATs)
 
1 and 3 
and the reduced folate carrier-1 (Nozaki et al., 2004). Extrusion from the cells across the 
luminal membrane into the
 
urine is mediated by the ATP-dependent efflux pumps, 
multidrug
 
resistance proteins (MRPs) 2 and 4 (Masuda et al., 1997;Chen et al., 2002;van 
Aubel et al., 2002). Furthermore, MTX is recognized
 
by luminal OAT4 (Takeda et al., 
2002), which reabsorbs anions
 
from the primary urine back into the tubular cells 
(Ekaratanawong et al., 2004). The interaction of NSAIDs with MTX uptake at
 
the 
basolateral membrane has been investigated recently, and
 
the results showed that several 
NSAIDs inhibited MTX uptake
 
via human OAT1 and OAT3 at clinically relevant 
concentrations (Takeda et al., 2002). Nevertheless, when studied in rat kidney
 
slices, the 
interaction was not as potent as presumed, probably
 
because reduced folate carrier-1, which 
is insensitive to NSAIDs,
 
also contributes significantly to tubular MTX uptake (Nozaki et 
al., 2004). To date, the effect of NSAIDs on the luminal
 
efflux of MTX via MRP2 and 
MRP4 has not yet been studied as
 
potential site of this drug-drug interaction. 
The expression of MRP2 (Schaub et al., 1997) and MRP4 (van Aubel et al., 2002) in the 
kidney is restricted to the apical luminal membrane of the proximal tubule cells. Mutations 
in the gene encoding
 
MRP2 (ABCC2) causing Dubin-Johnson syndrome, a rare form of
 
conjugated hyperbilirubinemia, can impair high-dose MTX elimination,
 
leading to renal 
toxicity in vivo (Hulot et al., 2005). Previous
 
studies showed that MRP4-mediated estradiol 
17-β-D-glucuronide transport was inhibited potently by several NSAIDs (Reid et al., 2003), 
suggesting that these drugs might be potential inhibitors
 
of other MRP4 substrates. In 
addition, luminal efflux transporters
 
may get exposed to relatively high inhibitor 
concentrations
 
because NSAIDs can be taken up actively into the proximal tubular
 
cells via 
basolateral OATs (Sekine et al., 1997;Apiwattanakul et al., 1999). The objective of this 
study was to investigate
 
the interaction potential of NSAIDs with the renal MTX efflux
 
transporters MRP2 and MRP4. For this purpose, we used membrane
 
vesicles isolated from 
cells overexpressing human MRP2 and MRP4.
 
Our findings show that various NSAIDs 
inhibit both MRP2- and
 
MRP4-mediated MTX transport, in general with higher inhibitory
 
potency against MRP4. Our study also shows different and sometimes
 
complex inhibitory 
patterns of the various NSAIDs tested. This
 
is the first study in which this putative drug-
drug interaction
 
is examined at the molecular level. 
Materials and Methods 
Materials. [3',5',7'-
3
H(n)]MTX sodium salt (51.5 Ci/mmol) was
 
purchased from Moravek 
Inc. (Brea, CA). The Bac-to-Bac and Gateway
 
system were purchased from Invitrogen 
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(Breda, The Netherlands).
 
Creatine phosphate and creatine kinase were purchased from 
Roche
 
Diagnostics (Almere, The Netherlands). NC45 filters were obtained
 
from Schleicher 
and Schuell (Den Bosch, The Netherlands). Protein
 
concentrations were determined with an 
assay kit from Bio-Rad
 
Laboratories (Veenendaal, The Netherlands). Celecoxib was 
purified
 
from 200-mg Celebrex capsules, Pfizer (Capelle a/d Ijssel, The
 
Netherlands) 
according to a previously described method (Tong et al., 2005). 
Cell Lines and Culture Conditions. The MRP2-overexpressing MDCKII
 
cell line was 
kindly provided by Dr. P. Borst (Dutch Cancer
 
Institute, Amsterdam, The Netherlands) and 
was cultured as described
 
previously (Evers et al., 1998). The nontransfected MDCKII cell
 
line was used as a control. HEK293 cells were grown in DMEM
 
supplemented with 10% 
fetal calf serum at 37°C under 5%
 
CO2-humidified air. 
Generation of Human MRP4 Baculovirus. The Bac-to-Bac system,
 
normally used for 
protein production in insect cells, was made
 
suitable for protein expression in mammalian 
cells by cloning
 
the vesicular stomatitis virus G protein cDNA behind the P10
 
promoter of 
the pFastBacDual vector. Next, the CMV promoter
 
and Gateway destination elements 
(cassette that contains the
 
chloramphenicol resistance gene and the ccdB gene flanked by
 
attR1 and attR2 sites) were introduced in the pFastBacDual vector.
 
The human MRP4 was 
cloned into the Gateway entry vector. The
 
sequence of this MRP4 construct is equal to 
GenBank accession
 
number NM_005845 [GenBank] except for the I18L polymorphism. 
This MRP4
 
cDNA was transferred to the newly constructed Bac-to-Bac vector
 
with the 
gateway LR reaction. Baculoviruses were produced as
 
described in the Bac-to-Bac manual. 
As a control, the enhanced
 
yellow fluorescent protein was also cloned into the gateway
 
entry vector (Invitrogen). 
Transduction of HEK293 Cells. HEK293 cells were cultured in
 
182-cm
2
 flasks until 70% 
confluence, after which the culture
 
medium was removed and 1.5 ml of virus and 3.5 ml of 
medium
 
were added. The cells were incubated for 30 to 60 min at 37°C,
 
after which 20 ml 
of medium was added. After 24 h of transduction,
 
sodium butyrate (5 mM) was added. 
Three days after transduction,
 
the cells were harvested. 
Isolation of Membrane Vesicles and Protein Analysis. Cells were
 
harvested by 
centrifugation at 3000g for 30 min. The pellets
 
were resuspended in ice-cold 
homogenization buffer (0.5 mM sodium
 
phosphate, 0.1 mM EDTA, pH 7.4) supplemented 
with protease inhibitors
 
(100 µM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin,
 
5 µg/ml 
leupeptin, 1 µM pepstatin, and 1 µM
 
E-64) and shaken at 4°C for 60 min. Lysed cells were 
centrifuged
 
at 4°C at 100,000g for 30 min, and the pellets were homogenized
 
in ice-cold TS 
buffer (10 mM Tris-HEPES and 250 mM sucrose,
 
pH 7.4) using a tight fitting Dounce 
homogenizer for 30 strokes.
 
After centrifugation at 500g at 4°C for 20 min, the supernatant
 
was centrifuged at 4°C at 100,000g for 60 min. The resulting
 
pellet was resuspended in TS 
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buffer and passed through a 27-gauge
 
needle 30 times. Protein concentration was 
determined by a Bio-Rad
 
protein assay kit. Crude membrane vesicles were dispensed in
 
aliquots, frozen in liquid nitrogen, and stored at –80°C until use. 
Immunoblotting. The membrane vesicle preparations were diluted
 
in TS buffer. The 
indicated amount of protein was size fractionated
 
on a 7.5% SDS-polyacrylamide gel and 
subsequently blotted on
 
nitrocellulose membrane. Affinity-purified, polyclonal anti-human
 
MRP2 (pAb hM2-p1) and anti-human MRP4 (pAb hM4-p4) antibodies
 
(1:1000) were used 
to detect human MRP2 and MRP4, respectively (van Aubel, et al., 2002;Smeets, et al., 
2004). Signals were
 
visualized with chemiluminescence (Amersham Biosciences, Diegem,
 
Belgium). 
Vesicular Transport Assays. Uptake of [
3
H]MTX into membrane
 
vesicles was performed 
as described previously (van Aubel et al., 1999). In brief, membrane vesicles were 
prewarmed for 1
 
min at 37°C and added to TS buffer, supplemented with an
 
ATP-
regeneration mixture (4 mM ATP, 10 mM MgCl2, 10 mM creatine
 
phosphate, and 100 
mg/ml creatine kinase) in a final volume
 
of 60 µl. The reaction mixture was incubated at 
37°C
 
for 15 min, and samples were taken from the mixture at indicated
 
times, diluted in 900 
µl of ice-cold TS buffer. Diluted
 
samples were filtered through 0.45-µm-pore NC filters
 
that 
were preincubated with TS buffer by a filtration device
 
(Millipore, Bedford, MA) using a 
rapid filtration method. After
 
adding 4 ml of scintillation fluid and subsequent liquid 
scintillation
 
counting, uptake of [
3
H]MTX into membrane vesicles was studied
 
by 
measuring radioactivity associated with the filters. In control experiments, ATP was 
substituted with AMP. Net ATP-dependent
 
transport was calculated by subtracting values 
measured in the
 
presence of AMP from those measured in the presence of ATP.
 
Measurements were corrected for the amount of ligand bound to
 
the filters (usually <2% of 
total radioactivity). Each experiment
 
was performed in triplicate. The sidedness of the 
membrane vesicles
 
was not determined. ATP-dependent uptake can only occur in inside-out
 
vesicles, and because inhibition by NSAIDs is expressed relatively
 
as percentage of MTX 
uptake, the result is not affected by differences
 
in expression levels and sidedness of the 
vesicles. 
Transport Inhibition Assays. To evaluate the inhibitory effects
 
of NSAIDs on MTX uptake 
mediated by MRP2 and MRP4, the previously
 
mentioned transport assay was performed 
using 0.5 µM [
3
H]MTX,
 
in the absence or presence of various concentrations of NSAIDs.
 
Hydrophilic NSAIDs, viz. salicylate, diclofenac, tolmetin, ibuprofen,
 
and naproxen, were 
dissolved in H2O. Hydrophobic NSAIDs, viz.
 
sulindac, indomethacin, etodolac, ketoprofen, 
phenylbutazone,
 
piroxicam, and celecoxib, were dissolved in dimethyl sulfoxide
 
(DMSO) 
and diluted with incubation medium. The final concentration of DMSO in the incubation 
medium was
 
adjusted to less than 1% (Apiwattanakul et al., 1999). We tested
 
the effect of 
1% DMSO and observed a reduction of approximately
 
20% in transport. Because in all 
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transport assays the same concentration
 
of DMSO was used as a control, this reduction did 
not influence
 
the results. In all experiments with hydrophobic NSAIDs, control
 
samples 
contained the same concentration of DMSO. 
Kinetic Analysis. All data were expressed as means ±
 
S.E. IC50 values of NSAIDs were 
obtained from curve fitting
 
of the resulting concentration-inhibition curves by nonlinear
 
regression analysis using GraphPad Prism software version 4.03
 
(GraphPad Software Inc., 
San Diego, CA). Statistical differences
 
were determined using a one-way analysis of 
variance with Dunnett's
 
post test. Differences were considered to be significant at
 
P < 0.05. 
Results 
Expression of MRP2 and MRP4 in Isolated Membrane Vesicles. Immunoblot
 
analysis 
was performed on membrane vesicles prepared from MDCKII
 
and HEK293 cells 
overexpressing human MRP2 and MRP4, respectively. Figure 1 demonstrates that both 
MRP2 and MRP4 were successfully
 
expressed and were detected as 190-kDa (Schaub et 
al., 1999;van Aubel et al., 2002) and 170 kd (Lee et al., 2000;van Aubel et al., 2002) bands, 
respectively, whereas control MDCKII and
 
HEK293 vesicles did not show any protein 
expression at the corresponding
 
heights. 
 
Fig. 1: Immunoblot analysis of MRP2 and 
MRP4 expression in membrane vesicles used 
for transport studies. Membrane vesicles were 
prepared from control MDCKII and HEK293 
as well as cells overexpressing human MRP2 
and MRP4, respectively. 
Time-Dependent Uptake of MTX by MRP2 and MRP4. Membrane vesicles
 
were 
incubated for 2.5, 5, 10, 15, 20, and 30 min at 37°C
 
in uptake medium containing 0.5 µM 
[
3
H]MTX. A relatively
 
low MTX concentration was chosen because the specific activity
 
of 
the radiolabel was not very high and for an accurate determination
 
of IC50 values, a 
substrate concentration well below the Km
 
must be used. The relative contribution of MRP2 
or MRP4 to overall
 
uptake was assessed in parallel experiments performed on membrane 
vesicles isolated from control MDCKII and HEK293 cells, respectively.
 
Both MRP2 and 
MRP4 mediated ATP-dependent [
3
H]MTX transport (Fig. 2). Transport of [
3
H]MTX 
increased with time, and the
 
uptake was linear over the first 20 min of the assay for both
 
MRP2 and MRP4. Uptake at 20 min remained linear up to the highest
 
[
3
H]MTX 
concentrations used in the experiments to assess the
 
concentration dependence of transport, 
viz. 2 mM for MRP2 and
 
1 mM for MRP4 vesicles (data not shown).  
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Fig. 2: Time-dependent uptake of [3H]MTX in MRP2 and MRP4 membrane vesicles. Vesicles were 
incubated for 2.5, 5, 10, 15, 20, and 30 min at 37°C in uptake medium containing 0.5 µM[3H]MTX. 
ATP-dependent [3H]MTX uptake was calculated by subtracting uptake in the presence of AMP from 
uptake in the presence of ATP in membrane vesicles from control (□) or MRP2-expressing (■) 
MDCKII cells and control (○) or MRP4-expressing (●) HEK293 cells. Data present mean and S.E. of 
at least three different experiments, each performed in triplicate. 
Concentration-Dependent Transport of MTX by MRP2 and MRP4. Membrane
 
vesicles 
were incubated for 15 min at 37°C with 
3
H-labeled
 
and unlabeled MTX to the final 
concentrations indicated (Fig. 3). ATP-dependent transport was calculated by subtracting 
the values
 
obtained in the presence of AMP from those in the presence of
 
ATP. MRP2- and 
MRP4-dependent uptakes were calculated by subtracting
 
nonspecific uptakes in control 
MDCKII and HEK293 vesicles, respectively.
 
MRP2 and MRP4 efficiently transported 
MTX, and the concentration
 
of MTX at half-maximal uptake rates (Km) was relatively 
higher
 
for MRP2 than for MRP4. The Km and Vmax values for MTX uptake
 
in MRP2 and 
MRP4 vesicles were 480 ± 90 and 220 ±
 
70 µM and 80 ± 10 and 280 ± 30 pmol/mg/min,
 
respectively. It should be noted that because of different expression
 
systems, the enrichment 
of the transporters may be different,
 
and therefore, it is only meaningful to compare Km 
values. 
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Fig. 3: Concentration-dependent uptake of [3H]MTX in MRP2 and MRP4 membrane vesicles. 
Vesicles were incubated for 15 min at 37°C with 3H-labeled and unlabeled MTX to the final 
concentrations indicated in the figure. ATP-dependent uptake is measured by subtracting uptake in 
the presence of AMP from that measured in the presence of ATP. ATP-dependent uptake of MTX by 
MRP2 (□) and MRP4 (●) was determined after subtraction of ATP-dependent uptake in the 
corresponding control vesicles from MDCKII and HEK293 cells, respectively. Data present mean 
and S.E. of at least three different experiments, each performed in triplicate. 
Effect of NSAIDs on MRP2- and MRP4-Mediated MTX Transport. Membrane
 
vesicles 
were incubated with 0.5 µM[
3
H]MTX at 37°C
 
for 15 min in the absence or presence of 
increasing concentrations
 
of the various NSAIDs (Figs. 4 and 5). All NSAIDs studied 
inhibited
 
MRP2- and MRP4-mediated MTX transport with different potencies
 
and 
sometimes complex kinetic interactions. The calculated IC50
 
values are given in Table 1. 
Figure 4 shows that salicylate
 
inhibited MTX transport with nearly the same IC50 values for
 
MRP2 and MRP4 and with the lowest inhibitory potency of all
 
the NSAIDs tested (Table 
1). Piroxicam gave a similar inhibitory
 
pattern, whereas the inhibitory potency of ibuprofen, 
naproxen,
 
sulindac, and tolmetin was significantly higher against MRP4-
 
than MRP2-
mediated MTX transport. Figure 5 shows that etodolac was the only NSAID that gave a
 
steep inhibition curve of MRP2-mediated MTX transport, with
 
a slope factor significantly 
higher than one. Furthermore, the
 
inhibitory pattern of diclofenac on MRP4-mediated 
transport
 
and of indomethacin and ketoprofen on MRP2-mediated MTX transport
 
could not 
be simply described according to a one-site competition
 
model but was fitted significantly 
better using the two-site
 
model. Phenylbutazone produced a bell-shaped curve against 
MRP2-
 
but not MRP4-mediated transport, with significant stimulation
 
up to 170 ± 16% at 
low and inhibition at higher concentrations.
 
Celecoxib, the only selective cyclooxygenase II 
inhibitor tested,
 
showed a mild but statistically significant stimulation of MRP4-mediated
 
MTX transport at low concentrations. In contrast to what has
 
been described by others 
(Zelcer et al., 2003), we could not
 
find a stimulatory effect of indomethacin on MRP2-
mediated MTX
 
transport. 
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Fig. 4: Effect of salicylate, piroxicam, ibuprofen, naproxen, sulindac, and tolmetin on MRP2- and 
MRP4-mediated [3H]MTX uptake in membrane vesicles. Vesicles were incubated with 0.5 
µM[3H]MTX at 37°C for 15 min, in the absence or presence of increasing concentrations of the 
NSAIDs tested. Uptake was measured by subtracting the background (AMP) from the ATP-dependent 
uptake. Respective [3H]MTX transport rates for MRP2 (□) and MRP4 (●) were expressed as a 
percentage of control uptake against the log NSAID concentration. Data present mean and S.E. of 
three different experiments, each performed in triplicate. 
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Fig. 5: Effect of etodolac, diclofenac, indomethacin, ketoprofen, celecoxib, and phenylbutazone on 
MRP2- and MRP4-mediated [3H]MTX uptake in membrane vesicles. Vesicles were incubated with 
0.5 µM[3H]MTX at 37°C for 15 min in the absence or presence of different concentrations of the 
NSAIDs tested. Uptake was measured by subtracting the background (AMP) from the ATP-dependent 
uptake. Respective [3H]MTX transport rates for MRP2 (□) and MRP4 (●) were expressed as a 
percentage of control uptake against the log NSAID concentration. Data present mean and S.E. of 
three different experiments, each performed in triplicate. 
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Table 1: IC50 values of various NSAIDs for MRP2- and MRP4-mediated MTX transport. 
 
 
 
 
 
 
 
 
 
 [3H]MTX uptake was measured by subtracting the background (AMP) from the ATP-dependent 
uptake. Each value represents the mean ± S.E. of data obtained from three separate experiments, 
each performed in triplicate, calculated by nonlinear regression analysis of the data from Figs. 4 and 
5. a Dose-inhibition curve with a slope factor > 1. High (H)- and low (L)-affinity IC50 determined 
according to a two-site competition model. 
Discussion 
Severe and sometimes fatal side effects have been observed in
 
patients after the 
coadministration of MTX and NSAIDs. To date
 
the specific mechanisms contributing to 
this interaction have
 
not been fully identified. It has been shown that inhibition
 
of 
basolateral MTX uptake in renal proximal tubules via OAT1
 
and 3 is an important site of 
competition with NSAIDs but not
 
as powerful to account for the full interaction. In the 
present
 
study, we show that a wide variety of NSAIDs inhibited MRP2-
 
and MRP4-
mediated MTX transport at concentrations to which the
 
transporters may be exposed under 
therapeutic conditions, adding
 
a new possible site and mechanism to the overall MTX-
NSAID interaction. 
Although all NSAIDs tested are weak organic acids, they are
 
chemically diverse and 
possess a wide range of pharmacokinetic
 
characteristics, which makes it difficult to study 
the relationship
 
between structure and inhibitory activity. In our study, sulindac
 
had the 
highest and salicylate the lowest inhibitory potency
 
for both MRP2 and MRP4. Etodolac 
 MRP2 MRP4 
 µM 
Salicylate 1760 ± 30 1500 ± 20 
Piroxicam 257 ± 2 216 ± 2 
Ibuprofen 930 ± 20 26.3 ± 0.3 
Naproxen 609 ± 7 42.3 ± 0.3 
Sulindac 38 ± 1 2.11 ± 0.02 
Tolmetin 494 ± 5 20.5 ± 0.3 
Etodolac 480 ± 2
a 120 ± 1 
Diclofenac 97 ± 1 0.006 ± 0.001 (H) 
    326 ± 6 (L) 
Indomethacin 0.06 ± 0.01 (H) 6.1 ± 0.1 
 46 ± 1 (L)    
Ketoprofen 1.4 ± 0.1 (H) 11.9 ± 0.1 
 470 ± 20 (L)    
Celecoxib 100 ± 2 35 ± 1
b 
Phenylbutazone 605 ± 4
b 130 ± 2 
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was the only NSAID tested with
 
an inhibitory curve with a slope factor significantly higher
 
than unity, indicating positive co-operativity in inhibition.
 
Most NSAIDs had a higher 
inhibitory potency against MRP4- than
 
MRP2-mediated transport. The effect of diclofenac 
on MRP4 and
 
of indomethacin and ketoprofen on MRP2 exhibited a two-site
 
competition 
model. Furthermore, phenylbutazone and celecoxib
 
showed a dual effect. At low 
concentrations, phenylbutazone
 
had a strong stimulatory effect on MTX transport via 
MRP2 but
 
not MRP4, whereas celecoxib stimulated MRP4 transport modestly.
 
At higher 
concentrations, phenylbutazone and celecoxib inhibited
 
both transporters. This is 
compatible with the suggestion that
 
both MRP2 (Zelcer et al., 2003) and MRP4 (van Aubel 
et al., 2005) have more than one binding site. This phenomenon was previously
 
explained 
by the existence of two independent binding sites,
 
one site that transports substrates and 
another site that can
 
allosterically modulate the substrate transport site (Zelcer et al., 2003). 
Compounds that can stimulate as well as inhibit
 
transport probably bind at low 
concentrations preferentially
 
to the modulatory site, whereas at high concentrations, they
 
can also compete for the substrate transport site. This type
 
of allosteric interaction seems a 
common characteristic of the
 
MRPs. Several NSAIDs belonging to the selective 
cyclooxygenase II
 
inhibitors were reported not to affect the clinical pharmacokinetics
 
of 
MTX (Schwartz et al., 2001;Hartmann et al., 2004), including
 
celecoxib (Karim et al., 
1999). This may be due to the low immunosuppressive
 
MTX dosages used in these studies. 
Our results show that celecoxib
 
can be a potent inhibitor of MRP2- and MRP4-mediated 
renal MTX
 
efflux. 
The MTX concentration of 0.5 µM we used in the inhibition
 
experiments is relatively 
low as compared with plasma concentrations
 
after therapeutic dosages, which are highly 
variable and may
 
range from 0.1 up to 20 to 50 µM. Because of tubular accumulation
 
of 
MTX via active uptake, it is likely that intracellular concentrations
 
will exceed the plasma 
concentration. Apparently, MRP4 transports
 
MTX with higher affinity than MRP2. 
Previous studies reported
 
that Km values of MTX were higher for MRP2 (2.5–3 mM) 
(Bakos, et al., 2000) than for MRP4 (0.22–1.3 mM) (Chen et al., 2002;van Aubel et al., 
2002), which is in line with
 
our results. In addition, the protein expression of MRP4 is
 
5-
fold higher than MRP2 in human kidney cortex (Smeets et al., 2004). Furthermore, by 
comparing the IC50 values of different
 
NSAIDs, we found that NSAIDs generally exhibited 
a higher inhibitory
 
potency against MRP4. Given this information, we would expect
 
that 
MRP4 plays a more important role than MRP2 in the inhibition
 
of renal MTX efflux by 
NSAIDs. On the other hand, a recent study
 
in Mrp2
-/-
 mice showed 1.8-fold higher plasma 
concentrations
 
of MTX as compared with wild-type mice. Although Mrp4 expression
 
was 
increased 2-fold in the knockouts, apparently it was not
 
able to compensate for the loss of 
Mrp2 in these mice (Vlaming et al., 2006). Furthermore, it was reported that in a patient
 
with MRP2 protein dysfunction caused by a genetic variation
 
in the MRP2/ABCC2 gene, 
MTX excretion was impaired, leading
 
to severe overdose manifestations as nephrotoxicity, 
amounting
 
to renal failure (Hulot et al., 2005). The apparent contradiction
 
between the 
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expected higher effects of MRP4 participating in
 
MTX elimination at the molecular level 
needs further investigation.
 
It is hard to define the relative influence of a certain NSAID
 
on 
the urinary excretion of MTX, making it very difficult to
 
recommend a specific NSAID 
with the lowest interaction potential
 
in patients. In addition to the inhibitory potency of the 
NSAIDs,
 
a number of other factors should be taken into consideration:
 
the variation in 
NSAID dosing, which, in case of salicylate,
 
may reach gram quantities per day producing 
serum concentration
 
ranging from several hundred micromolars to several millimolars 
(Cerletti et al., 2003), the concentration of unchanged NSAIDs
 
reached in proximal tubular 
cells by carrier-mediated uptake,
 
and the possible effects of NSAID metabolites on MTX 
efflux.
 
Because of extensive plasma protein binding ranging from 90
 
to 99%, the unbound 
concentrations of NSAIDs in plasma are low.
 
The estimated unbound therapeutic 
concentration of the most
 
potent inhibitors, sulindac and indomethacin, are approximately
 
1 
and 8 µM, respectively, which is in the range of their
 
IC50 values for MRP4 (Davies and 
Skjodt, 2000;Takeda et al., 2002b;Chen et al., 2006). For the other NSAIDs tested, 
unbound
 
plasma concentrations are considerably lower than their IC50
 
values, but it should 
be noticed that some of these compounds
 
are also actively taken up in the proximal tubular 
cells by
 
organic anion transporters, resulting in much higher concentrations
 
to which MRP2 
and MRP4 will be exposed (Apiwattanakul et al., 1999). 
In summary, our study shows that MRP2- and MRP4-mediated efflux
 
of MTX can be 
inhibited by various NSAIDs at therapeutically
 
relevant concentrations. Because MRP2 and 
MRP4 are important
 
efflux transporters for MTX in the kidney, they are potential
 
new sites 
of MTX-NSAIDs interaction. The relative contribution
 
of this mechanism to the overall 
inhibition of renal MTX excretion
 
by NSAIDs and the individual roles of MRP2 and MRP4 
herein need
 
to be established in future in vivo studies. 
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Summary 
Renal proximal tubule transporters can play a key role in excretion, pharmacokinetic 
interactions and toxicity of immunosuppressant drugs. Basolateral organic anion 
transporters (OAT) and multidrug resistance transporters (MRPs) contribute to the active 
tubular uptake and urinary efflux of these drugs, respectively. Here, we studied the 
interaction of different immunosuppressants with [
3
H]methotrexate ([
3
H]MTX) uptake in 
HEK293 cells over-expressing OAT1, and ATP-dependent transport in membrane vesicles 
isolated from MRP2- and MRP4-overexpressing HEK293 cells. Our results show that 
various immunosuppressants can significantly inhibit basolateral OAT1-mediated MTX 
uptake, including mycophenolic acid, mitoxantrone, cytarabine, hydrocortisone, vinblastine 
and vincristine, whereas cyclophosphamide stimulated uptake. MRP2- and MRP4-mediated 
transport were inhibited both by mycophenolic acid and tacrolimus, and stimulated by 
mitoxantrone and dexamethasone. Cyclosporine A, vincristine and vinblastine selectively 
inhibited MRP2, while 6-mercaptopurine only inhibited MRP4-mediated transport. 
Cytarabine and azathioprine had no effect on either transporter. These data suggest that 
alteration of basolateral and apical renal transporter activity may play a role in 
immunosuppressant drug interactions. 
Introduction 
Immunosuppressants are a structurally and functionally heterogeneous group of drugs, 
which are often concomitantly administered in combination regimens to treat organ 
transplant rejection and autoimmune diseases. Having a narrow therapeutic index, 
immunosuppressant co-treatment underlies the hazard of toxic adverse effects (Cattaneo et 
al., 2008). Active transport of immunosuppressants may have a great influence on their 
pharmacokinetics and pharmacodynamics (Christians et al., 2006;Mourad et al., 2008). 
Renal proximal tubule transporters play a key role in the excretion of various drug classes, 
including immunosuppressants, and their metabolites (El-Sheikh et al., 2008a). The 
expression of organic anion transporters (OATs) 1 and 3 in the proximal tubule basolateral 
membrane (Cha et al., 2001) and the multidrug resistance protein transporters MRP2 
(Schaub et al., 1997) and MRP4 (van Aubel et al., 2002) in the apical membrane contribute 
to active tubular uptake and the urinary efflux, respectively. The efficient OAT-mediated 
basolateral uptake may result in high intracellular drug concentrations (Nigam et al., 2007). 
At the apical side, MRPs control the intracellular concentration by active drug efflux into 
urine. Inhibition of these MRPs could lead to drug accumulation and subsequent 
nephrotoxicity, whereas inhibition of OATs may cause systemic side effects. Furthermore, 
MRP2 and MRP4 confer resistance to a broad range of immunosuppressant drugs used as 
anticancer agents, by extruding them out of the tumour cells thus decreasing their 
intracellular drug concentrations and diminishing chemotherapeutic effects (Bosch et al., 
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2006). The identification of MRP transport modulators is important for circumventing 
multidrug resistance during cancer chemotherapy (Ponte-Sucre, 2007). Some studies have 
attempted to predict the response of patients to chemotherapy depending on the presence of 
RNA expression or functional MRP proteins (Wolf et al., 2005;Burger et al., 2003). MRP 
over-expression, observed in some malignant tissues, was significantly associated with poor 
clinical outcome (Norris et al., 2005). The aim of this study was to investigate possible 
interactions of immunosuppressants with renal anionic drug transport systems.  We 
investigated the interaction of a broad range of immunosuppressant drugs with 
[
3
H]methotrexate ([
3
H]MTX) transport in HEK293 cells over-expressing human OAT1 and 
in membrane vesicles isolated from these cells over-expressing MRP2 or MRP4. Our 
results provide evidence that these renal transporters are potential sites for 
immunosuppressant drug interactions, which can be employed to overcome renal drug 
accumulation and subsequent nephrotoxicity, as well as to reverse tumour drug resistance 
in immunosuppressive chemotherapy.  
Materials and Methods 
Materials. [3',5',7'-
3
H(n)]MTX sodium salt (51.5 Ci/mmol) was
 
purchased from Moravek 
Inc. (Brea, CA). Creatine phosphate and creatine kinase were purchased from Roche
 
Diagnostics (Almere, The Netherlands). The Bac-to-Bac and Gateway
 
systems were 
purchased from Invitrogen (Breda, The Netherlands). Protein
 
concentrations were 
determined with an assay kit form Bio-Rad
 
Laboratories (Veenendaal, The Netherlands). 
NC45 filters were obtained
 
from Schleicher and Schuell (Den Bosch, The Netherlands).  
Generation of Human MRP2, MRP4, and OAT1 Baculovirus and HEK293 transduction. 
Human MRP2, MRP4 and OAT1 over-expression were performed as previously described 
(El-Sheikh et al., 2007). Briefly, the Bac-to-Bac system,
 
normally used for protein 
production in insect cells, was made
 
suitable for protein expression in mammalian cells. 
Then, the CMV promoter
 
and Gateway destination elements were introduced in the 
pFastBacDual vector.
 
The human MRP2, MRP4 and OAT1 were cloned into the Gateway 
entry vector and baculoviruses were produced as
 
described in the Bac-to-Bac manual. As a 
control, the enhanced
 
yellow fluorescent protein (EYFP) was also cloned into the gateway
 
entry vector (Invitrogen). HEK293 cells were grown until 70% confluence in 182-cm
2
 
flasks in DMEM
 
supplemented with 10% fetal calf serum at 37°C under 5%
 
CO2-
humidified air. The culture
 
medium was removed and 1.5 ml of virus and 3.5 ml of medium
 
were added. The cells were incubated for 30 min at 37°C,
 
after which 20 ml of medium was 
added. After 24 h of transduction,
 
sodium butyrate (5 mM) was added.  
Western blot of human OAT1. HEK-OAT1 and negative control cells were harvested after 
3 days of transduction. Cell pellets were re-suspended in 1 ml lysis buffer containing (per 
10 ml) 10 µl DNAse I (invitrogen) and a protease inhibitor cocktail tablet (Roche, 
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Mannheim, Germany). Lysed cells were snap-frozen in liquid nitrogen then thawed three 
times. This was followed by centrifugation at 16000g for 10 minutes. After the removal of 
the supernatant, the pellets were resuspended in lysis buffer and protein concentration 
determined and fixed to 2 mg/ml. Proteins (30 µg) were size fractionated
 
on a 7.5% SDS-
polyacrylamide gel and subsequently blotted on
 
nitrocellulose membrane. Affinity-purified, 
polyclonal rabbit serum anti-human OAT1 (1:5000) was used to detect human OAT1. The 
secondary antibody used was the fluorescent Alexa Fluor 680 (Invitrogen). Signals were 
visualized with a fluorescent method, using Odyssey infrared imaging system (Li-Cor 
Biosciences, Lincoln, USA). 
 OAT1 Cellular [
3
H]MTX Transport and Inhibition Assays. HEK-OAT1 and negative 
control cells were harvested after 2 days of transduction, and seeded in collagen pre-coated 
24-wells plates, at a density of 2 x 10
5
 cells/well. After 24 hours, the medium was removed 
and the cells were washed with 1 ml ice-cold HBSS/well (containing 1 mM CaCl2, 0.5 mM 
MgCl2, 0.4 mM MgSO4, 5 mM KCl, 0.4 mM KH2PO4, 4 mM NaHCO3, 138 mM NaCl, and 
0.3 mM Na2HPO4). The cells were then incubated in HBSS buffer containing 0.5 µM 
[
3
H]MTX with or without a range of concentrations of drugs to be tested. The transport was 
stopped after the indicated time by removing the medium and washing the cells twice with 
ice-cold HBSS buffer. Cells were lysed using 0.1% triton, vigorously vortexed for one 
minute, and centrifuged for 10 min at 16000g at 4 °C. To measure the amount of 
intracellular [
3
H]MTX, liquid scintillation radioactivity counting was performed on aliquots 
of the supernatant after adding 4 ml of scintillation fluid. Net OAT1-dependent transport 
was calculated by subtracting background values measured in control cells expressing 
EYFP. In parallel experiments, transduced cells were scraped, lysed with 0.1% triton, and 
their protein concentration was determined using Bio-Rad protein assay kit. Each 
experiment was performed in triplicate. 
Isolation of Membrane Vesicles and Protein Analysis. HEK-MRP2 and –MRP4 cells were 
harvested 3 days after transduction by centrifugation at 3000g for 30 min. The pellets
 
were 
resuspended in ice-cold homogenization buffer (0.5 mM Na2PO4, 0.1 mM EDTA, pH 7.4) 
supplemented with protease inhibitors
 
(100 µM phenylmethylsulfonyl fluoride, 5 µg/ml 
aprotinin,
 
5 µg/ml leupeptin, 1 µM pepstatin, and 1 µM
 
E-64) and shaken at 4°C for 60 min. 
Lysed cells were centrifuged
 
at 4°C at 100,000g for 30 min, and the pellets were 
homogenized
 
in ice-cold TS buffer (10 mM Tris-HEPES and 250 mM sucrose,
 
pH 7.4) 
using a tight fitting Dounce homogenizer for 30 strokes.
 
After centrifugation at 500g at 4°C 
for 20 min, the supernatant
 
was centrifuged at 4°C at 100,000g for 60 min. The resulting
 
pellet was resuspended in TS buffer and passed through a 27-gauge
 
needle 30 times. Protein 
concentration was determined by a Bio-Rad
 
protein assay kit. Crude membrane vesicles 
were dispensed in
 
aliquots, frozen in liquid nitrogen, and stored at –80°C until use. 
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MRP2 and MRP4 Vesicular Transport and Inhibition Assays. Uptake of [
3
H]MTX into 
membrane
 
vesicles was performed as described previously (El-Sheikh et al., 2008b). In 
brief, uptake of 0.5 µM [
3
H]-MTX into membrane vesicles was performed using a rapid 
filtration technique. TS buffer supplemented with a mixture of 4 mM ATP, 10 mM MgCl2 
and 0.2 mg/ml bovine serum albumin was added to the membrane vesicles in a final 
volume of 30 μl. To evaluate the inhibitory effects of different immunosuppressants on 
[
3
H]MTX uptake in MRP2 and MRP4 membrane vesicles, the transport assay was 
performed in the absence or presence of various concentrations of the drugs. The reaction 
was started by incubating the mixture at 37°C. After 15 minutes, reaction was stopped by 
placing samples on ice. After 1 minute, 150 μl ice cold TS buffer supplemented with 0.2 
mg/ml BSA was added to each reaction well. Diluted samples were filtered by a 
Multiscreen HTS-Vacuum Manifold filtration device (Millipore, Etten-Leur, the 
Netherlands) through 0.45-μm-pore 96-wells Millipore filters that were pre-incubated with 
TS buffer supplemented with 0.2 mg/ml BSA. After adding 4 ml scintillation fluid to each 
filter and subsequent liquid scintillation counting, uptake of [
3
H]-MTX into membrane 
vesicles was studied by measuring radioactivity associated to the filters. In control 
experiments, ATP was substituted with AMP. Net ATP-dependent transport was calculated 
by subtracting values measured in the presence of AMP from those measured in the 
presence of ATP. Each experiment was performed in triplicates. 
Kinetic Analysis. All data were expressed as means ±
 
S.D. IC50 values of different 
immunosuppressants tested were obtained from curve fitting
 
of the resulting concentration-
inhibition curves by nonlinear
 
regression analysis using GraphPad Prism software version 
4.03
 
(GraphPad Software Inc., San Diego, CA). One way ANOVA and Dunnett‟s multiple 
comparison were performed using the same software.  
Results  
Expression of OAT1 and [
3
H]MTX Transport Inhibition in Cells. Figure 1 demonstrates 
that, after immunoblotting of HEK-OAT1 cell lysate, OAT1 was successfully expressed 
and detected around 85 kDa (Motohashi et al., 2002). HEK293 cells over-expressing OAT1 
showed more than 3-fold higher [
3
H]MTX uptake compared to control cells. The net 
OAT1-dependent transport, calculated by subtracting background control levels, was linear 
up to 5 min (Fig. 2a). OAT1 cells were then incubated with 0.5 µM [
3
H]MTX in the 
presence or absence of 10 µM of different immunosuppressants for 5 min. Our results 
showed that, at this concentration, cyclophosphamide stimulated, whereas mycophenolic 
acid, mitoxantrone, cytarabine, hydrocortisone, vinblastine and vincristine significantly 
inhibited OAT1-mediated [
3
H]MTX transport (Fig. 2b). Furthermore, cyclosporine A, 
azathioprine, 6-mercaptopurine, tacrolimus, and dexamethasone had no effect on OAT1-
mediated [
3
H]MTX transport. 
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Fig. 1: Western blot and [3H]MTX transport activity 
in HEK-OAT1 cells. Upper panel: HEK-OAT1 cell 
lysate (50 µg) was fractionized on 7.5% SDS/PAGE 
gel and an OAT1 specific band was detected around 
85 kDa. Lower panel: Incubating HEK-OAT1 or 
control cells with 0.5 µM [3H]MTX shows more than 
3-fold higher uptake in OAT1 compared to control 
cells.  
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Fig. 2: Time-dependent transport and effect of different immuno-suppressants on [3H]MTX transport 
in HEK-OAT1 cells. A: HEK-OAT1 or control cells were incubated with 0.5 µM [3H]MTX for the 
indicated time, and net OAT1-dependent transport was calculated by subtracting the background 
control levels. B: Net transport of 0.5 µM [3H]MTX in absence of drugs tested was set to 100% 
(represented in the figure by Control) and was compared with transport of [3H]MTX in the presence 
of different immune-suppressants (10 µM). 
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Effect of Immunosuppressants on MRP2- and MRP4-mediated [
3
H]MTX Transport. To 
screen for interactions of different immunosuppressants with human MRP2- and MRP4-
mediated [
3
H]MTX transport, membrane vesicles isolated from HEK293 cells over-
expressing MRP2 or MRP4 were incubated with 0.5 µM [
3
H]MTX in the presence or 
absence of a range of concentrations of drugs to be tested. The incubation was conducted at 
37 °C for 15 minutes, which we previously found to be within the linear part of time-
dependent MTX uptake (El-Sheikh et al., 2007). Various drugs interacted differently with 
MRP2 and MRP4; eliciting inhibition, stimulation, or no effect on [
3
H]MTX transport (Fig. 
3). The IC50 values are summarized in table 1. Cytarabine and azathioprine were the only 
two drugs tested to show no effect on both MRP2- and MRP4-mediated [
3
H]MTX 
transport. Interestingly, 6-mercaptopurine, the active metabolite of azathioprine, inhibited 
MRP4- and had no effect on MRP2-mediated transport. Similarly, both vinblastine and 
vincristine inhibited MRP2 transportbut had no effect on MRP4. Nevertheless, the 
inhibitory pattern elicited by vinblastine followed a two-binding site model. Cyclosporine 
A exerted its inhibitory effects only on MRP2- and had no effect on MRP4-mediated 
transport, while tacrolimus, another calcineurin inhibitor, inhibited both MRP2 and MRP4 
with almost an identical pattern and IC50 value. Mycophenolic acid, cyclophosphamide and 
hydrocortisone also inhibited both transporters, but with an inhibitory pattern according to a 
two-site inhibition model. Mitoxantrone and dexamethasone stimulated MRP2 transport up 
to 190 ± 30 and 170 ± 20 % and MRP4 up to 144 ± 3 and 140 ± 3 %, respectively (n=3).  
Discussion 
We have previously investigated the role of MRP2 and MRP4 in the clinically reported 
interaction between MTX and non-steroidal anti-inflammatory drugs, and from these 
results we suggested that both transporters may have allosteric binding sites (El-Sheikh et 
al., 2007).  Here, we studied the interaction of different immunosuppressant drugs with 
[
3
H]MTX, which is a common substrate of OAT1 (Takeda et al., 2002), MRP2 (Masuda et 
al., 1997) and MRP4 (Chen et al., 2002). Our results show that several immunosuppressants 
interact with these renal transporters. Furthermore, the inhibitory effect of mycophenolic 
acid, cyclophosphamide and hydrocortisone on both MRP2 and MRP4, and that of 
vinblastine on MRP2 could be described best according to a two-site binding model.  
Mycophenolic acid potently interacted with all three transporters. This drug is mainly 
excreted into urine as its inactive 7-hydroxy-glucuronide metabolite (Staatz and Tett, 2007). 
Previous studies showed that mycophenolic acid or its glucuronide interacted with OAT1 
and MRP2 by inhibiting p-aminohippurate transport (Wolff et al., 2007;Takekuma et al., 
2007). Studies in rats suggested that mycophenolic acid may also be a substrate of Mrp2 
(Hesselink et al., 2005;Kobayashi et al., 2004;Westley et al., 2006), whereas the interaction 
with MRP4 has not been studied before. Cyclosporine A, in the present study, inhibited 
MRP2-mediated transport, but had no effect on OAT1 and MRP4.  
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Fig. 3: Effect of immunosuppressant drugs on MRP2- and MRP4-mediated [3H]-MTX uptake in 
membrane vesicles. Membrane vesicles over-expressing MRP2 (■) or MRP4 (○) were incubated with 
0.5 µM [3H]-MTX at 37°C for 15 minutes, in the absence or presence of different concentrations of 
the immunosuppressants tested. Uptake was measured by subtracting the background (AMP) from the 
ATP-dependent uptake. Respective transport rates were expressed as a percentage of uptake 
measured in the absence of the drug tested against the log drug concentration.  
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(Continue Fig. 3): Effect of immunosuppressant drugs on MRP2- and MRP4-mediated [3H]-MTX 
uptake in membrane vesicles.  
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Table 1: IC50 values of various immunosuppressants tested on MRP2- and MRP4-mediated 
[
3
H]MTX transport.  
 IC50 values (μM) 
 MRP2-mediated transport MRP4-mediated transport 
Mycophenolic acid 65x10-3 
200 
± 
± 
1x10-3 (H) 
3 (L) 
2.15 x10-3 
8.59 
± 0.01 x10-3 (H) 
0.03 (L)  
Cyclosporine A 41 ± 1                     n.i. 
Tacrolimus 15.2 ± 0.1 15.5 ± 0.1 
6-Mercaptopurine                    n.i. 10.7 ± 0.3 
Azathioprine                    n.i.                     n.i. 
Cytarabine                    n.i.                     n.i. 
Vinblastine 26 x10-3 
251 
± 
± 
1 x10-3 (H) 
5 (L) 
                    n.i. 
Vincristine 932 ± 43                     n.i. 
Cyclophosphamide 3.5 x10-3 
41 
± 
± 
0.1 x10-3 (H) 
2 (L) 
4.5 x10-3 
22 
± 
± 
0.4 x10-3 (H) 
1 (L) 
Hydrocortisone 3.9x10-3 
788 
± 
± 
0.1 x10-3 (H) 
53 (L) 
0.7 x10-3 
53 
± 
± 
0.1 x10-3 (H) 
1 (L) 
Dexamethasone§                   n.i.                     n.i. 
Mitoxantrone§                   n.i.                     n.i. 
 
Membrane vesicles were incubated with 0.5 μM [3H]MTX at 37°C for 15 minutes, in the absence or 
presence of different concentrations of the drugs tested. [3H]MTX transport was measured by 
subtracting the background (AMP) from the ATP-dependent uptake. Each value represents the 
mean ± S.D. of data obtained from three experiments, each performed in triplicate, calculated by 
non-linear regression analysis of the data from figures 3 and 4. High (H) and low (L) affinity IC50 
determined according to a two-site competition model.  n.i. = no inhibition. § Stimulation of MRP2-
mediated [3H]MTX transport by 170 ± 20 and 190 ± 30% and of MRP4-mediated MTX transport by 
140 ± 3 and 144 ± 3% by dexamethasone and mitoxantrone, respectively. 
Cyclosporine A is often concomitantly used with mycophenolic acid to treat solid organ 
transplantation rejection, and is known to alter mycophenolic acid serum levels (Staatz and 
Tett, 2007). Here, both cyclosporine A and mycophenolic acid inhibited MRP2-mediated 
transport, suggesting the possibility of a similar interaction at the renal level. This is in 
agreement with previous animal studies suggesting that cyclosporine A inhibits 
mycophenolic acid biliary excretion via interaction with hepatic rat Mrp2 (Hesselink et al., 
2005;Westley et al., 2006). Tacrolimus inhibited both MRP2 and MRP4 transport. The 
inhibitory effect of 10 µM tacrolimus on OAT1 was not statistically significant. Tacrolimus 
is another calcineurin inhibitor that may be concomitantly given to patients treated with 
mycophenolic acid. The presence of a clinical interaction between mycophenolic acid and 
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tacrolimus is still controversial (Brown et al., 2002;Hohage et al., 2005;Kagaya et al., 
2008). Here, tacrolimus and mycophenolic acid inhibited both MRP2- and MRP4-mediated 
transport, suggesting a possible interaction. Nevertheless, since mycophenolic acid is 
excreted mainly in urine in the glucuronide form, the interaction of this glucuronide with 
MRP2 and MRP4 needs further investigation. 
In the present study, 6-mercaptopurine inhibited MRP4-mediated transport, but had no 
effect on OAT1 or MRP2. This is in agreement with previous studies implicating MRP4 in 
chemotherapeutic resistance of 6-mercaptopurine (Chen et al., 2001), as well as in its renal 
efflux (Wielinga et al., 2002). The prodrug azathioprine is the imidazolyl derivative of the 
immunosuppressant 6-mercaptopurine. Interestingly, azathioprine had no effect on either 
OAT1-, MRP2-, or MRP4-mediated transport. Addition of an imidazole side chain to 6-
mercaptopurine apparently changes its inhibitory specificity for MRP4.  
Vinblastine and vincristine are antimicrotubule vinca alkaloids. Here, we show that both 
drugs inhibited OAT1- and MRP2- but had no effect on MRP4-mediated transport, 
suggesting their possible interference with renal secretion of common OAT1 and MRP2 
substrates. Our group previously showed that vinblastine is an Mrp2 substrate in the 
presence of reduced glutathione and that it inhibited rabbit Mrp2-mediated leukotriene C4 
transport (van Aubel et al., 1999). Recently, it has been shown that human MRP2 may 
accept vinblastine as a substrate as well (Zimmermann et al., 2008). Previous studies 
suggested that MRP2 confers resistance to vinblastine and vincristine cytotoxicity (Cui et 
al., 1999;van Zanden et al., 2005;Huang et al., 2008). However, there was no correlation 
between cellular cytotoxic resistance to vinblastine and vincristine and the level of MRP2 
expression in renal cancer cell lines (Ferguson et al., 2005), adding to the doubts about the 
clinical relevancy of these in vitro cytotoxicity studies (Steinbach et al., 2005).  
Cyclophosphamide and MTX are given concomitantly with the cytotoxic drug 5-
fluorouracil during the so-called “CMF” chemotherapy of breast cancer (Fojo and Coley, 
2007). Nearly 70% of the immunosuppressant drug cyclophosphamide is excreted in urine, 
which may be affected by renal function alterations (Zhang et al., 2005). It has been shown 
previously that MRP4 confers resistance to cyclophosphamide cytotoxic effects (Tian et al., 
2005). Here, we show that cyclophosphamide significantly stimulated MTX transport via 
OAT1, while it inhibited both MRP2- and MRP4-mediated transport. This combination of 
events may result in renal accumulation of MTX and may contribute to renal adverse 
effects. The in vivo implications of this finding need further investigation.  
Dexamethasone was shown to stimulate the rat biliary excretion of Mrp2 substrates, 
including glutathione, taurolithocholate sulphate and sulfobromophthalein (Suzuki et al., 
2003). This effect has been attributed to an up-regulation of Mrp2 by dexamethasone 
(Courtois et al., 1999;Turncliff et al., 2004). Here, dexamethasone stimulated both MRP2- 
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and MRP4-mediated transport directly, suggesting a novel mechanism by which this drug 
may enhance substrate transport. 
It should be noted that OAT3 is another basolateral transporter involved in renal uptake 
of MTX. In fact, MTX has more than 26-fold higher affinity to OAT3 than OAT1 (Takeda 
et al., 2002). In addition, studies indicated that other immunosuppressants possibly interact 
with OAT3, including 6-mercaptopurine (Mori et al., 2004) and mycophenolic acid (Wolff 
et al., 2007). In this study, we tried to express OAT3 as well in HEK293 cells. 
Unfortunately, until now we were unsuccessful in detecting any OAT3 expression or 
transport activity and we are in the process of further optimizing the transduction 
procedure. Clearly, to get a complete picture of renal immunosuppressant uptake via 
basolateral organic anion transporters, their interaction with OAT3 should be investigated 
in future experiments.  
In summary, this study provides evidence that immunosuppressant drugs can modulate 
OAT1-, MRP2-, and MRP4-mediated transport of MTX, contributing to the overall renal 
mechanisms of immunosuppressant drug interactions.  
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Summary 
Mycophenolic acid (MPA) is one of the immunosuppressant drugs of choice in 
treatment of organ transplantation rejection. Concomitantly administered 
immunosuppressants like cyclosporine (CsA), but not tacrolimus (Tac), are known to alter 
MPA serum levels. MPA is excreted in urine mainly as glucuronide metabolite (MPAG). 
Here, we investigated the role of efflux transporters in renal MPA excretion and drug 
interactions using isolated perfused kidney from TR
-
 rats deficient in multidrug resistance 
protein (Mrp) 2 and HEK293 cells over-expressing human MRP2 and MRP4. In rat kidney, 
MPA was conjugated to MPAG, which was excreted significantly less in TR
-
 compared to 
wild-type rats. CsA, but not Tac, inhibited renal MPAG excretion. We also identified MPA 
as a substrate of both human MRP2 and MRP4, whereas MPAG appeared to be only a 
substrate of MRP2. CsA inhibited MPAG transport via human MRP2, while Tac had no 
effect. Furthermore, CsA, but not Tac, inhibited MPA glucuronidation by kidney 
homogenates of both wild-type and TR
- 
rats, as well as by human UDP-glucuronosyl 
transferase 1A9. We conclude that MRP2 is the main human renal transporter involved in 
MPAG renal excretion. CsA, but not Tac, inhibits renal MPA glucuronidation and MRP2-
mediated MPAG secretion. 
Introduction 
Mycophenolic acid (MPA) is the active moiety of the immunosuppressant pro-drug 
mycophenolate mofetil (MMF), which is administered alone or concomitantly with other 
drugs like the calcineurin inhibitors cyclosporine A (CsA) or tacrolimus (Tac) to prevent 
solid organ transplant rejection (Shipkova et al., 2005). Unfortunately, the use of 
calcineurin inhibitors is often associated with iatrogenic nephrotoxicity. MMF may 
improve the calcineurin-induced deterioration of renal function (Flechner et al., 2008). 
Furthermore, due to its immune-modulating, anti-fibrotic and anti-proliferative effects, 
MMF is prescribed to non-transplant patients to treat several immunologically-mediated 
renal diseases (Stassen et al., 2007). 
MPA is subjected to phase II metabolism in several organs including liver, intestine, 
and kidney, where it is conjugated to form its main inactive metabolite 7-hydroxy-
glucuronide mycophenolic acid (MPAG) via uridine diphospho-glucuronosyl transferase 
(UGT) enzymes (Shipkova et al., 2001). In addition, some minor metabolites, including 
acyl-glucuronide, 7-O-glucoside, and acyl-glucoside are produced (Shipkova et al., 2005). 
The former is the only metabolite that retains some in vitro immunosuppressive activity. 
MPAG, the major MPA metabolite, may reach up to 100-fold higher concentrations than its 
parent drug in plasma (Elbarbry and Shoker, 2007), with 82% bound to plasma albumin 
(Shipkova et al., 2005). MPAG is actively secreted into the bile to the intestine, where it is 
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de-conjugated back to MPA by bacterial β–glucuronidase, and reabsorbed from the colon. 
Enterohepatic recycling of MPAG contributes to nearly 40% of MPA exposure, and results 
in a secondary MPA peak observed 8-12 hours after MMF administration (Staatz and Tett, 
2007). When MMF is given in combination with CsA, the second peak of MPA is 
diminished (Filler et al., 2001), and nearly double the dose of MMF is needed to achieve 
similar MPA levels to that when MPA is administered alone or in combination with Tac 
(Staatz and Tett, 2007). As a possible mechanism for a such pharmacokinetic interaction, 
several studies suggested that CsA interferes with the biliary excretion of MPAG (van 
Gelder et al., 2001.,Deters et al., 2005), possibly via inhibiting MPAG active transport by 
hepatic multidrug resistance protein (MRP) 2 (Kobayashi et al., 2004.,Westley et al., 
2006.,Hesselink et al., 2005).  
The kidney is the main organ for MPA elimination. About 95% of the administered 
MMF is recovered in urine almost exclusively as MPAG, with only less than 1% as MPA 
(Shipkova et al., 2005). Severe renal impairment in patients using MMF results in up to 6-
fold decrease in MPAG plasma clearance (Staatz and Tett, 2007). In the kidney, MPA and 
MPAG are subjected to filtration and active secretion. After active uptake of MPA and 
MPAG from blood into the proximal tubule cells via basolateral transporters, MPAG is 
actively pumped into the urine via apical transporters. MPA and MPAG interact with 
basolateral human renal organic anion transporters (OAT) 1 and 3 (Takekuma et al., 
2007.,Wolff et al., 2007). Furthermore, human OAT3 is involved in direct uptake of MPAG 
from blood into renal proximal tubule cells as a first step of active secretion (Uwai et al., 
2007). The second step involves urinary excretion. At the renal apical membrane, MRP2 
and MRP4 are involved in active renal secretion of a wide range of clinically important 
drugs (El-Sheikh et al., 2008.,Russel et al., 2008). However, to date, their contribution to 
the renal elimination of MPA and MPAG is not yet elucidated. Furthermore, the possible 
effect of calcineurin inhibitors on renal MPAG excretion is not clarified.  
Here, using HEK293 cells over-expressing human MRP2 and MRP4, we identified 
MPA as a substrate of both transporters, and MPAG as a substrate of human MRP2. We 
also demonstrate the inhibitory effect of CsA on human MRP2-mediated MPAG transport 
and UGT1A9-mediated MPA glucuronidation. Furthermore, the role of Mrp2 in renal 
MPAG excretion is characterized at the organ level, using isolated perfused kidneys from 
TR
-
 rats deficient in Mrp2. We also show that CsA, but not Tac, inhibits renal secretion of 
MPAG via combined inhibition of Mrp2-mediated MPAG transport as well as inhibition of 
renal MPA glucuronidation.   
Materials and Methods 
Materials. MPA, uridine 5‟-diphosphoglucuronic acid (UDPGA)-trisodium salt, (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), CsA, and Tac were 
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purchased from Sigma-Aldrich (St. Louis, MO, USA). MPAG used as a standard was 
kindly supplied by Roche Palo Alto (CA, USA). MPAG was also produced in our lab using 
recombinant human uridine diphosphoglucuronic acid glucuronosyltransferase 1A9 
(UGT1A9) enzyme (BD Biosciences, Woburn, USA) and its purity was confirmed using 
HPLC (see below).   
Culture and Transfection of HEK293 Cells. Generation of baculoviruses of human MRP2 
and MRP4, as well as the enhanced yellow fluorescent protein (EYFP; negative control) 
was performed as previously described (El-Sheikh et al., 2007). HEK293 cells were 
cultured in 182-cm
2
 flasks containing DMEM supplemented with 10% fetal calf serum at 
37°C under 5% CO2-humidified air until 70% confluence. To transfect HEK293 cells with 
baculovirus, the medium was replaced by a mixture of 1.5 ml of virus and 3.5 ml of 
medium. The cells were then incubated for 30 min at 37°C, after which 20 ml of medium 
was added. Sodium butyrate (5mM) was added after 24 h of transduction.  
Transport and Inhibition Assays in MRP2 and MRP4 Cells. MRP2, MRP4, and control 
cells were harvested after 2 days of transfection, and seeded in collagen pre-coated 24-wells 
plates, at a density of 2 x 10
5
 cells/well. After 24 hours, the plates were incubated on ice for 
one hour with a range of concentrations or combinations of drugs to be tested (either MPA 
or MPAG with or without CsA or Tac as indicated). To measure intracellular drug 
concentrations, cells were lysed using 0.1% triton, vigorously vortexed for one minute, 
centrifuged for 10 min at 16000g at 4 °C, and aliquots of the supernatant were injected onto 
the HPLC column. Parallel experiments to test the efflux step were performed, in which 
efflux was started by adding 300 μl of HBSS efflux medium/well and incubating the cells at 
37 °C. For time-dependent transport studies, cells were incubated in efflux medium for 15 
sec, 1, 2, 5, and 10 min. Where applicable, incubations were 5 min for MPA and 2 min for 
MPAG, where reaction rates were proven to be linear. The efflux medium was then 
removed, centrifuged for 10 min at 16,000g at 4 °C, and aliquots of the supernatant were 
injected onto the high performance liquid chromatography (HPLC) column. Net MRP2- or 
MRP4-dependent transport was calculated by subtracting background values measured in 
control cells. 
Cytotoxicity MTT Assays. MTT cytotoxicity assays were performed to measure the effect 
of MPA and its combination with either CsA or Tac on cell survival as previously 
described (Mosmann, 1983). Briefly, HEK cells transfected with EYFP, MRP2, or MRP4 
were harvested after 2 days of transfection, and seeded in collagen pre-coated 96-wells 
plates, at a density of 2.5 x 10
4
 cells/well. After 24 hours, MPA was added in different 
concentrations, with or without 10 µM of either CsA or Tac. Parallel experiments were 
performed using 100 µM vinblastine to produce maximum toxicity to cells or treated with 
no drug to provide a positive control. In addition, experiments in which 10 µM of either 
CsA or Tac were incubated without MPA were performed. After 24, 48 or 72 hours, cells 
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were treated with 2 mg/ml MTT. The formazan crystals formed were dissolved in 200 µl of 
dimethyl sulfoxide after 4 hours. The plates were measured immediately at 560 nm with a 
96-well plate reader (Bio-Rad Benchmark Plus microplate spectrophotometer). The cell 
number was recorded as optical density and cell survival was calculated according to the 
following equation: Survival (%) = [(sample absorbance – Vb absorbance) / (positive 
control absorbance – Vb absorbance)] X 100, where Vb absorbance is the maximum cell 
death due to vinblastine. 
Animal Experiments. All rats, weighing 220-290 g, were housed under pathogen-free 
routine laboratory conditions at the Central Animal facility of the Radboud University 
Nijmegen Medical Centre at least 1 week before experiments, with free access to standard 
laboratory chow and water. Male Wistar Hannover rats were obtained from Harlan, Zeist, 
the Netherlands and TR
-
 rats were bred in Nijmegen (Masereeuw et al., 2003). All 
experimental procedures were approved by the local Animal Care Committee. Rat kidney 
isolation and perfusion was performed as previously described (Heemskerk et al., 2008). 
After the right kidney was excised for perfusion experiments, rats were sacrificed, 
subsequently the left kidney was removed, snap-frozen in liquid nitrogen, and stored at -80 
°C for rat kidney homogenate experiments. Perfusion experiments were started by the 
addition of MPA or MPAG, with or without either CsA or Tac, which remained in the 
perfusion fluid during the rest of the experimental period (150 min). Urine and perfusion 
medium samples were collected during control and experimental periods over 10 min 
intervals. MPA and MPAG levels in all samples were determined using HPLC. For the 
determination of the glomerular filtration rate (GFR), 20 mg/l cyanocobalamin was added 
to the perfusion fluid, and its concentrations in perfusion medium and urine samples were 
determined colorimetrically directly after the experiment by means of spectrophotometry.  
In vitro glucuronidation of MPA by rat kidney homogenates and recombinant human 
UGT1A9 Enzyme. Renal MPAG formation in WH and TR
- 
rats was tested by using kidney 
homogenates. Kidneys of 3 different animals per group were weighed and homogenized 
25% (w/v) in ice cold HEPES/KCl/MgCl2 buffer pH 7.4 (50, 150, and 5 mM, respectively). 
After centrifugation of the homogenate at 2500g for 10 min at 4ºC, the protein 
concentration of the supernatant was determined, and was fixed to 5 mg/ml. Homogenates 
were then used for testing MPAG formation by incubation  with 1 mg/ml MPA and 5 mM 
of UDPGA for 15 min at 37ºC. To test the effect on human renal UGT, recombinant 
UGT1A9 (250 µg/ml in 0.1M Tris pH 7.5) replaced the rat kidney homogenate. For MPAG 
production, UGT1A9 was used under the same experimental conditions, but was incubated 
for 90 minutes. Parallel experiments were performed, where either CsA or Tac were added 
in a concentration of 80 µM. The reaction was stopped by centrifugation at 16,000g for 10 
min at 4ºC. Supernatant was measured using HPLC.  
 
  
 
 
 
Chapter 5 
 
 
80 
 
Quantification of MPA and MPAG using HPLC. MPA and MPAG were simultaneously 
measured using ion-paired reversed-phase HPLC with an ultraviolet detector set at 254 nm. 
The HPLC consisted of a P2000 pump, an AS3000 auto-sampler with a Pull-loop injection 
system, and a UV1000 detector (Thermo-Separation Products). Compounds were separated 
on a Chromolith performance RP-18e column (100 x 4.6 mm, Merck, Darmstadt, 
Germany). The temperature of the column was regulated at 40°C and the injection volume 
was 30 µl. The mobile phase composition was 5 mM K2HPO4 with 10 mM tetrabutyl 
ammonium hydrogen sulphate buffer adjusted to pH 7, and mixed with methanol (25% in 
buffer A and 50% in buffer B). The gradient program was: 0 min, 20% buffer B; 0-5 min, 
20-100% buffer B; 5-10 min, 100% buffer B, with a flow rate of 1 ml/min. The gradient 
was then immediately returned to 20% buffer B and the initial conditions were restored in 5 
min. MPAG and MPA eluted at 5 and 9 min, respectively. Calibration curves were 
performed in a concentration range of 0.125-5 µg/ml MPA and 0.3-5 µg/ml MPAG, with ≥ 
0.99 correlation coefficients for both standard curves. The detection limits were 0.05 µg/ml 
for MPA and 0.1 µg/ml for MPAG. 
Kinetic Analysis. All data were expressed as means ± S.D. The concentration that resulted 
in 50% reduction in cell survival (IC50 value) was determined from curve fitting of the 
resulting % survival by nonlinear regression analysis using GraphPad Prism software 
version 4.03 (GraphPad Software Inc., San Diego, CA). One way ANOVA, Dunnett‟s 
multiple comparison, and extra sum-of-squares F test for model comparison were 
performed using the same software.  
Results 
Transport of MPA and MPAG in MRP2- and MRP4-expressing cells. To investigate 
MPA and MPAG as possible candidate substrates for human MRP2 and MRP4, HEK cells 
over-expressing these transporters and EYFP as a control were pre-incubated with 100 µM 
MPA. HEK cells did not metabolize MPA, and no MPA metabolites were formed either 
intracellularly or seen in the efflux medium (data not shown). This is in line with absence 
of expression of MPA metabolizing enzyme UGT1A9 (Nakamura et al., 2008). Both MRP2 
and MRP4 cells mediated MPA efflux significantly higher than control cells (results not 
shown). MPA efflux showed time-dependent linearity up to 5 min for both MRP2 and 
MRP4 (figure 1A). Incubation of control, MRP2, and MRP4 cells with MPA at 4 °C 
indicates that MPA was taken up to a similar extent in all cells. To test the kinetics of MPA 
transport, the average intracellular MPA concentrations were plotted against the efflux rate, 
and the results show that MRP2 transported MPA with a Km value of 16 ± 4 µM and Vmax 
of 4.7 ± 0.7 µmol/min (figure 1B). MRP4 had less affinity for MPA, and the calculated Km 
value of 30 ± 15 µM was only a rough estimate, because it exceeds the highest intracellular 
concentration attained. MPAG appeared to be a substrate of MRP2 and not of MRP4. 
MPAG showed linear time-dependent efflux up to 2 min (figure 2A). Although it was 
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technically impossible to measure intracellular MPAG concentrations, clear MPAG efflux 
could be determined after loading MRP2, MRP4 and control cells with 10, 100, and 1000 
µM of MPAG. No significant difference between MRP4 cellular efflux and control 
background was found (figure 2B). On the other hand, significantly higher MPAG efflux 
rates were found in MRP2 over-expressing cells compared to control. 
Fig. 1: Time- and concentration-
dependent  efflux of MPA in MRP2 
and MRP4 cells. A: Efflux of MPA 
from HEK-MRP2 and -MRP4 cells, 
pre-incubated with 100 µM of the 
drug for one hour at 4 °C, was tested 
by incubation with HBSS efflux 
medium for 15 sec, 1, 2, 5, and 10 
min at 37°C. Background efflux from 
control cells was deducted and the 
resulting transporter-dependent efflux 
levels were linear up to 5 min for 
both MRP2 (●) and MRP4 (□). B: 
After pre-incubating control, MRP2 
and MRP4 cells with different 
concentrations of MPA at 4 °C for 
one hour, the average intracellular 
concentrations were assessed. Efflux 
levels at the same concentrations 
were tested by incubating the cells 
with HBSS efflux medium at 37°C for 
5 min and correcting for the 
background control levels. 
Intracellular concentrations were 
then plotted against the efflux levels. 
 
Effect of CsA and Tac on MPA and MPAG transport. To test the effect of CsA and Tac 
on MPA transport, MRP2 and MRP4 cells, as well as control cells were incubated with 50 
µM MPA with or without 1 or 8 µM of either CsA or Tac. CsA significantly inhibited 
MRP2-mediated MPA transport in both concentrations, but had no effect on MRP4. On the 
other hand, Tac inhibited MPA transport by both proteins only at the highest concentration 
(figure 3A). To test the effect of CsA and Tac on MPAG transport, MRP2 and control cells 
were incubated with 100 µM MPAG with or without 1 or 8 µM of CsA or Tac. CsA 
inhibited MRP2-mediated MPAG transport at both concentrations tested, while Tac had no 
effect (figure 3B). 
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Fig. 2: Efflux of MPAG from HEK-MRP2 
cells. A: MPAG efflux from MRP2 and 
control cells, pre-incubated with 100 µM of 
the metabolite at 4°C for one hour, was tested 
at 0, 15, 30 sec, 1, 2, and 5 min, and results 
were corrected for the background control 
levels. MRP2-dependent MPAG efflux was 
linear up to 2 min. B: After pre-incubating 
control (white bars), MRP2 (black bars) and 
MRP4 (grey bars) cells with 10, 100 and 
1000 µM MPAG, MPAG efflux was 
determined after incubating the cells with 
HBSS efflux medium at 37°C for 2 min. 
MRP2 cells showed significantly higher efflux 
compared to control cells and the efflux 
increased dose-dependently, while MRP4 
cellular efflux was not significantly difference 
from control (*P<0.05). 
 
 
 
 
 
 
Figure 3. Effect of CsA and Tac on MPA 
and MPAG efflux. A: MRP2 (black bars), 
MRP4 (grey bars) and control (white bars) 
cells were pre-incubated with 50 µM MPA 
with or without 1 or 8 µM of either CsA or 
Tac. MPA efflux was tested by incubating the 
cells with efflux medium for 5 min at 37°C. 
CsA significantly inhibited MRP2-mediated 
MPA efflux dose-dependently, while it had 
no effect on MRP4. Tac significantly 
inhibited MPA efflux by both transporters 
only at higher concentrations. B: MRP2 and 
control cells were pre-incubated with 100 µM 
MPAG with or without 1 or 8 µM of CsA or 
Tac. CsA inhibited, while Tac did not inhibit, 
MRP2-mediated MPAG transport (*P<0.01).  
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Potentiation of MPA cytotoxicity by CsA and Tac in MRP2 and MRP4 cells. We 
determined the cytotoxicity of MPA alone or in combination with CsA or Tac on HEK cells 
over-expressing MRP2 or MRP4, using an MTT cytotoxicity assay. First we tested the 
cytotoxic effect of MPA alone after 24, 48 and 72 hours. Our preliminary results indicated 
that MPA has dose- and time-dependent cytoxic effects on control cells, which is 
significantly reversed with either MRP2 or MRP4 over-expressions, and most pronounced 
after 72 hours (results not shown). Next, we tested the effect of either CsA or Tac alone on 
either MRP2- or MRP4-transfected cells. We found that the survival rates of these cells 
treated with 10 µM of either CsA or Tac for 72 hours were higher than 90% (results not 
shown). When the cells were subjected to a range of MPA concentrations, in combination 
with 10 µM of either CsA or Tac, MPA cytotoxicity was significantly potentiated by both 
drugs, with CsA having a significantly higher potency in MRP2 cells, and Tac in MRP4 
cells (figure 4). The kinetic analyses are shown in table 1. 
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Fig. 4: Effect of MPA alone or with either CsA or Tac on MRP2 and MRP4 cells viability determined 
by MTT cytotoxicity assay. MRP2 (A) and MRP4 (B) cells were incubated with different 
concentrations of MPA alone (□) or with 10 µM of either CsA (○) or Tac (●). After 72 hours, the 
survival of cells was determined using the MTT assay. Results were analyzed by non-linear 
regression and IC50 values were calculated which are summarized in table 1. 
 
Table 1: Effect of MPA alone or in combination with CsA or Tac on cytotoxicity in MRP2 and 
MRP4 cells. 
IC50 (μM) 
 MPA  MPA and CsA MPA and Tac 
MRP2 12.2 ± 0.3 1.33* # ± 0.01 9.4* ± 0.1 
MRP4 5.4 ± 0.1 1.79* ± 0.05 0.84*§ ± 0.01 
Cytotoxicity studies were performed and the IC50 values (mean ± SD, n=3 independent experiments) 
were calculated as described in “Materials and Methods” section. *P < 0.001 compared to MPA 
alone. #P < 0.001 compared to MPA in combination with Tac. §P < 0.001 compared to MPA in 
combination with CsA (P < 0.001). 
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Renal excretion and drug interactions of MPA and MPAG in perfused rat kidneys. To 
test the role of Mrp2 and the effect of CsA and Tac on renal excretion of MPA, WH and 
TR
-
 rat kidneys were perfused with MPA or MPAG with or without CsA or Tac. The renal 
functional parameters, including glomerular filtration rate (GFR), urine flow, fractional 
water reabsorption and renal perfusion pressure showed no significant differences between 
all groups (Table 2) and were comparable to our previous studies (Masereeuw et al., 2003). 
Rat kidneys were perfused with 10 µg/ml MPA, and urine samples were taken every 10 min 
for 150 min. MPA was cleared from the perfusion medium, which was not significantly 
different between WH and TR
-
 rat kidneys (figure 5A). Interestingly, rat kidneys 
conjugated MPA, and MPAG appearing in the perfusion medium was significantly higher 
in TR
-
 rat kidneys compared to WH rats. In urine samples, only MPAG was excreted 
without any trace of MPA or any other MPA metabolites, including the acid glucuronide. 
MPAG urinary excretion was significantly higher in WH rat kidneys than in that of TR
-
 rats 
deficient in Mrp2 (figure 5B). To test the effect of CsA and Tac on MPA excretion, kidneys 
were perfused with 10 µg/ml MPA with or without either 5 mg/L CsA or 100 µg/L Tac. 
Urinary MPAG excretion was significantly lower with CsA in both WH and TR
-
 rat 
kidneys, and was not affected by Tac (figure 6). Preliminary experiments in which rat 
kidneys were perfused with 8 µg/ml MPAG, showed lower average excretion rates in TR
-
 
compared to WH determined over a period of 30-120 min (MPAG clearance/GFR = 0.39 ± 
0.07 vs 0.55 ± 0.07, respectively; n = 2). Addition of CsA inhibited MPAG renal excretion 
in WH rats (0.44 ± 0.23; n=2). 
Table 2: Functional parameters of isolated perfused kidneys#.  
 Diuresis  
(μl.min-1) 
GFR  
(μl.min-1) 
FRwater  
(%) 
RPP  
(mmHg) 
WH + MPA 23 ± 2 301 ± 21 92 ± 1 73 ± 5 
TR- + MPA 28 ± 6 375 ± 58 92 ± 3 73 ± 6 
WH + MPA CsA 19 ± 3 295 ± 33 93 ± 1 80 ± 5 
TR- + MPA CsA 19 ± 3 284 ± 50 93 ± 2 80 ± 7 
WH + MPA Tac 24 ± 1 299 ± 43 92 ± 1 73 ± 3 
TR- + MPA Tac 25 ± 6 346 ± 40 93 ± 3 75 ± 6 
All functional parameters showed no statistically significant differences between the tested groups. 
#Values represented are means ± SD of all perfused kidneys included in the experiments (n= 4 to 6) 
over a period of 30 to 120 min after the addition of indicated drugs. GFR, glomerular filtration rate; 
FRwater, fractional water reabsorption; RPP, renal perfusion pressure.  
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Fig. 5: Renal handling of MPA in WH and TR- rat 
kidneys. MPA in a concentration of 10 µg/ml was 
added to perfusion medium of kidneys isolated 
from WH control and TR- rats deficient in Mrp2. 
A: The disappearance of MPA from the perfusate 
medium was measured, and showed no significant 
difference between TR- () and WH (▼) rats. On 
the other hand, the appearance of MPAG in the 
perfusion medium was significantly higher in TR- 
(□) than WH control rats (■) (*P<0.05).  B: the 
ratio of renal clearance of MPAG divided by GFR 
was plotted as a function of time, and showed 
significantly lower levels in TR- (□) than WH (■) 
rats (*P<0.001). Values above 1 (the dashed line) 
represent net tubular secretion of MPAG. 
 
 
 
 
Fig. 6: Effect of CsA and Tac on MPAG renal 
excretion in WH and TR- rat kidneys. MPA in a 
concentration of 10 µg/ml alone or in 
combination with 5 mg/L CsA or 100 µg/L Tac 
were added to the perfusion medium of kidneys 
isolated from WH control and TR- rats deficient in 
Mrp2. Renal excretion of MPAG was plotted as a 
function of time. In WH (upper panel) as well as 
in TR- rats (lower panel), CsA (▼), but not Tac 
(○), significantly inhibited renal MPAG excretion 
compared to MPA alone (■) (*P<0.01; 
**P<0.05). 
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Effect of CsA and Tac on MPA glucuronidation by rat kidney homogenates and human 
UGT1A9. Incubation of rat kidney homogenates with MPA in the presence of the cofactor 
UDPGA showed no significant difference in MPAG produced in both WH and TR
-
 samples 
(98 ± 7 and 99 ± 8 µM, respectively). Addition of CsA significantly inhibited kidney 
homogenate MPAG formation (figure 7), which was comparable in WH and TR
-
 rat kidney 
homogenates. To test the effect of CsA on MPAG production via human UGT1A9 enzyme, 
MPA was incubated with the enzyme in the presence of the cofactor with or without CsA, 
and our results indicate that CsA significantly inhibited UGT1A9-induced MPA 
glucuronidation. Addition of Tac had no effect on MPAG formation by both types of rat 
kidneys as well as by human UGT1A9. 
 
 
 
 
 
 
Fig. 7: Effect of CsA and Tac on MPA glucuronidation. Homogenates of WH and TR- rat kidneys, as 
well as human UGT1A9 enzyme were incubated with either 1 mg/ml MPA alone (white bars) or in 
combination with 80 µM of CsA (black bars) or Tac (grey bars). CsA, but not Tac, inhibited MPAG 
formation by both kidney homogenates (*P< 0.01) and human UGT1A9 enzyme (**P<0.001).  
Discussion 
In the present study, we demonstrate the role of the kidney and the possible contribution 
of the renal efflux transporters, MRP2 and MRP4, to MPA excretion and drug interactions 
with CsA and Tac. We demonstrate for the first time that renal MPAG excretion in the rat 
is Mrp2-dependent. Our results are supported by our findings at the molecular level, where 
we identify MPAG as a substrate of human MRP2. We also show that MPA itself is a 
substrate of both MRP2 and MRP4. Previous reports suggested that MPA and MPAG may 
interact with MRP2 in the liver. These reports included animal studies investigating biliary 
excretion of MPAG from TR
-
 rat livers deficient in Mrp2 (Kobayashi et al., 2004;Westley 
et al., 2006), human studies correlating MRP2 polymorphisms with MPA pharmacokinetics 
(Naesens et al., 2006;Miura et al., 2007), and molecular studies investigating inhibition of 
MRP2-mediated substrate transport (Takekuma et al., 2007). None of these studies 
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demonstrated direct transport of either MPA or MPAG by human MRP2, or suggested any 
role for MRP4 in MPA renal excretion.  
In patients, maximum MPA plasma concentrations of around 100 µM are reached, 97-
99% of which is bound to plasma proteins, exposing the kidney to about 1-3 µM free MPA 
(Staatz and Tett, 2007). In a patient suffering from hypoalbuminemia after renal 
transplantation, the free MPA level increased about 18% causing toxic effects (Mudge et 
al., 2004). Even with such high free levels, MPA reaching the proximal tubule is probably 
completely subjected to intracellular glucuronidation to form MPAG that is readily 
eliminated by the kidney. This may suggest that the role of MRP2 and MRP4 in renal MPA 
excretion is probably of minor importance. Nevertheless, we estimated the Km values of 
MPA for both MRP2 and MRP4 to be within the pharmacologically relevant 
concentrations, indicating that MRP2 and MRP4 expressed in other barrier tissues, like 
intestine, liver and blood cells (El-Sheikh et al., 2008) may contribute substantially to MPA 
absorption, distribution, excretion, and pharmacokinetic drug interactions.  
Inter-species differences between rats and humans in MPA pharmacokinetics have been 
suggested, as MPAG depends mainly on renal excretion in humans (Bullingham et al., 
1996), while its main route of elimination is biliary excretion in rats (Westley et al., 2006). 
Previous inhibition studies implied that such variation may be attributed to differences in 
the affinity of human and rat MRP2/Mrp2 to MPAG (Takekuma et al., 2007). It is thus 
possible that interactions at the level of renal human MRP2 are more pronounced compared 
to rats. Furthermore, in conditions with low MPAG biliary formation and excretion, as in 
case of hepatic impairment, renal glucuronidation of MPA is highly induced (Shipkova et 
al., 2005). This subjects the renal apical transporters to much higher MPAG levels and 
emphasizes the role of renal MRP2 in MPAG excretion.  
MPA has recently been suggested as a potential anti-cancer drug, and is currently under 
phase I clinical investigation in patients with multiple myeloma (Chen and Pankiewicz, 
2007). Cytotoxic effects of MPA have also been observed when normal human intra-
hepatic biliary epithelial cells were exposed to MPA in vitro (Liu et al., 2005). Here, we 
demonstrate that, by over-expressing MRP2 or MRP4, MPA cytotoxic effects seen in 
control cells were significantly reversed. In addition, combining MPA with either CsA or 
Tac reversed the transporter-induced resistance to MPA cytotoxicity. Expression of MRP2 
or MRP4 efflux transporters in tumor cells may thus contribute to their resistance against 
cytotoxicity by MPA.  
Our findings indicate that CsA, but not Tac, inhibited MPAG renal excretion from rat 
kidneys and directly blocked human MRP2-mediated MPAG transport. Several studies 
indicated that CsA interacts with MPA pharmacokinetics, while Tac does not (Hohage et 
al., 2005;Picard et al., 2006;Kagaya et al., 2008), although controversial findings have been 
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reported as well (Morissette et al., 2001). In vivo, concomitant CsA administration caused a 
significant decrease in MPA and increase in MPAG serum levels (Staatz and Tett, 2007). 
The decrease in MPA levels was explained by the interference of CsA with Mrp2-mediated 
hepatic re-cycling of MPAG (Kobayashi et al., 2004;Deters et al., 2005;Hesselink et al., 
2005). The inhibitory effect of CsA on renal MRP2-mediated MPAG excretion 
demonstrated here may explain the retention of MPAG seen in vivo. Interestingly, in this 
study, CsA also significantly inhibited MPAG renal excretion from TR
-
 rat kidneys, but 
still to a lesser extent compared to the wild type. This indicates that the inhibitory effect of 
CsA on renal MPAG excretion is likely to be multi-factorial. To date, the effect of CsA and 
Tac on MPA glucuronidation in humans is still contradictory. Some in vitro studies 
suggested that CsA and Tac may inhibit glucuronidation of MPA (Zucker et al., 
1999;Westley et al., 2008), while other studies showed that both drugs had no effect (Vietri 
et al., 2000;Balogh et al., 2003;Picard et al., 2006). Here, we investigated the effect of CsA 
and Tac on MPA glucuronidation via rat kidney homogenates and human UGT1A9, and we 
found that CsA, but not Tac, significantly inhibited MPA glucuronidation in both cases. We 
also found no difference in the formation of MPAG by kidney homogenates from both 
wild-type and TR
-
 rat strains, which is in agreement with previous studies conducted in rat 
liver microsomes (Westley et al., 2008). The inhibitory effect of CsA on MPAG formation 
is a possible explanation for the decrease in MPAG renal excretion encountered in the 
present study with TR
-
 rat kidneys deficient in Mrp2.  
In summary, the main apical renal transporter involved in renal excretion of MPA in its 
glucuronide inactive form is MRP2. CsA, but not Tac, interferes with MPAG renal 
excretion by inhibiting its renal UGT-mediated formation, as well as inhibiting its MRP2-
mediated transport. On basis of our findings, we suggest that at least part of the interaction 
with cyclosporine seen in vivo is mediated by inhibition of MPA renal glucuronidation and 
by decreased clearance of MPAG after cyclosporine co-administration.  
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Summary 
Multidrug resistance protein 4 (MRP4) transports a variety of endogenous and 
xenobiotic organic anions. MRP4 is widely expressed in the body and specifically localized 
to the renal apical proximal tubule cell membrane, where it mediates the excretion of these 
compounds into urine. To characterize the MRP4 substrate-binding site, the amino acids 
Phe
368
, Phe
369
, Glu
374
, Arg
375
, and Glu
378
 of transmembrane helix 6, and Arg
998
 of helix 12, 
localized in the intracellular half of the central pore, were mutated into the corresponding 
amino acids of MRP1 and MRP2. Membrane vesicles isolated from HEK293 cells over-
expressing these mutants showed significantly reduced methotrexate (MTX) and cyclic 
guanosine monophosphate (cGMP) transport activity compared to vesicles that expressed 
wild type MRP4. The only exception was substitution of Arg
375
 with serine, which had no 
effect on cGMP transport, but significantly decreased the affinity of MTX. Substitution of 
the same amino acid with a positively charged lysine returned the MTX affinity to that of 
the wild type. Furthermore, MTX inhibition of MRP4-mediated cGMP transport was non-
competitive and the inhibition constant was increased by introduction of the R375S 
mutation. A homology model of MRP4 showed that Arg
375
 and Arg
998
 face right into the 
central aqueous pore of MRP4. We conclude that positively charged amino acids in 
transmembrane helices 6 and 12 contribute to the MRP4 substrate-binding pocket. 
Introduction 
Proteins belonging to the ATP-binding cassette (ABC) superfamily play a crucial role in 
human physiology, pharmacology, and toxicology, as well as numerous pathological 
conditions. To date 48 human ABC transporter proteins have been identified, including 9 
multidrug resistance proteins (MRPs) belonging to the C subfamily (van de Water et al., 
2005). MRPs are not only important for the tumor cell resistance they confer to 
chemotherapeutic drugs, but also for their endogenous expression in normal human tissues. 
MRP4/ABCC4 is widely distributed in epithelial tissue and blood cells and highest 
expression has been found in kidney, lung, prostate, liver, tonsils and bladder (Borst et al., 
2007). In most epithelial cells MRP4 is located at the basolateral membrane, except for the 
renal proximal tubular cell where it is expressed apically (van Aubel et al., 2002). 
Structurally, the human MRP4 protein consists of 1325 amino acids comprising two 
membrane-spanning domains each consisting of 6 transmembrane α-helices (TM), with two 
cytosolic ATP-binding domains. MRP4 mediates ATP-dependent transport of various 
organic anions from the intracellular to the extracellular side (Russel et al., 2008). 
Substrates include endogenous compounds like the cyclic adenosine (cAMP) and guanosine 
(cGMP) monophosphate (van Aubel et al., 2002), folate (Chen et al., 2002), and uric acid 
(van Aubel et al., 2005), as well as drugs like the antiviral nucleoside monophosphate 
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analog PMEA (Schuetz et al., 1999) and the nucleobase analogs 6-mercaptopurine 
(Wielinga et al., 2002) and methotrexate (MTX) (Chen et al., 2002).  
The mode by which MRPs transport their substrates has still to be identified. Among the 
different MRPs, the structure-function relationship of MRP1 has been investigated most 
extensively (Deeley et al., 2006). Several mutational studies have shown that polar amino 
acids in transmembrane helices 11 and 17 of MRP1 are involved in substrate binding (Ito et 
al., 2001a;Ito et al., 2001b;Zhang et al., 2001;Koike et al., 2004;Zhang et al., 2006). In a 
model most of their side chains were found to line the "pore" adjacent to the membrane 
cytosol interface. In contrast with MRP1, limited knowledge regarding the amino acids 
involved in substrate specificity of MRP2 (Ito et al., 2001a) and MRP3 (Zhang et al., 
2003b) is available.  
To date, no attempt has been made to characterize the MRP4 substrate-binding site(s). 
In the present study we investigated the role of Phe
368
, Phe
369
, Glu
374
, Arg
375
, and Glu
378
 
present in transmembrane helix 6 (TM 11 in MRP1), and Arg
998
 in transmembrane helix 12 
(TM 17 in MRP1) in transport of cGMP and MTX. These amino acids are highly conserved 
in MRP4 among different species (Chen and Klaassen, 2004),  but  there is a large variety 
within the MRP subfamily (Fig. 1) that might point to a specific mechanistic importance of 
these amino acids. When they were substituted by their analogues from MRP1/MRP2, most 
mutations completely abolished MRP4 transport activity, except for Arg
375
 in which cGMP 
transport was preserved whereas the affinity for MTX was reduced. We studied this 
mutation in more detail and developed a homology model of MRP4 to explain the results. 
  
 
 
Fig. 1: Alignment of amino acid 
sequence of TM6 (TM11) of 
MRP4 for multiple species and 
human MRP1-6. The bold 
underlined amino acids have 
been mutated in this study. 
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Materials and Methods 
Materials. [3‟,5‟,7‟-3H(n)]-methotrexate sodium salt (51.5 Ci mmol-1) and [8-3H]-
guanosine-3‟,5‟-cyclic phosphate NH4 salt (7.7 Ci mmol
-1
)  were purchased from Moravek 
Inc. (Brea, CA). The Bac-to-Bac, Gateway system, culture medium, and Alexa Fluor 680 
goat anti-rabbits IgG secondary antibody were purchased from Invitrogen (Breda, the 
Netherlands). Methotrexate, guanosine 3‟5‟-cyclic monophosphate, and GenElute Plasmid 
Mini-Prep kit were purchased from Sigma. Fetal bovine serum was purchased from MP 
Biochemicals (the Netherlands). Multiscreen HTS-HV 0.45 μm 96-wells filters were 
obtained from Millipore (Etten-Leur, the Netherlands). Protein concentrations were 
determined with an assay kit form Bio-Rad Laboratories (Veenendaal, the Netherlands). 8-
Azidoadenosine 5‟-triphosphate 2‟,3‟-biotin-long chain-hydrazone (8N3ATP-2‟,3‟-Biotin-
LC-Hydrazone) was purchased from Affinity labeling Technologies (Nicholasville, KY), 
and from Streptavidin horseradish peroxidase conjugate Amersham GE Healthcare 
(Buckinghamshire, UK). 
Generation of Human MRP4 Baculovirus. Full-length of human MRP4 cDNA was 
generated as previously described (El Sheikh et al., 2007). Briefly, the Bac-to-Bac system, 
normally used for protein production in insect cells, was modified for protein expression in 
mammalian cells by introduction of the CMV promoter and Gateway destination elements 
(cassette that contains the chloramphenicol resistance gene and the ccdB gene flanked by 
attR1 and attR2 sites) in the pFastBacDual vector. In addition, the vesicular stomatitis virus 
G protein cDNA was cloned behind the P10 promoter of the pFastBacDual vector. The 
human MRP4 was cloned into the Gateway entry vector and transferred to the newly 
constructed Bac-to-Bac vector with the gateway LR reaction. Baculoviruses were produced 
as described in the Bac-to-Bac manual. As a negative control, the enhanced yellow 
fluorescent protein (EYFP) was also introduced into the Baculovirus expression system 
(Invitrogen). 
Site Directed Mutagenesis. PCR was performed on a template pENTR-MRP4 vector using 
two primers (forward and reverse) produced by Biolegio (Nijmegen, the Netherlands) 
bearing one or more mismatched bases at the site of residues to be mutated. In this PCR 
reaction, PfuUltra II fusion HS DNA polymerase with the supplied reaction buffer, and 
dNTP mix 12.5 mM each completed to 50 l end volume were used. PCR amplification 
consisted of initial denaturation at 94 C, followed by 20 cycles of denaturation at 94 C, 
annealing at 58 C, and elongation at 72 C for 14 minutes. The PCR product was cut by 
DpnI for 2 hours at 37 C and finally transformed into E. coli DH5 cells. pENTR-MRP4 
mutant plasmids were isolated using the GenElute Plasmid Mini-Prep kit (Sigma) from 
kanamycine resistant colonies. All mutations were confirmed by sequencing of the full-
length MRP4/ABCC4 DNA. Twelve mutants of the human MRP4 were generated: FF/L- 
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(F368L and F369-), ERE/SSQ (E374S, R375S, and E378Q), FFERE/L-SSQ (F368L, F369ـ, 
E374S, R375S, and E378Q), F368L, F369-, E374S, R375S, R375A, R375K, R375E, 
E378Q and R998A. 
Transduction of MRP4 and Mutants Expression Vectors in HEK293 Cells. HEK293 cells 
were cultured in 182 cm
2
 flasks till 40% confluency, after which the culture medium was 
removed and 3.5 ml fresh medium and 1.5 ml control EYFP, MRP4 or MRP4-mutant 
baculovirus were added. The cells were incubated for 15 min at 37°C, after which 20 ml 
medium was added. After 24 hours of transduction, sodium butyrate (5 mM) was added. 
Three days after transduction, the cells were harvested.  
Isolation of Membrane Vesicles and Protein Analysis. Cells were harvested by 
centrifugation at 3000g for 30 minutes. The pellets were re-suspended in ice-cold 
homogenization buffer (0.5 mM sodium phosphate, 0.1 mM EDTA, pH 7.4) supplemented 
with protease inhibitors (100 μM phenylmethylsulfonyl fluoride, 5 μg/ml aprotinin, 5 μg/ml 
leupeptin, 1 μM pepstatin, 1 μM E-64) and shaken at 4°C for 60 minutes. Lysed cells were 
centrifuged at 4°C at 100,000g for 30 minutes, and the pellets were homogenized in ice-
cold TS buffer (10 mM Tris-HEPES, 250 mM sucrose, pH 7.4) using a tight fitting Dounce 
homogenizer for 30 strokes. After centrifugation at 500g at 4°C for 20 minutes, the 
supernatant was centrifuged at 4°C at 100,000g for 60 minutes. The resulting pellet was re-
suspended in TS buffer and passed through a 27-gauge needle for 30 times. Protein 
concentration was determined by Bio-Rad protein assay kit. Crude membrane vesicles were 
dispensed in aliquots, frozen in liquid nitrogen, and stored at –80°C until use. 
Western Blotting. The membrane vesicle preparations (15 µg protein) were solubilized in 
SDS-PAGE sample buffer and separated on SDS gels containing 7.5% acrylamide 
according to Laemmli (Laemmli, 1970). Subsequently they were blotted on nitrocellulose 
membrane using the iBlot dry blotting system (Invitrogen, CA, USA). Polyclonal anti-
human MRP4 rabbit serum antibody (van Aubel et al., 2002) was used to detect human 
MRP4 and MRP4 mutants. The secondary antibody used was the fluorescent Alexa Fluor 
680 (Invitrogen). Signals were visualized with a fluorescent method, using Odyssey 
infrared imaging system (Li-Cor Biosciences, Lincoln, USA). 
Vesicular Transport Assays. Uptake of [
3
H]-MTX or [
3
H]-cGMP into membrane vesicles 
was performed using a rapid filtration technique. TSB buffer (TS buffer with 0.2 mg/ml 
bovine serum albumin) supplemented with a mixture of 4 mM ATP, 10 mM MgCl2 was 
added to the membrane vesicles in a final volume of 30 μl. The reaction was started when 
the mixture was incubated at 37°C. After 15 minutes, reaction was stopped by placing 
samples on ice. After 1 minute, 150 μl ice cold TSB buffer was added to each reaction well. 
Diluted samples were filtered by a Multiscreen HTS-Vacuum Manifold filtration device 
(Millipore, Etten-Leur, the Netherlands) through 0.45-μm-pore 96-wells Millipore filters 
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that were pre-incubated with TSB buffer. After adding 4 ml scintillation fluid to each filter 
and subsequent liquid scintillation counting, uptake of [
3
H]-MTX or [
3
H]-cGMP into 
membrane vesicles was studied by measuring radioactivity associated with the filters. In 
control experiments, ATP was substituted with AMP. Net ATP-dependent transport was 
calculated by subtracting values measured in the presence of AMP from those measured in 
the presence of ATP. Each experiment was performed in triplicate using three different 
batches of membrane vesicles.  
Vesicular Inhibition Assays. To evaluate the inhibitory effects of MTX on [
3
H]-cGMP 
uptake in MRP4 and MRP4-R375S membrane vesicles, the previously mentioned transport 
assay was performed using 1, 10, and 100 μM cGMP, in the absence or presence of MTX 
concentrations ranging from 1 to 600 μM. Net MRP4- or MRP4 mutant-dependent 
transport was calculated by subtracting background values measured in EYFP-transfected 
control vesicles.  
Kinetic Analysis. All data were expressed as means ± S.D. Curve-fitting of the resulting 
concentration-dependent transport curves was performed by nonlinear regression analysis 
using GraphPad Prism software version 4.03 (GraphPad Software Inc., San Diego, USA). 
Results of the inhibition assays were analyzed using Dixon‟s method, to estimate the 
inhibitory potency (Ki). 
Immunoprecipitation and Photo-affinity labelling. Wild type MRP4, negative (EYFP) 
control and mutants (300 µg protein vesicles) were incubated with 5 mM MgCl2 and 100 
µM Azido ATP-Biotin (Schafer et al., 2001) for 5 minutes on ice. The mixture was photo-
linked using UV light for 10 minutes. Immunoprecipitation of the photo-linked sample was 
performed using MRP4 polyclonal antibody (10µl/sample) (van Aubel et al., 2002)  linked 
to protein A immobilized on agarose (50% w/v, KemEnTec, Copenhagen, Denmark) (30 
µl/sample). The immunoprecipitated protein was blotted (see Western blotting) and 
visualized with Streptavidin horse radish peroxidase. 
Molecular modeling of MRP4. The homology model of MRP4 was built with the 
YASARA molecular modeling program (Krieger et al., 2002). A common problem when 
building models of membrane proteins is the limited availability of experimental data. In 
case of MRP4, the related X-ray structure of MsbA appeared to be incorrect and was 
retracted, which left the structure of the bacterial ABC transporter Sav1866 from S.aureus 
solved at 3.0 Å resolution (Dawson and Locher, 2006) as the only available template for the 
transmembrane domain (PDB entry 2HYD). The cytosolic ATP-binding domain is on the 
other hand well represented in the PDB. We therefore selected the more closely related 
ATP-binding domain from human MDR1 solved at 1.5 A resolution (Ramaen et al., 2006), 
aligned it to Sav1866 with YASARA‟s MUSTANG module (Konagurthu et al., 2006) and 
then fused it with the Sav1866 transmembrane domain to create a hybrid-template. The 
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alignment of the MRP4 sequence against this template was created with the T-Coffee 
multiple alignment algorithm (Notredame et al., 2000), using an additional 48 intermediate 
sequences to guide the alignment. These 48 sequences were randomly selected from 
Swissprot/TrEMBL, with the requirement that their transmembrane domains be closer to 
both the template and MRP4, than the template is to MRP4. The resulting alignment was 
manually tuned to account for single residue insertions and deletions in the membrane 
helices, which contain several Gly/Pro mediated deviations from ideality in the Sav1866 
template. Loops were modeled by scanning a non-redundant subset of the PDB (>8000 
structures) for fragments with matching anchor points, a minimal number of bumps and 
maximal sequence similarity. Side-chains were added with YASARA‟s implementation of 
SCWRL (Canutescu et al., 2003), then the model was subjected to an energy minimization 
with the YAMBER force field as described previously (Krieger et al., 2004;Krieger et al., 
2006). Since no membrane was present during this minimization, the backbone of residues 
copied from the template was kept fixed. Validation of the model with WHAT_CHECK 
(Hooft et al., 1996) yielded an average quality Z-score of –2.2, which is better than the 
template (-2.9). A PDB file of the model and the alignment are available from the authors 
upon request. 
Results 
Three mutants of human MRP4 were generated and expressed in HEK293 cells. In 
mutant FF/L- Phe
368
 and Phe
369
 in TM6 were replaced by their analogs of MRP1/MRP2 
(Leu and nothing, respectively). In the second mutant ERE/SSQ Glu
374
, Arg
375
, and Glu
378
 
in TM6 were also replaced by their analogs in MRP1/MRP2 (Ser, Ser, and Gln, 
respectively). The final mutant FFERE/L-SSQ was a combination of mutant FF/L- and 
mutant ERE/SSQ. Western blot analysis of membrane vesicles prepared from HEK293 
cells over-expressing wild type MRP4 and the three mutants showed comparable 
expression levels (Fig. 2A). Often two bands are visible, of which the mutual ratio varies in 
different preparations. PNGase F treatment showed that the most intense band that runs at 
170 kDa is the glycosylated MRP4 protein and the band that runs at 140 kDa, is the 
unglycosylated MRP4 band (data not shown).  MRP4-mediated ATP-dependent transport 
of 0.5 µM [
3
H]-MTX or 1 µM [
3
H]-cGMP was 950 ± 60 and 114 ± 7 pmol/mg 
protein/minute, respectively. In figure 2B the transport activity of the mutants is compared 
to that of the wild type. Transport of both substrates in all mutants was significantly 
decreased compared to that of the wild type transporter. Moreover, the transport activity 
levels were comparable to that of the negative control.  
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Fig. 2: Western blot analysis (A), 0.5 µM [3H]-
MTX (B), and 1 µM [3H]-cGMP (C) transport 
activity of wild type, FF/L-, ERE/SSQ, and 
FFERE/L-SSQ MRP4 transporter proteins. 
Upper panel (A) represents a Western blot of 
membrane vesicles isolated from HEK293 cells 
over-expressing MRP4 or MRP4 mutants 
FF/L-, ERE/SSQ, and FFERE/L-SSQ as well 
as a negative control detected by polyclonal 
anti-human MRP4 (representative of three). 
The MRP4 wild type transport activity for 
[3H]-MTX (950 ± 60 fmol/mg protein/minute) 
and [3H]-cGMP (114 ± 7 fmol/mg 
protein/minute) was set at 100%. 
 
 
 
To investigate the substitution of the amino acids of the previous mutants in more detail 
we constructed the single mutants F368L, F369-, E374S, R375S, and E378Q. Again the 
membrane vesicles of all mutants showed expression levels comparable to wild type MRP4 
(Fig. 3A). The transport activity of both [
3
H]-MTX and [
3
H]-cGMP (0.5 µM and 1 µM, 
respectively) was significantly reduced in mutants F368L, F369-, E374S, and E378Q 
compared to wild type MRP4 (Fig. 3). Interestingly, cGMP transport activity of mutant 
R375S was 98  2 % of wild type, whereas its MTX transport activity was only 55  2 %.  
Next, we determined the transport activity of the mutants and wild type transporter at 
different substrate concentrations. Figure 4 shows the Michaelis-Menten plot for MTX and 
cGMP. Mutants F368L, F369-, E374S, and E378Q showed transport activity levels that 
were comparable to that of the negative control at all concentrations tested for both MTX 
and cGMP. The maximum transport rate (Vmax) for the wild type and R375S mutant was 
280 ± 60 and 270 ± 120 pmol/mg protein/min for MTX and 370 ± 30 and 270 ± 70 
pmol/mg protein/min for cGMP, respectively. The apparent affinity (Km) of wild type 
MRP4 and mutant R375S was 230  90 and 720  320 µM for MTX and 610  70 and 610 
 80 µM for cGMP, respectively. The Km for cGMP was not influenced by substitution of 
Arg
375
 with Ser, whereas it was increased three fold for MTX. 
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Fig. 3: Western blot analysis (A), 0.5 µM [3H]-
MTX (B), and 1 µM [3H]-cGMP (C) transport 
activity of wild type, F368L, F369-, E374S, 
R375S, and E378Q MRP4 transporter proteins. 
Upper panel (A) represents a Western blot of 
membrane vesicles isolated from HEK293 cells 
over-expressing MRP4 or MRP4 mutants 
F368L, F369-, E374S, R375S, and E378Q as 
well as negative control detected by polyclonal 
anti-human MRP4 (representative of three). 
The MRP4 wild type transport activity for 
[3H]-MTX (970 ± 80 fmol/mg protein/minute) 
and [3H]-cGMP (106 ± 7 fmol/mg 
protein/minute) was set at 100%. 
 
 
 
Fig. 4: Concentration-dependent uptake of 
[3H]-MTX and [3H]-cGMP in membrane 
vesicles expressing human MRP4 mutants. 
Control (▲), wild type (■), F368L (●), F369- 
(□), E374S (), R375S (○), and E378Q (x) 
MRP4 membrane vesicles were incubated with 
[3H]-MTX (upper graph) or [3H]-cGMP 
(lower graph) concentrations indicated in the 
figure. ATP-dependent uptake was measured 
by subtracting uptake in the presence of AMP 
from that measured in the presence of ATP. 
Mean values ± SE of three enzyme 
preparations are shown. 
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To test the interaction of MTX and cGMP in more detail we analyzed the possible 
inhibitory effect of MTX on [
3
H]-cGMP uptake for wild type and R375S mutant MRP4. A 
Dixon plot of net cGMP transport by wild type and R375S in the absence or presence of 
increasing MTX concentrations was constructed and analyzed by linear regression (Fig. 5). 
Remarkably, the intersection of the 3 lines representing MTX inhibition curves at different 
cGMP concentrations was at the x-axis for both wild type and R375S mutant, indicating a 
non-competitive inhibitory effect. The inhibition constant (intersection with the x-axis), Ki, 
for wild type MRP4 was 164  4 µM compared with 470  70 µM for mutant R375S.  
At this moment it was, however, not clear whether this effect was due to the 
introduction of a polar serine or the deletion of the positively charged arginine. In the next 
experiment we replaced arginine with alanine, lysine, and glutamic acid. Furthermore, we 
also substituted the arginine present in TM12 for alanine. Figure 6A shows an equal level 
of protein expression of wild type as well as R375A, R375K, R375E, and R988A mutants. 
The MTX and cGMP transport activity of the wild type and mutants was measured and 
shown in figure 6B. Mutating the Arg
375
 residue into alanine or glutamic acid significantly 
decreased the transport activity for both MTX and cGMP, while mutating it into lysine 
retained the transport activity (96  12 % for MTX and 97  16 % for cGMP). In addition, 
the transport levels of R988A showed no significant difference from the negative control.  
To determine the Km values of the different mutants for MTX and cGMP 
concentration-dependent transport experiments were performed (Fig. 7). The transport 
activities of R375A, R375E, and R988A for MTX and cGMP did not differ from that of the 
negative control. The Vmax values for MTX were 250  20 and 190  10 pmol/mg 
protein/min and those for cGMP were 420  10 and 420  20 pmol/mg protein/min for wild 
type and R375S mutant, respectively. The Km values of wild type MRP4 and R375K were 
230  90 and 250  20 µM for MTX and 610  70 and 640  60 µM for cGMP, 
respectively. Thus, R375K retained substrate affinity comparable to the wild type for both 
MTX and cGMP.  
To determine whether the MRP4 mutants showed normal ATP binding, azido-ATP-
biotin photolabeling of mutants was compared with that of wild-type and negative control 
(Fig. 8). The vesicles of MRP4 wild type and mutants showed increased 8-azido-ATP-
biotin binding compared with the negative control. In all mutant preparations the 8-azido-
ATP-biotin binding was comparable to that of the wild type. Moreover, the binding of 8-
azido ATP-biotin was almost completely diminished when ATP was added. 
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Fig. 5: Dixon plot showing the MTX inhibition 
of cGMP transport by human MRP4 and mutant 
R375S. Membrane vesicles were incubated with 
1 μM (open circle), 10 μM (closed triangles), or 
100 μM (open squares) [3H]-cGMP in the 
presence or absence of MTX concentrations 
ranging from 1 to 600 μM. Specific uptake of 
MRP4 (upper graph) and mutant R375S (lower 
graph) was determined after subtraction of the 
negative control. The inhibition constant (Ki) 
can be estimated from the intersection point of 
the 3 lines with the x-axis. Mean values ± SE of 
three enzyme preparations are shown. 
 
 
 
 
Fig. 6: Western blot analysis (A), 0.5 µM [3H]-
MTX (B), and 1 µM [3H]-cGMP (C) transport 
activity of wild type, R375A, R375K, R375E, 
and R998A MRP4 transporter proteins. Upper 
panel (A) represents a Western blot of 
membrane vesicles isolated from HEK293 cells 
over-expressing MRP4 or MRP4 mutants 
R375A, R375K, R375E, and R998A as well as 
negative control detected by polyclonal anti-
human MRP4 (representative of three). The 
MRP4 wild type transport activity for [3H]-MTX 
(980  20 fmol/mg protein/minute) and [3H]-
cGMP (125  13 fmol/mg protein/minute) was 
set at 100%. 
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Fig. 7. Concentration-dependent uptake of [3H]-
MTX and [3H]-cGMP in membrane vesicles 
expressing human MRP4 mutants. Control (▲), 
wild type (■), R375A (●), R375K (○), R375E 
(), and R998A (x) MRP4 membrane vesicles 
were incubated with [3H]-MTX (upper graph) or 
[3H]-cGMP (lower graph) concentrations 
indicated in the figure. ATP-dependent uptake 
was measured by subtracting uptake in the 
presence of AMP from that measured in the 
presence of ATP. Mean values ± SE of three 
enzyme preparations are shown. 
 
 
 
Fig. 8: Western blot of immunoprecipitated azido-ATP-biotin photolabeled wild type and mutant 
transporter proteins. 300 µg protein vesicles was labeled with 100 µM azido-ATP-biotin and the 
MRP4 proteins were immunoprecipitated with MRP4 polyclonal antibody linked to agarose protein A 
beads. The immunoprecipitated protein was blotted and visualized with streptavidin HRP. The 
addition of 5 mM ATP prevented photolabeling (data not shown).  
To link the functional consequences of the mutations back to their structural basis, we 
built a homology model of MRP4 using the known X-ray structures of the bacterial ABC 
transporter Sav1866 from S. aureus (Dawson and Locher, 2006) and the ATP-binding 
domain of human P-glycoprotein/MDR1 as templates (Ramaen et al., 2006) (Fig. 9A). 
Sav1866 forms a dimer, while MRP4 encodes both copies in a single sequence. The 
predicted location of the mutated residues is shown in figure 9B. Based on this model, one 
can postulate that Arg
375
 and Arg
998
 face right into the pore and are thus very likely to 
interact directly with MTX and cGMP. 
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Fig. 9. Homology model of human MRP4 (A). The first half of the protein containing transmembrane 
helices 1 to 6 and the first ATP-binding domain is colored with a gradient from blue over orange to 
cyan. The second half of the protein (corresponding to the second monomer in the dimeric Sav1866 
modeling template) is shown in grey. A 180-degree rotation around the vertical axis would yield an 
almost identical picture of helices 7 to 12 and the second ATP-binding domain. Panel B shows a 
close-up of the channel formed by the 12 transmembrane helices, looking from the inside to the extra 
cellular side. The mutants described in this work are indicated. Graphics created with 
www.YASARA.org. 
Discussion 
To characterize the MRP4 substrate-binding site we investigated the influence of Phe
368
, 
Phe
369
, Glu
374
, Arg
375
, and Glu
378
 of transmembrane helix 6, and Arg
998
 of helix 12 on 
cGMP and MTX transport. These amino acids were substituted by their corresponding 
amino acids of MRP1 and MRP2. Most mutations completely abolished MRP4 transport 
activity. The only exception was substitution of Arg
375
 with serine, which had no effect on 
cGMP transport, but significantly decreased the affinity for MTX. Substitution of the same 
amino acid with a positively charged lysine returned the MTX affinity to that of the wild 
type. A homology model of MRP4 confirmed the crucial role of Arg
375
 and showed that it 
faced right into the central pore.  
Wild type MRP4 and all mutants were equally expressed in vesicles isolated from 
transduced HEK293 cells. Nevertheless, several MRP4 mutants (FF/L-, ERE/SSQ, 
FFERE/L-SSQ, F368L, F369-, E374S, R375A, R375E, E378Q, and R998A) showed 
significantly diminished transport activity of either MTX or cGMP compared with that of 
wild type MRP4. This indicates that Phe
368
, Phe
369
, Glu
374
, Arg
375
, and Glu
378
, present in 
TM6, and Arg
998
, present in TM12, might comprise an important part of MRP4 substrate-
binding site. Indeed, studies with LmrA, a bacterial ATP-dependent multidrug transporter, 
show that TM3, TM5 and TM6 (also TM9, TM11, and TM12) are involved in substrate 
binding (Ecker et al., 2004). These TMs have one face of the helix exposed to the pore, 
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which forms a pathway for substrates through the membrane. Experimental evidence has 
shown that conformational changes of the nucleotide-binding domains (NBD) of P-
glycoprotein/MDR1, leads to reorientation of the TM helices (Loo et al., 2007). TM6 is 
connected to NBD1 and changes in the position or orientation of TM6 resulting from 
mutations, may cause a conformational or positional change in NBD1 leading to 
diminished binding of ATP and transport activity (Zhang et al., 2004). We tested if the 
mutants were able to bind azido-ATP-biotin and observed no difference in binding between 
MRP4 and the mutants.  
All the amino acids mutated in the present study are highly conserved in MRP4 among 
different species (Chen and Klaassen, 2004). There is, however, a big difference within the 
MRP subfamily that might point to a specific mechanistic importance of these amino acids. 
The two phenylalanines at position 368 and 369 in MRP4 are unique and absent in other 
MRPs. Replacement of these two amino acids by a single leucine (their counterpart in 
MRP1, 2, 3, and 5) resulted in the lack of MTX and cGMP transport. The Phe
369
, predicted 
to face outside the central pore and attach helix 6 to helix 3, most likely has a role in 
maintaining the structural integrity of the transporter. Phe
368
 faces into the pore and could 
mediate stacking interactions with the planar rings of cGMP and MTX. The negatively 
charged glutamic acid residues at position 374 and 378 of MRP4 correspond to a serine and 
glutamine, respectively, in MRP1, 2, and 6. The replacement of these two MRP4 amino 
acids by serine and glutamine also resulted in the lack of MTX and cGMP transport. Zhang 
et al. (Zhang et al., 2004) showed that replacement of MRP1 Ser
604
 (corresponding to 
E374S in MRP4) with alanine selectively increased 17β-estradiol 17-(β-D-glucuronide) 
transport. In the model, Glu
374
 and Glu
378
 form salt bridges with Arg
317
 and Arg
262
, which 
points towards a role in maintaining the structural integrity of the transporter. 
In this study we showed that the positively charged arginine residue at position 375 is 
important for MRP4-mediated MTX but not cGMP transport. The importance of positively 
charged amino acids to the binding and transport functionality was previously indicated for 
MRP1 (Zhang et al., 2003a). Deletion of the hydroxyl group of MRP1 residue 605 
(S605A), corresponding to R375A in MRP4, decreased resistance to vincristine, VP-16, 
and doxorubicin (Zhang et al., 2004). Moreover, the Q359K/T360K mutation 
(corresponding to MRP4 Glu
374
 and Arg
375
) in the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein causes cystic fibrosis (Quint et al., 2005). 
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Table 1: Transporter kinetic values and inhibition constants. 
 MTX cGMP  
 Km (µM) Vmax (pmol/mg/min) Km (µM) Vmax (pmol/mg/min) Ki (µM) 
Data from fig. 3 and 4: 
MRP4 230 ± 90 280 ± 60 610 ± 70 370 ± 30 164 ± 4 
R375S 720 ± 320 270 ± 120 610 ± 80 270 ± 70 470 ± 70 
Data from fig. 4: 
MRP4 230 ± 90 250 ± 20 610 ± 70 420 ± 10  
R375K 250 ± 20 190 ± 10 640 ± 60 420 ± 20  
 
In the present study, substitution of MRP4 Arg
375
 with serine resulted in a lower affinity 
for MTX, but the affinity for cGMP did not change (Table 1). Furthermore, the MTX 
inhibition constant for cGMP transport by mutant R375S was significantly lower than that 
of the wild type. When the arginine at position 375 of MRP4 was substituted with lysine, 
another positively charged amino acid, MTX and cGMP transport activities were similar to 
that of the MRP4 wild type. For MTX affinity the positive charge of MRP4 residue 375 is 
critical. When this charge is removed (R375S) the MTX affinity decreases or transport 
activity is absent (R375A and R375E). This positive charge is less important for cGMP 
transport, because in the presence of a hydroxyl group (R375S) the transport properties 
seem unchanged. As soon as this hydroxyl group is removed (R375A) or replaced with a 
(negatively charged) acidic group (R375E) transport of cGMP is absent. Our observation 
that the R375S mutation has a larger effect on MTX transport could be explained by the 
fact that MTX contains two negative charges that need to be compensated, while cGMP 
only has one. In any case our results show that lysine is equally well suited as arginine to 
mediate this interaction.  
Photolabelling and mutational studies aimed at predicting regions of MRP1 protein that 
contribute to the substrate-binding sites have outlined the possible role of TM17 (Daoud et 
al., 2001;Deeley et al., 2006), which corresponds to TM12 in MRP4. In the present work, 
we mutated Arg
998
 located at MRP4 TM12 into alanine. Substitution of this positively 
charged amino acid resulted in nearly complete abolishment of transport activity for either 
MTX or cGMP. It was reported that the corresponding amino acid Arg
1257
 in MRP2 showed 
decreased transport activity of glutathione-methylfluorescein when substituted with alanine 
(Ryu et al., 2000). Moreover, alanine substitution of Arg
1249
 in MRP1 (also corresponding 
to R998A) impaired MRP1-mediated LTC4 transport and reduced vincristine resistance 
(Ren et al., 2002). This indicates the participation of TM12 to the MRP4 binding pocket 
and emphasizes the importance of positively charged amino acids for MRP4 transport 
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activity. Although mutagenesis studies confirm the functional requirement of a positive 
charge at Arg
375
, this has not been confirmed for Arg
998
. Glutamic acid (R998E) and lysine 
(R998K) mutants would be needed to strengthen this conclusion.  
Complex substrate-transporter interactions have been described previously for ABC 
transporters like P-glycoprotein/MDR1 (Martin et al., 2000), MRP1 (Leslie et al., 2001), 
MRP2 (Zelcer et al., 2003), and MRP4 (van Aubel et al., 2005). These complexities were 
attributed to multiple allosteric-binding sites. Here, we encountered similar complex 
transport inhibition patterns. Mutant R375S and wild type MRP4 possessed similar 
affinities for cGMP, but the MTX affinity of this mutant was nearly 3-fold lower than that 
of the wild type. This implicates that these two MRP4 substrates do not share the same 
substrate-binding site. This was also implied by the non-competitive inhibitory effect of 
MTX on MRP4-mediated cGMP transport. Therefore, we propose that MRP4 can bind two 
substrates at different regions within the aqueous cavity involving overlapping amino acids. 
This could partly explain the complex inhibitory and stimulatory kinetics that we 
encountered in previous studies (van Aubel et al., 2005;El Sheikh et al., 2007). Our data are 
indicative; they are nonetheless based on a homology model and mutagenesis studies, both 
of which contain certain experimental caveats. 
We conclude that amino acids in the transmembrane helices 6 and 12 may comprise a 
crucial part of the MRP4 substrate-binding site. The importance of a positive charge at 
residue 375 seems evident for MTX transport, but not for cGMP. This residue, which is 
predicted to be in the aqueous cavity of the inner leaflet of the membrane, clearly affects 
substrate specificity. Furthermore, a non-competitive inhibition between MTX and cGMP 
has been revealed, indicating separate MRP4 substrate-binding sites.  
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Summary 
The xanthine oxidase inhibitors allopurinol and oxypurinol are used to treat 
hyperuricemia, while loop and thiazide diuretics can cause iatrogenic hyperuricemia. Some 
uricosuric drugs as well as salicylate have a bimodal action on urate renal excretion. The 
mechanisms of action of these hypo- and hyperuricemic drugs on renal tubular urate 
handling have not been fully elucidated. Recently, we identified the multidrug resistance 
protein MRP4 as the first proximal tubule luminal efflux transporter for urate. Here, we 
studied the effect of these drugs on [
14
C]urate transport using HEK293 cells over-
expressing human MRP4 and in membrane vesicles isolated from these cells. Our results 
show that allopurinol stimulated MRP4-mediated cellular urate efflux and that allopurinol 
and oxypurinol both stimulated urate transport by MRP4 in membrane vesicles up to 190  
50% and 136  17%, respectively. Bumetanide and torasemide had no effect, while 
furosemide, chlorothiazide, hydrochlorothiazide, salicylate, benzbromarone, and 
sulfinpyrazone inhibited urate, at concentrations  ranging from nanomolar up to millimolar 
levels. Probenecid stimulated urate transport at 0.1 μM  and inhibited transport at higher 
concentrations. These data suggest that inhibition of MRP4-mediated urate efflux by 
furosemide and thiazide diuretics could play a role in their hyperuricemic mechanisms. 
Furthermore, stimulation of MRP4-mediated renal urate efflux could be a novel mechanism 
in the hypouricemic action of allopurinol and oxypurinol. In conclusion, MRP4 may 
provide a potential target for drugs affecting urate homeostasis, which needs to be further 
evaluated in vivo. 
Introduction 
The kidney plays a dominant role in urate elimination. After filtration of nearly all 
plasma urate through the glomerulus, it undergoes complex bidirectional steps of 
reabsorption and secretion in the proximal tubule, resulting in a net urinary excretion of less 
than 10% of the filtered amount. Uric acid, the final breakdown product of purines in 
humans, has important biological roles as endogenous danger signal in the immune system 
and free radical scavenger involved in antioxidant protection and determining longevity 
(Hediger et al., 2005). It is a weak organic acid, which, at physiologic serum pH, exists in a 
monovalent anionic form. Normally, the human plasma uric acid concentration is about 300 
μM (5 mg.dl-1). Hyperuricemia is characterized by a persistent increase of plasma 
concentrations above 400 μM, in which monosodium urate monohydrate crystals may be 
deposited in tissues causing several pathological conditions, including acute gouty arthritis, 
urolithiasis and obstructive uropathy (Terkeltaub et al., 2006). 
Multiple transporters in the proximal tubule are involved in regulating renal urate 
excretion. The apical organic anion transporters OAT4 (Hagos et al., 2007) and URAT1 
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(Enomoto et al., 2002) reabsorb filtered urate from the primary urine into the tubular cells. 
At the basolateral membrane, OAT1 (Ichida et al., 2003) and OAT3 (Bakhiya et al., 2003) 
are involved in the active uptake of plasma urate as a first step in its tubular secretion. 
Recently, we identified urate as a substrate of the ATP-dependent unidirectional efflux 
transporter, multidrug resistance protein 4 (MRP4/ABCC4), which is localized to the apical 
proximal tubule cell membrane (van Aubel et al., 2002;van Aubel et al., 2005). To date, 
MRP4 is the only known human transporter that may contribute to the secretion of urate 
across the apical membrane. Since urate is almost completely reabsorbed after its 
glomerular filtration (Anzai et al., 2007), net urinary excretion is mainly dependent on 
tubular secretion. Recently, it was reported that the angiotensin II receptor blocker losartan 
may influence plasma urate levels via an inhibitory effect on renal MRP4-mediated 
transport (Sato et al., 2008). Other compounds that can alter serum urate concentrations 
include drugs used in treatment of gout and hyperuricemia like xanthine oxidase inhibitors 
and uricosurics (Hoskison and Wortmann, 2006), as well as drugs that can cause iatrogenic 
hyperuricemia like loop (Brater, 1996) and thiazide diuretics (Huen and Goldfarb, 2007). 
The prototypic nonsteroidal anti-inflammatory drug salicylate has long been known to have 
a biphasic action on urate plasma concentration (Yu and Gutman, 1959). The goal of this 
work was to investigate the effect of these drugs on MRP4-mediated urate transport. Using 
HEK293 cells over-expressing human MRP4 and membrane vesicles isolated from these 
cells, we show that many of these drugs can alter urate transport by MRP4, which could 
contribute to their overall effects on renal urate handling. 
Materials and Methods  
Materials. [8-
14
C]urate (53 mCi mmol
-1
) was purchased from Moravek Inc. (Brea, CA). 
The Bac-to-Bac and Gateway system were purchased from Invitrogen (Breda, The 
Netherlands). NC45 filters were obtained from Schleicher and Schuell (Den Bosch, The 
Netherlands). Creatine phosphate and creatine kinase were purchased from Roche 
Diagnostics (Almere, The Netherlands). Protein concentrations were determined with an 
assay kit from Bio-Rad Laboratories (Veenendaal, The Netherlands). All drugs tested were 
purchased from Sigma-Aldrich (St. Louis, MO, USA), with the exception of torasemide 
that was extracted using methanol from Torasemid 10 mg tablets (Actavis, Germany) and 
its purity was confirmed using mass spectrometry and proton nuclear magnetic resonance. 
Generation of human MRP4 baculovirus and transduction of HEK293 cells. Generation 
of human MRP4 baculovirus was performed as previously described (El-Sheikh et al., 
2007). Briefly, the Bac-to-Bac system, normally used for protein production in insect cells, 
was made suitable for protein expression in mammalian cells. The human MRP4 and the 
enhanced yellow fluorescent protein (EYFP; control) were cloned into the Gateway entry 
vector (Invitrogen). Baculoviruses were produced as described in the Bac-to-Bac manual. 
To transduce HEK293 cells with human MRP4 baculovirus, cells were cultured in 182-cm
2
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flasks containing DMEM supplemented with 10% fetal calf serum at 37°C under 5% CO2-
humidified air until 70% confluence. The medium was replaced by 1.5 ml of virus and 3.5 
ml of medium and the cells were incubated for 30 min at 37°C, after which 20 ml of 
medium was added. Sodium butyrate (5 mM) was added after 24 h of transduction.  
Time-dependent diffusion and efflux assays in MRP4 cells. For cellular transport assays, 
HEK-MRP4 cells as well as control cells were harvested after 2 days of transfection, and 
seeded in collagen pre-coated 96 wells plates, at a density of 2.5 x 10
4
 cells per well. After 
24 hours, the medium was removed and plates were incubated on ice with 50 μM [14C]urate 
in HBSS medium (containing 1 mM CaCl2, 0.5 mM MgCl2, 0.4 mM MgSO4, 5 mM KCl, 
0.4 mM KH2PO4, 4 mM NaHCO3, 138 mM NaCl, and 0.3 mM Na2HPO4) for testing the 
diffusion step. After 15 seconds, 10, 20, and 30 minutes, the diffusion was stopped by 
removing the diffusion medium and washing the cells with ice-cold HBSS buffer. Cells 
were then lysed in 0.1% triton and 4 ml of scintillation fluid was added to measure the 
amount of [
14
C]urate in the cells, using liquid scintillation radioactivity counting. For 
testing time-dependent efflux of [
14C]urate, cells were incubated in 50 μM of the 
radiolabeled compound for 30 minutes on ice. After removing the diffusion medium and 
washing the cells with ice-cold HBSS buffer, the efflux step was started by adding 100 μl 
of HBSS per well and incubating the cells at 37°C for 15 seconds, 2, 3, 5 and 10 minutes. 
The efflux medium was then removed and placed in vials to count the radioactivity. Each 
experiment was performed in triplicate. 
Effect of drugs on [
14
C]urate efflux from MRP4 cells. To evaluate the effect of different 
drugs on [
14
C]urate efflux, HEK-MRP4 cells, as well as control cells were incubated in 
HBSS containing 50 μM of [14C]urate for 30 minutes in the presence or absence of 100 μM 
of the tested drug. Drugs were dissolved in dimethyl sulfoxide (DMSO), with the exception 
of salicylate, which was dissolved in H2O. The concentration of DMSO was fixed to 0.1% 
in all samples. This concentration was tested and was shown to exert no significant effect 
on the assay. After removing the diffusion medium and washing the cells with ice-cold 
HBSS buffer, 100 μl of HBSS efflux buffer was added per well and plates were incubated 
at 37°C in a water bath for 3 min. The efflux medium was then removed and placed in vials 
to count the radioactivity. Net MRP4-dependent transport was calculated by subtracting 
background values measured in control cells.  
Isolation of membrane vesicles and protein analysis. Three days after cell transduction 
with MRP4 or EYFP-control virus, the cells were harvested by centrifugation at 3000g for 
30 min. The cell pellets were resuspended in ice-cold homogenization buffer (0.5 mM 
sodium phosphate, 0.1 mM EDTA, pH 7.4) supplemented with protease inhibitors (100 μM 
phenylmethylsulfonyl fluoride, 5 μg.ml-1 aprotinin, 5 μg.ml-1 leupeptin, 1 μM pepstatin, 1 
μM E-64) and shaken at 4°C for 60 min, followed by centrifugation at 4°C at 100,000g for 
30 min. The pellets were homogenized in ice-cold TS buffer (10 mM Tris-HEPES, 250 mM 
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sucrose, pH 7.4) with a tight fitting Dounce homogenizer (30 strokes). After centrifugation 
at 500g at 4°C for 20 min, the supernatant was centrifuged at 100,000g, 4°C for 60 min. 
The resulting pellet was resuspended in TS buffer and passed through a 27-gauge needle 30 
times. The protein concentration was determined using Bio-Rad protein assay kit. Crude 
membrane vesicles were dispensed in aliquots, frozen in liquid nitrogen, and stored at -
80°C until use. 
Vesicular transport assays. Uptake of [
14
C]urate into membrane vesicles was performed as 
described previously (van Aubel et al., 2005). In brief, membrane vesicles were pre-
warmed for 1 min at 37°C and added to TS buffer, supplemented with an ATP-regeneration 
mixture (4 mM ATP, 10 mM MgCl2, 10 mM creatine phosphate, 100 mg ml
-1
 creatine 
kinase) in a final volume of 60 l. The reaction mixture was incubated at 37°C for indicated 
times, and samples were diluted in 900 l of ice-cold TS buffer. Diluted samples were 
filtered through 0.45-m-pore NC filters that were preincubated with TS buffer by a 
filtration device (Millipore, Bedford, MA). Liquid scintillation counting was performed 
after adding 4 ml of scintillation fluid and the uptake of [
14
C]urate into membrane vesicles 
was studied by measuring radioactivity associated with the filters. In control experiments, 
ATP was substituted with AMP. Net ATP-dependent transport was calculated by 
subtracting values measured in the presence of AMP from those measured in the presence 
of ATP. Measurements were corrected for the amount of [
14
C]urate bound to the filters 
(usually 2% of total radioactivity). Each experiment was performed in triplicate.  
Effect of drugs on [
14
C]urate transport in MRP4 vesicles. To evaluate the effect of 
different drug concentrations on [
14
C]urate transport mediated by MRP4, the previously 
mentioned transport assay was performed using HEK-MRP4 vesicles incubated in 100 M 
[
14
C]urate, in the absence or presence of different concentrations of drugs tested. All drugs 
were dissolved in DMSO, with the exception of salicylate that was dissolved in H2O. The 
final concentration of DMSO in the incubation medium was adjusted to 1%, which did not 
have any significant effect on the vesicular transport assay.  
Kinetic analysis. All data were expressed as means ± S.E. IC50 values of drugs tested were 
obtained from curve fitting of the resulting concentration-inhibition curves by nonlinear 
regression analysis using GraphPad Prism software version 4.03 (GraphPad Software Inc., 
San Diego, CA). One way ANOVA, Dunnett‟s multiple comparison, and extra sum-of-
squares F test for model comparison were performed using the same software. 
Results 
Time-dependent diffusion and efflux of [
14
C]urate by HEK-MRP4 cells. HEK293 cells 
over-expressing MRP4 were incubated on ice in HBSS medium containing 50 μM 
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[
14
C]urate. The relative contribution of MRP4 to overall transport was assessed in parallel 
experiments
 
performed on HEK293
 
cells transfected with the control vector expressing 
enhanced yellow fluorescent protein (EYFP). Diffusion of [
14
C]urate into both type of cells 
was similar and increased linearly up to 20 minutes, after which it remained stable for 2 
hours (Fig. 1A). Thus, loading the cells for 30 minutes on ice was chosen before the efflux 
assay was started. Time-dependent efflux of [
14
C]urate from HEK-MRP4 and control cells 
was measured at 15 seconds, 2, 3, 5 and 10 minutes (Fig. 1B).  Net MRP4-dependent urate 
transport was calculated from the difference between HEK-MRP4 and HEK-EYFP efflux, 
and appeared to increase linearly up to 3 minutes (Fig. 1C). 
 
 
 
Fig. 1: Time-dependent uptake and efflux 
of [14C]urate in MRP4 cells. To compare 
the urate uptake in HEK-MRP4 cells to 
that in control cells, cells were incubated 
for 15 seconds, 10, 20, 30 minutes, and 2 
hours at 4°C with HBSS diffusion medium 
containing 50 μM [14C]urate (A). After 
incubation of MRP4 and control cells with 
50 μM [14C]urate for 30 minutes at 4°C, 
efflux was tested by incubating the cells in 
HBSS efflux medium at 37°C  for 15 
seconds, 2, 3, 5 and 10 minutes (B). 
MRP4-mediated [14C]urate efflux was 
calculated by subtracting control cell 
levels (C). 
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Effect of hypouricemic and hyperuricemic drugs on MRP4-mediated [
14
C]urate efflux. 
The effect of different drugs that can alter serum uric acid was tested on urate efflux from 
HEK-MRP4 and HEK-EYFP control cells. Cells were pre-incubated on ice for 30 minutes 
in HBSS medium containing 50 μM [14C]urate in presence or absence of 100 μM of the 
drugs tested (Fig. 2). MRP4-dependent urate transport was calculated from the difference 
between HEK-MRP4 and HEK-EYFP efflux in presence and absence of the drugs. Urate 
efflux without the tested drugs was set at 100%. It was assumed that like urate the tested 
drugs entered the cells by diffusion, but since uptake was not measured intracellular 
concentrations were not known. Furosemide, chlorothiazide, hydrochlorothiazide, 
benzbromarone, probenecid, sulfinpyrazone, and salicylate reduced MRP4-mediated 
[
14
C]urate transport to 29 ± 9, 21 ± 9, 32 ± 11, 7 ± 6, 23 ± 10, 38 ± 13, 69 ± 16 % of control 
MRP4 urate transport, respectively, while bumetanide, torasemide, and oxypurinol had no 
significant effect. Interestingly, allopurinol stimulated [
14
C]urate MRP4 efflux by 146 ± 
5%.  
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Fig. 2: Effect of hypouricemic and hyperuricemic drugs on [14C]urate efflux from MRP4 cells. MRP4 
and control cells were incubated with 50 µM [14C]urate at 4°C for 30 minutes, in the absence or 
presence of 100 μM concentration of the drugs tested. [14C]Urate efflux was measured after 3 minutes 
at 37°C. Net MRP4-mediated efflux was calculated by subtracting the background control levels. 
Urate efflux was expressed as a percentage of uptake measured in presence of the solvent (0.1% in all 
samples) . Values are shown as means and S.E. of 3 different experiments. * Statistically significant 
changes (p0.01) analysed by one way ANOVA and Dunnett’s multiple comparison test.  
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Time-dependent uptake of [
14
C]urate in MRP4 vesicles. Membrane vesicles isolated from 
HEK293 cells over-expressing human MRP4 were incubated for 0, 5, 10, and 15 minutes at 
37°C in uptake medium containing 100 µM [
14
C]urate. Parallel experiments were 
performed on control membrane vesicles isolated from HEK-EYFP
 
cells. ATP-dependent 
transport was determined by subtracting the values
 
obtained in the presence of AMP from 
those in the presence of
 
ATP. MRP4-dependent urate transport was calculated by 
subtracting
 
the nonspecific uptake in control vesicles, and is shown in Figure 3.  Transport 
of [
14
C]urate increased
 
with time and the uptake was linear
 
over the first 15 min of the 
assay. Accordingly, a 10 minute incubation period was chosen for the kinetic and 
interaction experiments. 
Fig. 3: Time-dependent uptake of 
[14C]urate in MRP4 membrane 
vesicles. Time course of the uptake 
of [14C]urate in control HEK-EYFP 
and MRP4 over-expressing 
membrane vesicles was measured at 
a concentration of 100 µM. After 
incubation for 0, 5, 10, and 15 
minutes at 37°C, the ATP-dependent 
[14C]urate uptake was calculated by 
subtracting the uptake in presence of 
AMP from uptake in the presence of 
ATP for MRP4 and control vesicles. 
MRP4-mediated [14C]urate transport 
was calculated by subtracting the 
non-specific uptake in control 
vesicles and was analyzed by linear 
regression analysis. 
Concentration-dependent transport of [
14
C]urate by MRP4 vesicles. Membrane vesicles 
isolated from control and MRP4 over-expressing HEK293 cells were incubated for 10 
minutes at 37°C with [
14
C]-labeled and unlabelled urate to the final concentrations 
indicated (Fig. 4). ATP-dependent [
14
C]urate transport was calculated by subtracting
 
the 
values obtained in the presence of AMP from those in the presence
 
of ATP and after 
correction for ATP-dependent transport in control vesicles,
 
MRP4 showed a positive 
cooperative allosteric interaction with
 
urate, which is in accordance with previous results 
(van Aubel et al., 2005).  The data were described significantly better according to a Hill 
equation with a coefficient of 2.1 ± 0.2 as compared with a simple single-binding site
 
model 
(p < 0.005, F test). The urate concentration at half-maximum uptake rate (Km) was 237 ± 14 
μM, and the maximum transport rate (Vmax) 300 ± 11 pmol.mg
-1
.min
-1
. 
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Fig. 4: Concentration-dependent uptake of [14C]urate in MRP4 membrane vesicles. The uptake rates 
of urate by MRP4 and HEK-EYFP control vesicles were measured at different concentrations of 
[14C]- urate. Net ATP-dependent transport was calculated by subtracting background levels in 
absence of ATP (substituted by AMP). MRP4-dependent transport was determined by subtracting 
control transport, and non-linear regression analysis was performed. Data were described 
significantly better according to a Hill equation with a slope factor (n) of 2.1 (solid line) as compared 
to a model with n=1 (dotted line), indicating positive cooperativity (p<0.005, F test). Values are 
shown as means and S.E. of 3 different experiments performed each in triplicate. 
 
Effect of hypouricemic and hyperuricemic drugs on MRP4-mediated [
14
C]urate 
transport. HEK-MRP4 membrane vesicles were incubated with 100 µM [
14
C]urate at 37°C 
for 10 minutes, in the absence or presence of increasing concentrations of the different 
drugs tested (Fig. 5 and 6). No significant effect of these drugs was observed on urate 
uptake in control vesicles (results not shown). Furosemide, chlorothiazide, 
hydrochlorothiazide, benzbromarone, sulfinpyrazone, and salicylate inhibited [
14
C]urate 
transport with different inhibitory potencies (Table 1). With the exception of furosemide, 
the inhibition curves of these drugs could not be described simply according to a one-site 
competition model, but were fitted significantly better using the two-site model. Probenecid 
stimulated MRP4-mediated urate transport up to 132 ± 8 % at a concentration of 0.1 µM 
and acted as an inhibitor at higher concentrations, thereby producing a bell-shaped curve. 
Both allopurinol and oxypurinol significantly stimulated transport up to 190 ± 50 and 136 ± 
17 %, respectively, in the high micromolar-low millimolar range, while bumetanide and 
torasemide had no effect at all concentrations tested. 
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Fig. 5: Effect of diuretics on MRP4-mediated 
[14C]urate uptake in membrane vesicles. The 
uptake of 100 μM [14C]urate by MRP4 and 
HEK-EYFP control membrane vesicles was 
measured at 37°C for 10 minutes, in the 
presence or absence of different drugs. ATP-
dependent uptake was calculated by 
subtracting the background (AMP) from the 
ATP-dependent uptake. Respective transport 
rates were expressed as a percentage of 
uptake measured in the absence of the drug 
against log drug concentration. Values are 
shown as means and S.E. of 3 different 
experiments performed each in triplicate. 
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Fig. 6: Effect of sulfinpyrazone, benzbromarone, probenecid, salicylate, allopurinol and oxypurinol 
on MRP4-mediated [14C]urate uptake in membrane vesicles. Membrane vesicles were incubated with 
100 μM [14C]urate at 37°C for 10 minutes, in the absence or presence of different concentrations of 
the drugs tested. Uptake was measured by subtracting the background (AMP) from the ATP-
dependent uptake. Respective transport rates were expressed as a percentage of uptake measured in 
the absence of the drug against log drug concentration. Values are shown as means and S.E. of 3 
different experiments performed each in triplicate. 
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Table 1: IC50 values of various drugs tested on MRP4-mediated [
14C]urate transport. 
Drugs MRP4-mediated urate transport (μM) 
Furosemide 1.29 ± 0.01 
Bumetanide  n.i.  
Torasemide  n.i.  
Chlorothiazide 0.241x10-3 
10.4 
± 
± 
0.005x10-3 (H) 
0.1 (L) 
Hydrochlorothiazide  1.9 
220 
± 
± 
0.1 (H) 
3 (L) 
Salicylate 2.1 
1547 
± 
± 
0.1 (H) 
25 (L) 
Sulfinpyrazone 0.16 
40 
± 
± 
0.02 (H) 
1 (L) 
Benzbromarone 0.104 
15.6 
± 
± 
0.01 (H) 
0.2 (L) 
Probenecid 132 ± 0.2a 
Allopurinolb  n.i.  
Oxypurinolb  n.i.  
Membrane vesicles were incubated with 100 μM [14C]urate at 37°C for 10 minutes, in the absence or 
presence of different concentrations of the drugs tested. [14C]-uric uptake was measured by 
subtracting the background (AMP) from the ATP-dependent uptake. Each value represents the 
mean ± S.E. of data obtained from three separate experiments, each performed in triplicate, 
calculated by non-linear regression analysis of the data from figures 5 and 6. High (H) and low (L) 
affinity IC50 determined according to a two-site competition model.  n.i. = no inhibition. 
a At low 
probenecid concentration (0.1 μM) urate transport was stimulated by 132 ± 8%. b Stimulation of urate 
transport upto190 ± 50% at 200 μM allopurinol, and 136 ± 17% at 100 μM oxypurinol, respectively. 
Discussion 
Renal excretion of urate is one of the main factors controlling its plasma levels. 
Previously we identified urate as a substrate of the renal proximal tubule efflux transporter 
MRP4 (van Aubel et al., 2005) , but hardly any information is available on the effect of 
hyper- and hypouricemic drugs on this transport step. Recently, angiotensin II receptor 
blockers have been proposed to modulate plasma urate partially through their effect on 
MRP4-mediated urate efflux (Sato et al., 2008). In the present work, we investigated the 
effects of diuretics, xanthine oxidase inhibitors and uricosuric drugs on urate efflux by 
MRP4.  Using membrane vesicles isolated from HEK293 cells over-expressing human 
MRP4, we confirmed our previous findings that MRP4-mediated urate transport is 
characterized by a positive cooperative allosteric interaction (van Aubel et al., 2005). In 
addition, we showed that different types of drug known to alter serum urate levels could 
affect MRP4-mediated urate transport, which could contribute to their overall effects on 
renal urate excretion.  
  
 
 
 
  
 
 
 
Table 2: Therapeutic plasma concentrations of hypo- and hyperuricemic drugs and transporters regulating their renal proximal tubular handling  
Drugs Cmax (μM) Protein binding (%) Transporter 
Furosemide 0.8 (Bard et al., 2004) 96-98 (Prandota and Pruitt, 
1975) 
OAT3b (Hasannejad et al., 2004) 
   MRP4a (Hasegawa et al., 2007) 
Bumetanide 0.04 (Bard et al., 2004) 95 (Pentikainen et al., 1985) OAT3b (Hasannejad et al., 2004) 
   OAT4a (Hasannejad et al., 2004) 
Torasemide 0.5 (Bard et al., 2004) 99 (Knauf and Mutschler, 
1998) 
OAT4a (Vormfelde et al., 2006) 
Chlorothiazide 0.3 (Welling and Barbhaiya, 
1982) 
70 (Shah et al., 1984) OAT1b (Hasannejad et al., 2004) 
Hydrochlorothiazide  0.1 (Weir et al., 1998) 40-60 (Friedman, 1988) OAT1b (Hasannejad et al., 2004) 
   MRP4a (Hasegawa et al., 2007) 
Salicylate 351 (Keystone et al., 1982) 58 (Dollery, 1991b) OAT1b (Apiwattanakul et al., 1999), 2b and 3b 
(Khamdang et al., 2002) 
   OAT4a (Khamdang et al., 2002), URAT1a (Anzai et al., 
2007) 
Sulfinpyrazone 7 (Dieterle et al., 1975) 98-99 (Perel et al., 1964) - 
Benzbromarone 0.8 (Ferber et al., 1981) 99 (Walter-Sack et al., 
1988) 
- 
Probenecid 42 (Selen et al., 1982) 90 (Dayton et al., 1963) - 
Allopurinol 9 (Turnheim et al., 1999) < 5 (Dollery, 1991a) OAT2b (Kobayashi et al., 2005) 
Oxypurinol 25 (Turnheim et al., 1999) 17 (Dollery, 1991a) URAT1a (Iwanaga et al., 2005) 
Clinically relevant maximum steady-state drug plasma concentrations (Cmax) and the 
a apical and b basolateral proximal tubular membrane 
transporters known to be involved in their renal handling. 
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Several loop and thiazide diuretics are known to decrease the fractional excretion of 
urate and cause hyperuricemia as a side effect (Feig, 1986;Huen and Goldfarb, 2007). One 
of the suggested underlying mechanisms is their effect on renal urate secretion. Recently, 
hydrochlorothiazide and furosemide were identified as substrates of human MRP4 
(Hasegawa et al., 2007). In the same study, bumetanide inhibited MRP4-mediated 
dehydroepiandrosterone sulfate (DHEAS) transport. Here, we found that furosemide and 
hydrochlorothiazide inhibited MRP4-mediated urate transport, whereas bumetanide had no 
effect. Apparently, bumetanide is an inhibitor of DHEAS, but not urate, transport. This is in 
line with our previous findings, in which we have shown that a compound can inhibit one 
MRP4 substrate while not affecting the other because of multiple binding sites (van Aubel 
et al., 2005). Also torasemide had no effect on MRP4-mediated urate transport. It has been 
reported that both bumetanide (Hasannejad et al., 2004) and torasemide (Vormfelde et al., 
2006) are substrates of OAT4, via which their exchange for urate may contribute to their 
hyperuricemic effects. 
The xanthine oxidase inhibitor allopurinol and its active metabolite oxypurinol are used 
in the treatment of hyperuricemia-related conditions. Here, we showed that both oxypurinol 
and allopurinol significantly stimulated MRP4-mediated urate transport, suggesting a novel 
mechanism that may contribute to their plasma urate lowering effect. This is in agreement 
with the complex transport kinetics previously encountered (van Aubel et al., 2005;El-
Sheikh et al., 2007), which could be explained by the presence of two independent transport 
sites and an allosteric site, interacting in a positively cooperative manner. Whether the 
stimulatory effect of oxypurinol and allopurinol is due to co-transport or an allosteric effect 
needs further investigation. Oxypurinol may also affect renal urate handling as a substrate 
of URAT1 exchanger (Iwanaga et al., 2005), whereas allopurinol was reported to have no 
significant effect on URAT1-mediated urate exchange (Enomoto et al., 2002). 
The anti-inflammatory drug salicylate can cause urate retention in plasma at doses less 
than 300 mg per day  (Louthrenoo et al., 2002), which is reversed to uricosuria at a dose 
higher than 3 g per day. The mechanism of the uricosuric effect at high doses has been 
partially explained by inhibition from the luminal side of URAT1-mediated urate 
reabsorption (Enomoto et al., 2002). In addition, salicylate itself is a substrate of URAT1 
(Anzai et al., 2007), where it can possibly compete with urate for reabsorption. Here, we 
showed that salicylate was able to inhibit MRP4-mediated urate transport, with a high 
affinity site IC50 value of 2 μM, which is an attainable concentration even at very low doses 
of salicylate. Nevertheless, the contribution of the high affinity site to overall urate 
excretion may be of minor relevance, and it is more likely that salicylate exerts its low dose 
hyperuricemic effect via interacting with OAT1 and OAT3 (Apiwattanakul et al., 
1999;Khamdang et al., 2002). 
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Similar biphasic effects on renal urate handling have been described for other uricosuric 
drugs like probenecid and sulfinpyrazone (Yu and Gutman, 1955). The main uricosuric 
mechanism proposed for these drugs is inhibition of urate reabsorption via URAT1 
(Enomoto et al., 2002), with benzbromarone showing the highest inhibitory potency (Yu et 
al., 2007). In addition, benzbromarone and sulfinpyrazone are reported to inhibit the low 
affinity urate reuptake transporter OAT4 (Hagos et al., 2007), whereas probenecid inhibits 
both OAT1 and OAT3 transport activity (Takeda et al., 2001). In the present study, 
benzbromarone and sulfinpyrazone inhibited MRP4-mediated urate transport according to a 
two-site binding model. Probenecid acted as an  inhibitor of urate transport at 
concentrations above 5μM, but stimulated transport up to 132% at low concentrations 
(0.1μM). The inhibition of MRP4-mediated urate efflux by these drugs may be another 
factor in their paradoxical effects on renal urate handling. At higher concentrations, their 
inhibitory effect on MRP4 is probably of minor importance compared to the strong 
uricosuric action via inhibition of URAT1- and OAT4-mediated urate reabsorption. 
Although transport studies performed in isolated membrane vesicles overexpressing a 
specific transporter lack regulatory and feedback phenomena that are present in a cellular 
environment, they provide a useful tool to investigate transport mechanisms and inhibition 
kinetics. In the present work, we studied the effect of different drugs on human MRP4-
mediated urate transport in both intact cells and isolated membrane vesicles. Our 
observations were similar, with the exception of oxypurinol which did not show a 
significant effect on urate efflux from intact cells, whereas it stimulated MRP4-mediated 
urate transport in vesicular transport studies. It is possible that in the intact cellular system, 
oxypurinol may not have reached a sufficient concentration to stimulate MRP4 urate efflux. 
To translate our findings to the clinical situation, it is important to realize the role of 
active proximal tubule transporters, mainly OATs, in concentrating each of the tested drugs 
intracellularly via basolateral uptake or apical reabsorption, thereby subjecting MRP4 to 
higher drug levels compared to that in plasma. This concentrating effect of OATs is 
associated with their role in renal toxicity (Sweet, 2005) and emphasizes the importance of 
apical MRPs as an efflux detoxifying route as well as a site for drug interactions. The 
maximum plasma steady-state concentrations and plasma protein binding of the drugs 
studied in the present work as well as the transporters involved in their renal proximal 
tubular handling are summarized in table 2. Most of these compounds have a high plasma 
protein binding. Therefore, unbound fractions are much lower than the total maximum 
steady state concentrations. However, as shown in table 2, several organic anion uptake 
transporters may account for high intracellular concentrations in renal proximal tubule. We 
previously showed up to 20-fold accumulation of salicyluric acid and hydrochlorothiazide 
in rat kidney (Cox et al., 1989;Masereeuw et al., 1997), indicating that local proximal 
tubular concentrations may reach even higher levels. Furthermore, studies in Mrp4 
knockout mice have shown that Mrp4 accounts for the luminal efflux of furosemide and 
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hydrochlorothiazide at therapeutic plasma concentrations (Hasegawa et al., 2007). 
Accordingly, this may result in intracellular concentrations of the diuretics furosemide, 
chlorothiazide and hydrochlorothiazide that could be sufficient to inhibit MRP4-mediated 
urate transport at pharmacologically relevant concentrations. 
In addition to the obvious effects on renal urate excretion, MRP4 presumably has a role 
in regulating urate levels in various tissues where it is expressed, including the liver 
(Gradhand et al., 2007), vascular smooth muscle (Mitani et al., 2003), brain (Hirrlinger et 
al., 2005), intestine (Zimmermann et al., 2005), blood cells (Kock et al., 2007), and 
placenta (Azzaroli et al., 2007). The role of MRP4 may have different implications 
depending on the tissue and side of cell membrane in which MRP4 is expressed. MRP4 
expressed apically in the intestine might be a site where allopurinol stimulates the luminal 
efflux of urate (Shaw and Parsons, 1984;Li et al., 2007). In vascular smooth muscle, where 
urate is taken up by URAT1 (Price et al., 2006), efflux via MRP4 could play a role in 
regulating intracellular urate levels. Interestingly, urate has been implicated in the 
pathogenesis of hypertension and microvascular diseases (Hediger et al., 2005) and 
stimulation of urate efflux may be a mechanism contributing to the beneficial effects of 
allopurinol in urate-induced vascular pathology (Mazzali et al., 2002;George et al., 2006). 
Furthermore, the inhibition of erythrocyte-mediated ATP-dependent urate transport by 
salicylate (Lucas-Heron and Fontenaille, 1979) may be explained by the interaction at the 
erythrocyte MRP4 level. 
In summary, our study shows that MRP4-mediated efflux of urate can provide a 
potential target for drugs affecting plasma urate levels. In addition to their known effects on 
renal urate uptake transporters, altering MRP4-mediated urate secretion may be a novel 
mechanism in the hyperuricemic effects of diuretics and hypouricemic effects of xanthine 
oxidase inhibitors. The human apical urate efflux transporter MRP4 could provide a new 
target for the development of drugs in the treatment of hyperuricemia. Its relative 
importance as opposed to the other renal urate transporters needs to be verified in vivo. In 
addition, the results of this study also indicate that potential drug-drug interactions may 
occur between the studied hypo- and hyperuricemic drugs and other MRP4 substrates. 
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Summary 
Urate 1 transporter (URAT1) and multidrug resistance protein 4 (MRP4) are considered 
key players in regulating renal urate homeostasis. We have previously tested the effect of 
drugs known to alter serum urate levels on MRP4. Here, we investigated the effect of 
hyper- and hypouricemic drugs on URAT1-mediated [
14
C]urate transport in cells. Our 
results showed that the Km value of [
14
C]urate transport was 270 ± 40 µM. 
Hydrochlorothiazide cis-stimulated, while chlorothiazide, benzbromarone, probenecid, 
sulfinpyrazone, salicylate, oxypurinol, and penicillin cis-inhibited URAT1-mediated urate 
transport in HEK293 cells. We also have successfully double-transduced these cells to 
simultaneously over-express both URAT1 and MRP4 transporters. To gain further insight 
in the mechanism of urate exchange, we employed membrane vesicles isolated from 
HEK293 cells over-expressing URAT1. We confirmed membrane vesicle activity by 
kinetic analysis and inhibition assays. Using membrane vesicles, we showed that 
benzbromarone competitively, while chlorothiazide non-competitively cis-inhibited 
URAT1-mediated urate transport. In addition, chlorothiazide, but not benzbromarone, 
trans-stimulated urate transport. Membrane vesicles over-expressing URAT1 transported 
[
14
C]urate bidirectionally and uptake was increased by an outward directed chloride 
gradient, which was further trans-stimulated by urate. In conclusion, the URAT1 protein is 
a gradient-sensitive bi-directional exchanger that could play a role in drug-induced renal 
uricemic effects. 
Introduction 
The human kidney is the main excretory organ of urate, the major end product of purine 
metabolism. Renal urate excretion is complex and includes glomerular filtration, secretion 
and reabsorption steps. The transport of urate across renal membranes is conducted via a 
number of active transporters (Anzai et al., 2007). At the renal basolateral membrane, 
organic anion transporters (OAT) 1 and 3 transport urate from the blood into the proximal 
tubule cells (Ichida et al., 2003;Bakhiya et al., 2003). At the renal apical membrane, the 
asymmetrical urate transporter OAT4 is involved in urate reabsorption (Hagos et al., 2007). 
Recently, two other renal urate transporters were described; OAT10 (Bahn et al., 2008) and 
SLC2A9 (Vitart et al., 2008). Human multidrug resistance protein 4 (MRP4), a well-
characterized ATP-dependent transporter involved in renal excretion of a large diversity of 
endogenous and exogenous compounds (Russel et al., 2008), is involved in active renal 
secretion of urate (van Aubel et al., 2005). Urate 1 transporter (URAT1), which, unlike 
MRP4, has a narrow substrate specificity (Enomoto et al., 2002) is involved in renal 
regulation of urate. The contribution of URAT1 to the overall renal urate handling is clearly 
manifested in a group of Japanese patients presenting with severe renal hypouricemia due 
to malfunctions in URAT1 (Komatsuda et al., 2006). To date, little is known about the 
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mechanisms of transport of URAT1. The limited number of previous studies were 
conducted on URAT1 over-expressing Xenopus oocytes and HEK293 cells (Enomoto et al., 
2002;Iwanaga et al., 2005;Yu et al., 2007;Sato et al., 2008). Here, we designed and 
validated an URAT1 over-expressing membrane vesicular system, providing a simple tool 
suitable for conducting exchange experiments. Furthermore, we studied the properties of 
URAT1 as a gradient-sensitive bidirectional urate exchanger and as a target for drugs that 
may alter serum homeostasis by interacting with URAT1-mediated urate reabsorption. In 
addition, we also developed and characterized a transient double transduced HEK293 cell 
over-expressing human MRP4 and URAT1.  
Materials and Methods 
Materials. [8-
14
C]urate (53 mCi/mmol) was purchased from Moravek Inc. (Brea, CA). The 
Bac-to-Bac and Gateway system were purchased from Invitrogen (Breda, The 
Netherlands). NC45 filters were obtained from Schleicher and Schuell (Den Bosch, The 
Netherlands). Protein concentrations were determined with an assay kit form Bio-Rad 
Laboratories (Veenendaal, The Netherlands). All drugs tested were purchased from Sigma-
Aldrich (St. Louis, MO, USA). 
Isolation and Cloning of Human URAT1. Total RNA was isolated from human kidney 
cortex by using trizol (Invitrogen, Breda, The Netherlands), chloroform and isopropanol 
and was reverse-transcribed in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 10 mM 
dithiothreitol, 3 mM MgCl2, supplemented with 0,625 mM dNTP, 0,75 M reverse primer 
URAT1_rev1 [CTAAAACTGTGTGGATTTTAGG], and 200 U of Moloney murine 
leukemia virus reverse transcriptase (Invitrogen, Breda, The Netherlands). For 
amplification of URAT1 cDNA primers were designed on basis of the published human 
sequence (nucleotides 1 to 1662, Genbank accession number NM_144585). The forward 
primer URAT1_attB1_For1 [5‟-GGGGACAAGTTTGTACAAAA-AAGCAGGCTTCGC 
CACCATGGCATTTTCTGAACTCCTG-3‟; the attB1 site for the Gateway system is 
underlined, a partial Kozak sequence in bold, and ATG is italic] and the reverse primer 
URAT1_attB2_Rev1 [5‟-GGGGACCACTTTGTACAAGAAAGCTGGGTCC-TAAAACT 
GTGTGGATTTTAGG-3‟; the attB2 site is underlined] were used to amplify the cDNA. 
PCR was performed with the Pfu Turbo PCR enzyme system (Stratagene, La Jolla, CA). 
Amplifications were performed for 35 cycles of 94
o
C for 45 s, 60
o
C for 30 s, and 72
o
C for 3 
min. The PCR product obtained was purified and cloned into pDONR201 by the BP 
gateway reaction and this formed the pENTR201-URAT1.  
Generation of Human URAT1 and MRP4 Baculoviruses and Transduction of HEK293 
Cells. Human URAT1 and MRP4 baculoviruses were generated as previously described (El 
Sheikh et al., 2007). Briefly, the Bac-to-Bac system, normally used for protein production 
in insect cells, was made suitable for protein expression in mammalian cells. The human 
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URAT1, MRP4, and the enhanced yellow fluorescent protein (EYFP; control) were cloned 
into the Gateway entry vector (Invitrogen). Baculoviruses were produced as described in 
the Bac-to-Bac manual. To transduce HEK293 cells with URAT1 or control baculoviruses, 
cells were cultured in 182-cm
2
 flasks containing DMEM supplemented with 10% fetal calf 
serum at 37°C under 5% CO2-humidified air until 70% confluence. The medium was 
replaced by 1.5 ml of virus completed to 5 ml by medium. To double-transduce the cells to 
over-express both MRP4 and URAT1, equal volumes (1.5 ml from each) were added and 
completed to 5 ml by medium. To subject control cells to the same virus amounts, extra 1.5 
ml of EYFP baculovirus were added to EYFP, URAT1 or MRP4 control cells. After 
incubating the cells for 30 min at 37°C, 20 ml of medium was added. Sodium butyrate (5 
mM) was added after 24 h of transduction.  
Transport and Inhibition Assays in Cells. For cellular transport assays, after 2 days of 
transduction, cells were harvested and seeded for 24 hours in collagen pre-coated 96 wells 
plates, at a density of 2.5 X 10
4
 cells/well. Cellular monolayers of transduced cells were 
seeded in 96-wells plates. The medium was removed and plates were incubated in HBSS 
medium (containing 1 mM CaCl2, 0.5 mM MgCl2, 0.4 mM MgSO4, 5 mM KCl, 0.4 mM 
KH2PO4, 4 mM NaHCO3, 138 mM NaCl, and 0.3 mM Na2HPO4) at 27°C supplemented by 
10 μM [14C]urate with or without the different drugs to be tested in the indicated 
concentrations. The transport was stopped after the indicated time by removing the 
medium, washing the cells with ice-cold HBSS buffer, and lysing them using 0.1% triton. 
To measure the amount of [
14
C]urate actively taken up into the cells, liquid scintillation 
radioactivity counting was performed on lysed cells after adding 4 ml of scintillation fluid. 
In parallel experiments, transduced cells were scraped, lysed with 0.1% triton, and their 
protein concentration was determined using Bio-Rad protein assay kit. The uptake levels of 
URAT1 over-expressing cells were corrected with those of control cells. Each experiment 
was performed in triplicate.  
Immunoblotting of MRP4/URAT1 Double Transduced Cells. Pellets of transduced cells 
were resuspended in 1 ml lysis buffer containing (per 10 ml) 10 µl DNAse I (invitrogen) 
and a protease inhibitor cocktail tablet (Roche, Mannheim, Germany). Lysed cells were 
snap-frozen in liquid nitrogen then thawed three times. This was followed by centrifugation 
at 16000g for 10 minutes. After the removal of the supernatant, the pellets were 
resuspended in lysis buffer and protein concentration determined and fixed to 2 mg/ml. 
Proteins were size fractionated
 
on a 7.5% SDS-polyacrylamide gel and subsequently blotted 
on
 
nitrocellulose membrane. Affinity-purified, polyclonal rabbit serum anti-human MRP4 
(pAb hM4-p4; 1:5000) was used to detect human MRP4 (Smeets et al., 2004). For 
generating human URAT1 antibodies, using the URAT1_Ab1_For1 primer [5‟-
GGGGGGATCCGGCTGGATTGGGGCCTGCAG-3‟; the restriction site for BamHI is 
underlined] and the URAT1_Ab1_Rev1 primer [5‟-GGGGGAATTCCAGGG-TGCCCAG 
GCTGGCAG-3‟; the restriction site for EcoRI is underlined] the encoding cDNA was 
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amplified from pENTR201-URAT1 and cloned in-frame into the expression vector pGEX-
3x (Pharmacia, Woerden, The Netherlands). Briefly, the glutathione S-transferase (GST) 
fusion protein was expressed in DH5 Escherichia coli cells and isolated by glutathione-
Sepharose 4B (Amersham, Uppsala, Sweden) affinity chromatography. Rabbits were 
immunized and boosted two times with fusion protein (400 and 2 X 200 g, respectively), 
followed by collection of serum. This polyclonal rabbit anti-human URAT1 antibody (pAB 
hURAT1; 1:5000) was used to detect expression of human URAT1. The secondary 
antibody used was the fluorescent Alexa Fluor 680 (Invitrogen). Signals were visualized 
with a fluorescent method, using Odyssey infrared imaging system (Li-Cor Biosciences, 
Lincoln, USA). 
Isolation of HEK-URAT1 Membrane Vesicles. For membrane vesicle transport assays, 
three days after transduction of HEK cells with URAT1 or EYFP control, the cells were 
harvested by centrifugation at 3000g for 30 min and pellets were stored at –80 °C until 
membrane vesicles were isolated. HEK-URAT1 and control cellular pellets were 
resuspended in ice-cold homogenization buffer (0.5 mM sodium phosphate, 0.1 mM 
EDTA, pH 7.4) supplemented with protease inhibitors (100 μM phenylmethylsulfonyl 
fluoride, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 1 μM pepstatin, 1 μM E-64) and shaken at 
4°C for 60 min. The lyzed cells were centrifuged at 4°C at 100,000g for 30 min and the 
resulting pellets were homogenized in ice-cold TS buffer (10 mM Tris-HEPES, 250 mM 
sucrose, pH 7.4) with a tight-fit Dounce glass homogenizer (30 strokes). The homogenate is 
centrifuged at 500g at 4°C for 20 min, and the supernatant was centrifuged at 100,000g, 
4°C for 60 min. The resulting pellet was resuspended in chloride-gradient buffer (10 mM 
Tris-HEPES, 250 mM sucrose, and 100 mM KCl pH 7.4) unless otherwise indicated. To 
test the trans-effects, chloride-gradient buffer was supplemented with the drug to be tested 
in the indicated concentrations. The resuspended pellets were passed through a 27-gauge 
needle 30 times. The protein concentration was determined using Bio-Rad protein assay kit. 
Crude membrane vesicles were dispensed in aliquots, snap-frozen in liquid nitrogen, and 
stored at -80°C until use. 
HEK-URAT1 Membrane Vesicular Transport and Inhibition Assays. To test the uptake 
of [
14
C]urate and the cis-effects exerted by different drugs tested, 6 µl URAT1 membrane 
vesicles were thawed and added to TS-potassium gluconate incubation buffer (10 mM Tris-
HEPES, 250 mM sucrose, 100 mM potassium gluconate pH 7.4) pre-warmed to 27°C, 
supplemented with 100 µM [
14
C]urate (unless otherwise indicated) with or without 
different drugs tested, in a final volume of 116 l. The reaction mixture was incubated for 
indicated times, and samples were diluted in 900 l of ice-cold TS buffer to stop the 
reaction. Diluted samples were immediately filtered through 0.45-m-pore NC filters that 
were pre-incubated with incubation buffer by a filtration device (Millipore, Bedford, MA). 
Liquid scintillation counting was performed after adding 4 ml of scintillation fluid and the 
uptake of [
14
C]urate into membrane vesicles was studied by measuring radioactivity 
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associated with the filters. Parallel experiments were performed using control vesicles and 
net URAT1-dependent transport was calculated by subtracting background control values. 
Measurements were corrected for the amount of [
14
C]urate bound to the filters (usually 
2% of total radioactivity). The uptake levels of URAT1 vesicles were corrected with those 
of control vesicles. Each experiment was performed in triplicate.  
Kinetic Analysis. All data were expressed as means ± S.D. IC50 values of drugs tested were 
obtained from curve fitting of the resulting concentration-inhibition curves by nonlinear 
regression analysis using GraphPad Prism software version 4.03 (GraphPad Software Inc., 
San Diego, CA). One way ANOVA and Dunnett‟s multiple comparison tests were 
performed to determine the statistical significance using the same software. Results of 
chlorothiazide and benzbromarone inhibition assays were analyzed using Dixon‟s method, 
to estimate the binding affinity (Ki) reflecting the inhibitory potency. 
Results 
 [
14
C]Urate Time- and Concentration-Dependent Transport in URAT1 Cells. Cellular 
transport studies were performed, using URAT1 over-expressing cells as well as control 
cells, incubated with 10 µM [
14
C]urate for the indicated time points in Fig. 1A. URAT1-
mediated [
14
C]urate uptake, driven by intracellular anions, was nearly 3-fold higher 
compared to control cells after 1 min incubation (results not shown). URAT1 transport was 
linear up to 1 min. Therefore, subsequent cellular experiments were incubated for 1 min. 
The kinetics of URAT1-mediated urate transport in cells over-expressing URAT1 was 
tested using [
14
C]urate concentrations up to 700 µM. A Km of 270 ± 40 µM and a Vmax of  
87 ± 5 pmol/mg/min was determined (Fig. 1B).  
Effect of Drugs on [
14
C]Urate Transport in URAT1 Cells. Cells over-expressing URAT1, 
as well as controls, were incubated in the presence of 10 µM [
14
C]urate with different 
concentrations of drugs, [
14
C]urate transport in the absence of the different drugs was set at 
100% (Fig. 2). Chlorothiazide, probenecid, benzbromarone, sulfinpyrazone, salicylate, 
oxypurinol, and penicillin cis-inhibited URAT1-mediated urate transport in cells. The 
estimated IC50 values are depicted in Table 1. Hydrochlorothiazide, on the other hand, 
stimulated urate transport up to 170 ± 30 % in cells. 
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Fig. 1: Time- and concentration-
dependent transport of [14C]urate by 
HEK293-URAT1 cells. A: After 
incubation of URAT1 cells with 10 µM 
[14C]urate, time-dependent uptake was 
measured at indicated time points. 
URAT1-dependent uptake showed linear 
transport in time up to 1 minute. B: 
URAT1 cells were incubated  for 1 min 
with increasing urate concentrations. See 
text for kinetic parameters derived from 
this curve.  
 
 
 
 
Characterization of MRP4/URAT1 Double-Transduced Cells. HEK293 cells were 
transduced with baculovirus and MRP4 or URAT1 were expressed separately or together 
(Fig. 3). The expression levels of single or co-expressed MRP4 or URAT1 were 
comparable in all experiments. We have previously observed that MRP4 may show more 
than one band in the Western blot, and we confirmed that this is due to different 
glycosylation levels of the protein (El-Sheikh et al., 2008b). This probably applies to 
URAT1, as we observed two bands when we performed a Western blot of human renal 
bursh border membranes using URAT1 antibody (results not shown). Conducting cellular 
transport assays revealed that the accumulation of [
14
C]urate in cells transduced with the 
uptake transporter URAT1 was significantly higher than control levels. On the other hand, 
cells transduced with the efflux transporter MRP4 showed lower accumulation levels of 
[
14
C]urate than control cells, probably due to the efflux of urate by MRP4. Double 
transduced HEK-MRP4/URAT1 cells showed a level of [
14
C]urate accumulation that was 
intermediate between the single MRP4- and URAT1-transduced cells. 
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Fig. 2: Effect of drugs on [14C]urate uptake by URAT1 cells. URAT1 over-expressing cells as well as 
controls were incubated with 10 µM [14C]urate in absence or presence of a range of concentrations 
of drugs. Urate transport in absence of drugs was set to 100%. After analysis of the inhibition curves 
by non-linear regression, IC50 values were estimated (Table 1). 
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Fig. 3: Functional expression of 
human MRP4 and URAT1 in HEK293 
double-transduced cells. Upper panel: 
Western blot showing the expression of 
human MRP4 (170 kDa) and URAT1 
(60 kDa). Lower panel: Transport of 10 
µM [14C]urate in HEK293 cells 
overexpressing MRP4 or URAT1. 
 
 
 
 
Characterization of URAT1-mediated [
14
C]Urate Transport in Membrane Vesicles. 
Membrane vesicles isolated from cells over-expressing URAT1 and control cells were 
incubated with 100 µM [
14
C]urate. URAT1-mediated [
14
C]urate uptake (in exchange for 
100 mM Cl
-
) was 3-fold higher compared to control vesicles after 30 sec incubation (results 
not shown). Net URAT1 transport was calculated by subtracting control levels and showed 
linearity up to 30 sec (Fig. 4A).Vesicles over-expressing URAT1 and control vesicles were 
also incubated with a range of [
14
C]urate concentrations up to 2 mM. A Km value of 660 ± 
60 µM, and a Vmax value of 870 ± 30 pmol/mg/min were determined (Fig. 4B).  
Effect of Drugs on [
14
C]Urate Transport in URAT1 Vesicles. To compare cellular and 
vesicular results, inhibition studies previously performed on cells were also conducted on 
membrane vesicles over-expressing URAT1 as well as controls. Vesicles were incubated 
with 10 µM [
14
C]urate and different concentrations of drugs. URAT1-mediated [
14
C]urate 
transport in absence of drugs was set at 100%. Effect of the different drugs was represented 
as a percentage of control (Fig. 5). Similar to our findings in cells, hydrochlorothiazide 
stimulated (up to 140 ± 8 %), whereas chlorothiazide, probenecid, benzbromarone, 
sulfinpyrazone, salicylate, oxypurinol, and penicillin cis-inhibited URAT1-mediated urate 
transport in vesicles. The estimated IC50 values varied between cellular and vesicular 
studies (Table 1). 
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Fig. 4: Time- and concentration-
dependent transport of [14C]urate by 
HEK293-URAT1 membrane vesicles. 
A: URAT1 membrane vesicles were 
incubated with 100 µM [14C]urate with 
an inside-out gradient of 100 mM KCl. 
The urate transport of URAT1 vesicles 
was corrected with transport of control 
and showed linear transport up to 30 
seconds. B: URAT1 membrane vesicles, 
having an inside-out gradient of 100 
mM KCl, were incubated for 15 sec with 
urate concentrations indicated. See text 
for kinetic parameters derived from this 
curve. 
 
 
 
Interaction of Chlorothiazide and Benzbromarone on [
14
C]urate Transport in URAT1 
Membrane Vesicles. Chlorothiazide and benzbromarone were chosen to be further 
investigated to clarify the mechanism of their inhibition using membrane vesicles over-
expressing URAT1. Vesicles were incubated with one of 3 different concentrations of 
[
14
C]urate, in the presence or absence of various concentrations of the drug to be tested. The  
cis-inhibition curves obtained were analyzed by linear regression (Fig. 6). The resulting 
graph (a Dixon plot) showed that the intersection of the 3 lines representing the drug 
inhibition curves at 3 different [
14
C]urate concentrations was at the x-axis for 
chlorothiazide, indicating a non-competitive inhibitory effect. On the other hand, the 3 lines 
for benzbromarone intersected at the y-axis, indicating competitive inhibition. Ki values 
were 398 ± 3 and 0.019 ± 0.008 µM for chlorothiazide and benzbromarone, respectively. 
To test the trans-effects of these two drugs on [
14
C]urate transport, the intra-vesicular 
chloride-gradient buffer was supplemented with either 10 µM chlorothiazide or 100 nM 
benzbromarone during the membrane vesicle isolation step. Chlorothiazide significantly 
trans-stimulated net URAT1-dependent [
14
C]urate transport by 165 ± 18%, while 
benzbromarone showed no significant difference to the control [
14
C]urate transport levels 
(98 ± 11%). We also tested the trans-effect of 10 nM and 1 µM benzbromarone, but could 
not detect a trans-stimulatory effect on [
14
C]urate transport (results not shown). 
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Fig. 5: Effect of drugs on [14C]urate transport by URAT1 in membrane vesicles. Membrane vesicles 
over-expressing URAT1 as well as their corresponding controls were incubated with 100 µM 
[14C]urate in the absence or presence of a range of concentrations of drugs indicated. Urate 
transport in absence of drugs was set to 100%. The IC50 values estimated by linear regression 
analysis are summarized in table 1. 
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Table 1. IC50 values of various drugs tested on URAT1-mediated [
14C]urate transport in cells and 
membrane vesicles. 
 IC50 (μM) 
Drugs URAT1 cells URAT1 vesicles  
Chlorothiazide 12 ± 0.3 351 ± 6 
Benzbromarone 6.5 x10-3 ± 0.2 27 x10-3 ± 1x10-3 
Probenecid 0.65 ± 0.02 45 ± 2 
Sulfinpyrazone 19.5 x10-3 ± 0.4 x10-3 8.6 ± 0.3 
Salicylate 97 ± 3 1470 ± 100 
Oxypurinol 0.36 ± 0.02 9.2 ± 0.6 
Penicillin 47 ± 2 680 ± 30 
Each value represents the mean ± S.D. of data obtained from three separate experiments, each 
performed in triplicate, calculated by non-linear regression analysis of the data from figures 2 and 5. 
Gradient-Dependent Effects on [
14
C]urate Transport in URAT1 Membrane Vesicles. To 
test the effect of different chloride concentration gradients on URAT1-mediated [
14
C]urate 
transport, the intra-vesicular chloride-gradient buffer used in membrane vesicle isolation 
contained 0-300 mM KCl. Our results show that, by increasing the chloride gradient, 
URAT1-mediated [
14
C]urate transport increased linearly up to the highest level of chloride 
gradient tested (Fig. 7A). To test the possibility of bi-directional exchange of urate, 
URAT1-mediated transport of [
14
C]urate was tested in membrane vesicles containing intra-
vesicular KCl, urate or KCl plus urate. Net [
14
C]urate transport mediated by URAT1 in 
exchange for intra-vesicular urate was comparable to that of KCl gradient-dependent levels. 
The additional [
14
C]urate transport created by either KCl or urate gradient separately was 
significantly less than when both KCl and urate were present together intra-vesicularly 
(Fig. 7B). This finding revealed that urate and KCl synergistically stimulated [
14
C]urate 
transport via URAT1 up to 166 ± 14% (P < 0.001) (results not shown).  
Discussion 
Only a limited number of reports investigated urate transport and drug interactions at 
URAT1 level (Enomoto et al., 2002;Iwanaga et al., 2005;Yu et al., 2007;Sato et al., 2008). 
We used HEK293-URAT1 uptake studies and an URAT1 vesicular transport system to 
investigate the molecular role of eight drugs that are known to affect the physiological urate 
concentration. We showed that hydrochlorothiazide cis- and chlorothiazide trans-effects on 
URAT1 may contribute to their hyperuricemic effects. Probenecid, sulfinpyrazone, and 
benzbromarone inhibited urate transport via URAT1, which is in agreement with previous 
studies (Enomoto et al., 2002;Yu et al., 2007). Moreover, we demonstrated that oxypurinol 
and salicylate also inhibit URAT1, which may contribute to their overall effects on renal 
urate handling. Finally, we have shown that penicillin inhibits URAT1-mediated urate 
transport, which may contribute to its uricosuric effect. 
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Fig. 6: Effect of chlorothiazide and 
benzbromarone on [14C]urate transport in 
URAT1 membrane vesicles. Different 
concentrations of chlorothiazide (upper panel) 
or benzbromarone (lower panel) were 
incubated with [14C]urate in concentrations of 
50, 100 and 150 µM for inhibition 
experiments of chlorothiazide and 50, 150 and 
300 µM for that of benzbromarone. The 
inhibition curves at the 3 different [14C]urate 
concentrations were analyzed by linear 
regression and a Dixon plot of the reciprocal 
of velocity against inhibitor concentration was 
constructed. See text for estimated Ki values. 
 
 
 
 
Fig. 7: Effect of different Cl- gradients on 
[14C]urate in URAT1 membrane vesicles. A: 
URAT1 and control membrane vesicles with 
intra-vesicular chloride-gradient buffer ranging 
from 0 to 300 mM of KCL were used to test 
[14C]urate transport in a concentration of 100 
µM. Control levels were deducted and net 
URAT1-dependent transport is shown. B: 
Membrane vesicles over-expressing URAT1 as 
well as their corresponding controls with intra-
vesicular KCl (67 mM), urate (1 mM), or both 
KCl and urate (67 and 1 mM, respectively) were 
used to test [14C]urate transport in a 
concentration of 50 µM.  
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Species differences make it extremely difficult to find a suitable animal model to test 
the kinetics of renal urate transport. Accumulation of urate in humans and higher primates 
is due to genetic silencing of the uricase enzyme which converts urate to allantion in other 
species (Taniguchi and Kamatani, 2008). Furthermore, the mouse ortholog of human 
URAT1, the mouse renal-specific transporter (RST), has nearly 4-fold less affinity for urate 
(Km of 1.2 mM) (Hosoyamada et al., 2004) than human URAT1. In vitro trials have been 
performed to demonstrate urate transport in vesicles isolated from human renal apical 
membrane (Roch-Ramel et al., 1994), yet it lacked the specificity to correlate such transport 
with a certain transporter. 
In the present study, URAT1 cells mediated [
14
C]urate transport with an apparent Km of 
nearly 270 µM, which is in agreement with the Km for urate previously reported using 
oocytes (Enomoto et al., 2002). URAT1 vesicles, driven solely by a 100 mM KCl 
outwardly directed gradient, had a nearly 3-fold higher apparent Km than that of the 
HEK293 cells. When we studied the effect of a variety of drugs that can affect serum urate 
levels on URAT1-mediated urate transport, the inhibitory potency of the drugs tested varied 
between membrane vesicles and cells. These differences may be explained by the lack of 
other possible intracellular anions as well as accessory proteins like PDZK1 known to 
regulate URAT1-mediated urate transport (Anzai et al., 2004). Nevertheless, the results in 
both membrane vesicles and cells were identical concerning the order of inhibitory potency 
(benzbromarone > sulfinpyrazone > oxypurinol > probenecid > chlorothiazide > penicillin 
> salicylate). This indicates that the vesicular system can be efficiently used in high-
throughput screening of URAT1 substrate/inhibitors.  
We used our vesicular system, in parallel with URAT1 cells to test [
3
H]folate, 
[
3
H]methotrexate, and [
3
H]taurocholate as URAT1 substrates. We also tested the effect of 
cyclosporine A as an inhibitor, because of its known hyperuricemic side effect. None of 
these compounds proved to interact with URAT1 (results not shown). This may indicate the 
specificity of URAT1 to compounds structurally related to purines. Using URAT1 
membrane vesicles, we show for the first time that [
14
C]urate transport can be driven by an 
opposite  urate gradient and that it can, synergistically with a chloride gradient, stimulate its 
own uptake. Our findings indicate that URAT1 bi-directionally transports urate in a 
direction opposite to that of the driving gradient.  
Thiazide diuretics are known to decrease the fractional excretion of urate and may cause 
hyperuricemia (Huen and Goldfarb, 2007). One of the suggested mechanisms is by 
modulation of renal urate secretion. We have previously shown that hydrochlorothiazide 
and chlorothiazide could inhibit MRP4-mediated urate efflux (El-Sheikh et al., 2008a). 
Here, we investigated for the first time the interaction of these thiazide diuretics with the 
URAT1 transporter, and our results show that hydrochlorothiazide cis-stimulated urate 
transport via URAT1. Interestingly, chlorothiazide non-competitively cis-inhibited and 
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trans-stimulated URAT1-mediated transport. The chlorothiazide Ki (nearly 400 µM) is 
probably too high to be pharmacologically relevant. On the other hand, chlorothiazide 
trans-stimulated URAT1-mediated urate transport up to nearly 170 % at a much lower, 
therapeutically relevant, concentration (10 µM). Hydrochlorothiazide cis- and 
chlorothiazide trans-effects may thus contribute to their hyperuricemic effects.  
In the present study, probenecid, sulfinpyrazone, and benzbromarone inhibited urate 
transport via URAT1, which is in agreement with previous studies (Enomoto et al., 
2002;Yu et al., 2007). The IC50 values representing the inhibitory potency of these 
uricosuric drugs were within pharmacologically relevant levels. Their net uricosuric effects 
are probably mediated via the interaction with several other renal urate transporters. 
Benzbromarone and sulfinpyrazone are known to inhibit urate the apical reuptake 
transporter OAT4 (Hagos et al., 2007), and probenecid inhibits both OAT1 and OAT3 
transport activity in the basolateral membrane (Takeda et al., 2001). Previously, we showed 
that these drugs interact with MRP4-mediated urate transport, which may explain their 
paradoxical biphasic effects on urate excretion (El-Sheikh et al., 2008a). The competitive 
inhibition of benzbromarone exerted on URAT1-mediated urate transport could indicate 
that it as a possible substrate of URAT1.  
Oxypurinol, the xanthine oxidase inhibitor used in the treatment of hyperuricemia, and 
salicylate, the prototypic non-steroidal anti-inflammatory drug, are known to alter serum 
urate levels. We have previously shown that oxypurinol stimulated while salicylate 
inhibited MRP4-mediated urate transport (El-Sheikh et al., 2008a). Here, we demonstrated 
the effect of oxypurinol and salicylate on URAT1, and showed that both inhibited urate 
transport, which may contribute to their overall effects on renal urate handling. This is in 
agreement with previous studies suggesting oxypurinol and salicylate as substrates of 
URAT1 (Iwanaga et al., 2005;Anzai et al., 2007).  
Penicillin is known to cause uricosuria in vivo (Sommers and Schoeman, 1987). 
Penicillin interacts with several transporters involved in urate transport, including OAT1 
(Jariyawat et al., 1999), OAT3 (Cha et al., 2001;Vanwert et al., 2007), and OAT4 (Cha et 
al., 2000). Here we show that penicillin inhibited URAT1-mediated urate transport, which 
may contribute to its uricosuric effect. Our results also indicate that previous experiments 
with HEK293 cells over-expressing URAT1 and penicillin added to the culture medium (to 
prevent microbial infection) (Yu et al., 2007), may have been confounded due to the effect 
of penicillin on URAT1-mediated transport.  
In the present study, we succeeded in double transducing HEK293 cells and transiently 
over-expressing MRP4 and URAT1. We demonstrated the expression of both transporters 
and the transport of [
14
C]urate, which is a substrate of both transporters. Double-
transduction is a useful screening tool for common substrates/inhibitors especially for 
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efflux transporters, because some compounds cannot access these transporters without 
carrier-mediated cellular uptake. Futhermore, multi-transporter expression systems may 
more closely resemble the physiological situation.  
In summary, using URAT1 over-expressing membrane vesicles, we demonstrated that 
URAT1 is a gradient-sensitive bi-directional exchanger, that may be a target for drugs that 
alter serum urate, including thiazide diuretics, uricosurics, and penicillin.  
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Introduction 
Renal tubular transport has recently been recognized as an important pharmacokinetic 
determinant contributing to immunosuppressant drug disposition, their adverse effects and 
transporter-mediated drug-drug interactions (Christians et al., 2006;Mourad et al., 2008). 
Because of the chemical diversity of immunosuppressants and the number of renal 
transporters involved, the underlying mechanisms are not yet fully elucidated. Furthermore, 
renal transporters interact with a wide variety of endogenous and exogenous compounds, as 
reviewed in chapter 2. They may affect immunosuppressant drug disposition or their 
excretion can be affected by concomitant intake of immunosuppressants. In this thesis, an 
attempt was made to unravel some of the mechanisms of immunosuppressant handling by 
renal drug transporters and their interaction with other compounds. Chapters 3-5, 7 and 8 
described interactions of a number of immunosuppressants and non-immunosuppressants 
with the renal transporters MRP2, MRP4, OAT1, and/or URAT1. In chapters 3 and 5, the 
participation of the apical efflux transporters, MRP2 and MRP4, in the clinically reported 
drug-drug interactions between MTX and NSAIDs (Frenia and Long, 1992), and 
mycophenolic acid (MPA) and cyclosporine (CsA) (Filler et al., 2001;Hohage et al., 
2005;Picard et al., 2006) were described. Furthermore, in chapter 5, MPA and MPAG were 
identified as novel substrates of human MRP2. In addition to MTX and MPA, in chapter 4 
the interaction was studied of a number of immunosuppressants with OAT1, MRP2, and 
MRP4. In chapters 7 and 8, drugs were studied that promote the urinary excretion of urate 
as well as drugs that can cause hyperuricemia, a major side effect of immunosuppressant 
therapy. Uricosurics, xanthine oxidase inhibitors, diuretics, and NSAIDS were shown to 
interact with renal urate transport via MRP4 and URAT1. These results indicate the 
importance of renal transporters in immunosuppressant drug elimination and 
pharmacokinetic drug-drug interactions. 
Immunosuppressant drug interactions: From Bench to Bedside  
Some reviews suggested that clinically reported transporter-mediated drug interactions 
could have been predicted from in vitro data, after suitable in vivo correlations (Endres et 
al., 2006;Ghibellini et al., 2007). In this thesis, for example, both allopurinol and 6-
mercaptopurine interacted with MRP4, and others showed 6-mercaptopurine and some of 
its metabolites to be substrates of MRP4 (Wielinga et al., 2002). The possibility that the 
life-threatening clinically reported iatrogenic toxicity, associated with the combined use of 
these two drugs (Kennedy et al., 1996) is, at least in part, MRP4-mediated, should be 
investigated. To identify the contribution of MRP4 to the overall renal 6-mercaptopurine-
allopurinol interaction, the use of Mrp4 knockout mice may be suitable (Kruh et al., 2007). 
The main toxic effect of 6-mercaptopurine is myelosuppression. MRP4 confers transporter-
mediated protection against 6-mercaptopurine-induced hematopoietic toxicity 
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(Krishnamurthy et al., 2008). The possibility that allopurinol interacts with MRP4, not only 
at the renal, but also at the myeloid progenitor cell level, thereby reversing MRP4-mediated 
protection, should be clarified. It is important, though, to realize that other factors should be 
considered in predicting clinically relevant drug-drug interactions from in vitro studies. One 
is drug-induced transporter regulation. 6-Mercaptopurine was reported to up-regulate 
MRP4 and down-regulate uptake transporters in leukemic cells (Peng et al., 2008). Similar 
effects by 6-mercaptopurine at the level of the kidney should be investigated. Furthermore, 
the role of renal transporters other than MRP4 should not be underestimated. Both 6-
mercaptopurine and allopurinol were shown to be a substrate of OAT3 (Kobayashi et al., 
2004;Mori et al., 2004), which may participate in their clinical interaction. 
Another factor may be metabolic drug-drug interactions. 6-Mercaptopurine is 
metabolized via xanthine oxidase and thiopurine methyltransferase. Allopurinol, inhibits 6-
mercaptopurine first pass metabolism via inhibition of xanthine oxidase (Sahasranaman et 
al., 2008), but has no effect on thiopurine methyltransferase (Oselin and Anier, 2007). 
Fortunately, the 6-mercaptopurine-allopurinol interaction can be utilized beneficially in 
therapy of patients resistant to 6-mercaptopurine treatment (Sparrow et al., 2005).  
Other renal transporter-mediated drug-drug interactions presented in this thesis may 
also be clinically relevant. 6-Mercaptopurine and salicylate were shown to interact with 
MRP4 in chapters 3, 4 and 7, which may participate in their clinically reported interaction 
(Lowry et al., 2001;Gilissen et al., 2005). In chapter 4, 6-mercaptopurine interacted with 
MRP4-mediated MTX transport, which may contribute to the interaction seen in vivo 
(Innocenti et al., 1996). Similarly, the interaction of MTX and probenecid with MRP4, as 
described in chapters 3, 4 and 7, may be, at least in part, responsible for the retention of 
MTX seen in patients who also received probenecid (Aherne et al., 1978). The 
identification of novel renal transporter substrates and/or inhibitors, as presented in this 
thesis, may be considered a step forward in the attempt to predict clinically relevant renal 
drug-drug interactions from in vitro studies (Lin, 2007).  
Transporter-mediated drug interactions in the kidney may have also implications for 
transporters expressed in other organs. With the expanding knowledge of transporter tissue 
distribution, basic in vitro transport studies may predict oral bioavailability (Takano et al., 
2006), levels of immunosuppressants entering the blood-brain and blood-CSF barriers 
(Ohtsuki and Terasaki, 2007), levels reaching the fetus through the placenta (Weier et al., 
2008) or via milk (Ito and Alcorn, 2003), and liver secretion (Faber et al., 2003). In 
addition to normal tissues, tumor cells are known to over-express transporters upon 
chemotherapy resulting in multidrug resistance (Hait and Yang, 2005). The 
immunosuppressant drug, CsA, was shown to modulate multidrug resistance conferred by 
P-glycoprotein, MRP1, Breast Cancer Resistance Protein, and Lung Resistance Protein 
(Qadir et al., 2005). In agreement, CsA and tacrolimus modulated MPA cytotoxicity in 
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MRP2 and MRP4 over-expressing cells possibly by inhibiting MPA efflux, resulting in 
enhanced cellular concentrations (chapter 5). In addition, NSAIDs interacted with MTX 
transport via MRP2 and MRP4 (chapter 3), an interaction that might explain the 
potentiation of chemotherapeutic efficacy in vitro and in vivo (de Groot et al., 2007). It is 
possible that other less cytotoxic drugs interacting with MRP2 and MRP4 transport may 
reverse transporter-mediated resistance to cytotoxicity. Patients resistant to 
immunosuppressant chemotherapy may thus benefit as well from the identification of 
specific transporter blockers or modulators. 
Immunosuppressant Elimination: Kidney versus Liver 
The renal and hepatobiliary systems are the main routes by which drugs and their 
metabolites are eliminated. In general, amphipathic drugs with relatively higher molecular 
weights (> 300-500 Da) and high protein binding are mainly excreted into bile, while 
hydrophilic drugs with low molecular weight and less protein binding are predominantly 
excreted in urine (Schwenk, 1987). In contrast to the liver, the kidney also has a filtration 
apparatus, the glomerulus, which aids in urinary excretion of unbound drugs. Despite that 
both organs have active transport systems for uptake, efflux, and reabsorption, they have 
different roles in immunosuppressant drug-induced toxicity. Several immunosuppressants 
depend on renal clearance as their main route of elimination, like MPA and MTX (Staatz 
and Tett, 2007;Skarby et al., 2003). Renal basolateral OATs mediate their tubular 
accumulation to concentrations higher than in plasma (Cox et al., 1989;Masereeuw et al., 
1997), which may be a first step in drug-induced nephrotoxicity (Sweet, 2005). The 
extrusion by the apical MRP efflux transporters of compounds with a tendency to 
accumulate into the urine, has a major role in preventing possible OAT-mediated 
nephrotoxic effects. Inhibition of these OATs and/or MRPs could lead to systemic 
accumulation of their substrates, and may cause generalized toxicity (Nigam et al., 2007). 
This is evident in case of renal impairment, where severe MPA and MTX systemic 
toxicities were reported (MacPhee et al., 2000;Strang and Pullar., 2004).  
In the liver, compounds subjected to active hepatic uptake are either effluxed back into 
the portal blood or secreted into bile. Biliary excretion of MPA and MTX subjects these 
drugs to enterohepatic recycling and gastrointestinal side effects (Staatz and Tett, 
2007;Griffin and Said, 1987). The relative contribution of kidney and liver in drug 
elimination and toxicity is thus determined by the number of transporters involved and their 
subcellular localization. MRP4, for example, is targeted to the apical membrane of renal 
proximal tubule cells (van Aubel et al., 2002), whereas in the liver, MRP4 is localized 
basolaterally (Rius et al., 2003). Since MRP4 accepts various drugs as substrates (Russel et 
al., 2008), its basolateral localization in the liver may contribute to hepatic efflux of these 
drugs into the blood stream. However, under normal conditions hepatic expression of 
MRP4 is low.  Renal MRP4 expression, on the other hand, is high and the apical 
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localization suggests a prominent role in drug elimination and ameliorating drug-induced 
toxicity. Animal studies using Mrp4 knockout mice showed the importance of this 
transporter in the renal excretion of furosemide, thiazides, antiviral drugs, and 
cephalosporins (Ci et al., 2007;Imaoka et al., 2007;Hasegawa et al., 2007).  
Renal and hepatic transporters are also differentially regulated. For example, MTX 
administration down-regulated Mrp2 in liver and ileum, but had no effect on renal  
expression in rats (Shibayama et al., 2006). This has been suggested to serve as a 
detoxifying mechanism to minimize MTX intestinal absorption and enterohepatic 
circulation, without decreasing MTX renal excretion. Ischemia reperfusion of rat livers also 
had a differential regulatory effect, as it decreased hepatic and increased renal expression of 
Mrp2 (Tanaka et al., 2008). In addition, Mrp2 is up-regulated in the kidney after endotoxin 
exposure but down-regulated in the liver (Heemskerk et al., 2007). At the same time, 
basolateral uptake carriers in the kidney were down-regulated (Heemskerk et al., 
unpublished), suggesting a concerted action between uptake and efflux transporters to 
preserve renal tubular cells from damage. Age and gender are other factors that may  
differentially affect renal and hepatic transporter expression levels (Maher et al., 2005.,Lu 
and Klaassen, 2008). 
Interplay Between Immunosuppressant Transport and Metabolism  
Until recently, the main focus of research has been on understanding the interindividual 
variation in immunosuppressant biotransformation, since it was considered the primary 
factor controlling drug systemic exposure. For example, immunosuppressants like 
mycophenolate mofetil and azathioprine are prodrugs that must be metabolised to their 
pharmacologically active forms, MPA and 6-mercaptopurine, respectively. In addition, 
metabolism also contributes to drug efficacy and is considered a major factor in limiting 
drug-induced toxicity. For example, the glucuronidation of MPA (Betonico et al., 2008) 
and methylation of 6-mercaptopurine (Wang and Weinshilboum, 2006) inactivate these 
drugs. It was suggested that renal metabolism plays a larger role in immunosuppressant 
disposition than previously thought, as the kidney showed 3-fold higher glucuronidation of 
MPA compared to the liver (Picard et al., 2005). Renal impairment not only affect 
metabolism and transport of a number of cytotoxic immunosuppressants in the kidney 
(Rahman and White, 2006), but also influences transport and metabolism of drugs in extra-
renal tissues, as liver and intestine (Nolin et al., 2008). The role of drug-drug interactions at 
the level of metabolizing enzymes was addressed in chapter 5, where it was shown that 
CsA, but not tacrolimus, inhibited MPA renal glucuronidation via UGT1A9 enzyme. This 
may be a novel mechanism contributing to previously reported interactions between these 
two calcineurin inhibitors and MPA (Hohage et al., 2005;Picard et al., 2005;Kagaya et al., 
2008).  
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Renal Transporters and Drug-Induced Uricemic Effects 
Several immunosuppressants retain cytotoxic effects and are used in cancer 
chemotherapy (Guba et al., 2004). A major side effect encountered when treating 
malignancies is tumour lysis syndrome. This syndrome is an oncologic emergency 
characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, 
which may lead to severe and sometimes fatal oliguric renal failure. Hyperuricemia is 
mainly due to massive tumour tissue destruction and subsequent metabolism of nucleic acid 
to urate. Immunosuppressants that were associated with this syndrome include MTX, 
vincristine and cyclophosphamide (Pumo et al., 2007). Apart from tumour lysis syndrome, 
post-transplant hyperuricemia is a prominent side effect of CsA immunosuppressant 
therapy (Mazzali, 2005). The kidneys have a crucial role in urate homeostasis, as they 
excrete nearly 70% of urate produced daily and control systemic urate balance. Basolateral 
OAT1 and OAT3 mediate cellular uptake of urate (Eraly et al., 2008). In the renal apical 
membrane, MRP4 is the only known transporter to date that actively secretes urate (van 
Aubel et al., 2005), while OAT4 and URAT1 are exchangers that reabsorb urate from pre-
urine (Enomoto et al., 2002;Hagos et al., 2007). Several groups of drugs administered 
concomitantly with immunosuppressants may alter serum urate levels (Daskalopoulou et 
al., 2005). Chapters 7 and 8 addressed the effect of a number of these drugs on urate 
handling by MRP4 and URAT1. In chapter 8, probenecid, sulphinpyrazone, benzbromarone 
and salicylate inhibited, at least in part, urate transport by URAT1. However, these drugs 
were also shown to inhibit MRP4-mediated urate  transport (chapter 7). This dual mode of 
action influencing reabsorption as well as secretion may cause the paradoxical biphasic 
effects of these drugs on renal urate handling (Yu and Gutman, 1955;Louthrenoo et al., 
2002). Both allopurinol and oxypurinol stimulated MRP4-mediated efflux of urate and 
inhibited URAT1-mediated reabsorption (chapter 7 and 8). This dual uricosuric action may 
contribute to allopurinol and oxypurinol hypouricemic effects known to be mediated 
mainly via inhibiting xanthine oxidase-mediated urate formation. Chlorothiazide and 
hydrochlorothiazide are diuretics known to induce hyperuricemia. In chapter 7, both drugs 
inhibited urate renal efflux via MRP4. In addition, in chapter 8 chlorothiazide trans-
inhibition and hydrochlorothiazide cis-stimulation of URAT1-mediated urate reabsorption 
was found. Indeed, the dual action of thiazide diuretics on MRP4/URAT1 may contribute 
to their clinical hyperuricemic side effects (Huen and Goldfarb, 2007). The 
immunosuppressant with highest incidence of hyperuricemia, CsA, was shown not to 
interact with MRP4 in chapter 4. Testing the direct effect of CsA on urate-mediated 
transport by MRP4 or URAT1 also revealed no effect on either transporter (results not 
shown). However, it is possible that CsA mediates its renal hyperuricemic effects through a 
novel urate transporter, OAT10, which was recently identified (Bahn et al., 2008). 
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What Can we Learn from Modeling the MRP4 Binding Site? 
In chapters 3, 4 and 7, the interactions of several compounds with MRP4-mediated 
transport could not be explained by a simple one site binding, and some were suggestive of 
multiple allosteric substrate binding sites. These compounds included MPA, 
cyclophosphamide, hydrocortisone, diclofenac, salicylate, sulfinpyrazone, benzbromarone, 
chlorothiazide, and hydrochlorothaizide. Our group previously reported similar complex 
interactions for urate, i.e. inhibition of MTX, stimulation of cGMP, and no effect on cAMP 
transport via MRP4 (van Aubel et al., 2005). In chapter 6, the MRP4 substrate binding site 
was studied in more detail, using MTX as a model substrate. The interaction of the 
immunosuppressant drug MTX and the second messenger cGMP, both substrates of MRP4, 
showed a non-competitive pattern, which is only possible if these two substrates do not 
share the same binding site. Substituting the amino acid Arg
375
, present in MRP4 
transmembrane helix 6, with the amino acid serine showed no effect on cGMP transport, 
but significantly decreased the affinity to MTX, suggesting the contribution of Arg
375
 in 
MTX, but not cGMP, binding. From this mutational study, the importance of amino acids 
in transmembrane helix 6 and 12 in MRP4 substrate binding is highlighted, suggesting that 
polymorphisms in this region may have clinical implications. Unfortunately, available data 
regarding genetic variability of MRP4 are limited. In a study conducted on 48 Japanese 
subjects, 257 variations in MRP4 were identified, from which the majority were found in 
intronic sequences, with only three non-synonymous SNPs in exons 4, 8, and 18, leading to 
the amino acid changes Cys171Gly, Lys302Asn, and Glu757Lys, respectively (Saito et al., 
2002). The latter two amino acid changes were also detected in a recent study conducted on 
Caucasian subjects (Gradhand et al., 2008).  
To date, limited functional in vitro transport and clinical data have been reported for 
non-synonymous SNPs in MRP4. One study found a significant association between 
T4131G SNP in MRP4 with higher lamivudine triphosphate concentrations in HIV-positive 
patients, suggesting lower MRP4 expression (Anderson et al., 2006). Lower MRP4 
expression has been illustrated at the protein level in liver samples from patients with GT or 
TT variants at the same position (Gradhand et al., 2008). Another study performed on 
Japanese subjects focused on G2269A SNP in MRP4 (Krishnamurthy et al., 2008). This 
study showed an association between MRP4 G2269A SNP and hematopoietic 6-
mercaptopurine toxicity due to impairment of MRP4 cell membrane localization. These few 
studies addressing MRP4 SNPs clearly indicate that genetic transporter polymorphisms 
may significantly contribute to inter-individual immunosuppressant pharmacokinetic 
variations. Variations have been also attributed to genetic polymorphisms in 
immunosuppressant metabolizing enzymes (Mourad et al., 2008).  
  
 
 
 
Chapter 9 
 
 
 
154 
 
Future perspectives 
Pharmacokinetic drug interactions involving immunosuppressants are a major obstacle 
preventing successful transplant graft preservation, treatment of autoimmune diseases, and 
cancer chemotherapy. These interactions may be the ultimate cause of death in some 
patients (Singh et al., 1986;Flippin et al., 2000). Trials of drug combinations intentionally 
aiming at decreasing adverse effects or increasing drug efficacy utilize known 
pharmacokinetic interactions. In vitro experiments are usually the trigger that directs the 
attention to possible beneficial drug combinations.  Here, we solved a part of the puzzle by 
putting a few pieces in their right place. This thesis directs the attention to the urgent need 
to develop a comprehensive substrate-screening method to identify the mechanisms of renal 
transport, and predict possible interactions and other factors that influence 
immunosuppressant pharmacokinetics.  
To date, the role of renal transporters in immunosuppressant drug interactions is not yet 
fully addressed. The role of renal breast cancer resistance protein (BCRP) (Huls et al., 
2008) and MRP5 (van de Water et al., 2007) in renal drug elimination should be revealed. 
Interaction of MTX and CsA with BCRP (Xia et al., 2007), and MRP5 transport of 6-
mercaptopurine and MTX (Wielinga et al., 2002;Wielinga et al., 2005) are preliminary 
findings indicating a role of these transporters in immunosuppressant drug elimination. 
Insight in activities or expression levels of these renal transporters and their contribution in 
immunosuppressant drug handling may aid in determining their clinical potential to 
increase immunosuppressant drug efficacy or decrease the side effects.  
Appreciating the different factors affecting renal drug elimination is important in 
addressing immunosuppressant drug-drug interactions. Concomitantly administered 
immunosuppressants may compete for plasma protein binding, increasing the free fraction 
of one or both drugs (Staatz and Tett, 2007) and subjecting the renal transporter to higher 
drug levels. Furthermore, active renal transporters can dramatically concentrate drugs intra-
renally, as our group previously showed (Cox et al., 1989;Masereeuw et al., 1997). In 
addition, genetic variability in transporter and metabolizing enzyme function accounts for 
20-90 % of interindividual variations in immunosuppressant pharmacokinetics and -
dynamics (Thervet et al., 2008). It should be defined whether there are any correlations 
between genetic polymorphisms and drug efficacy on the one hand and toxicity on the 
other. The relevant polymorphisms should subsequently be characterized at the molecular 
level in terms of changes in kinetics and expression. The ultimate step will then be to 
include routine genotyping in immunosuppressant therapy. 
To date, transport assays in cells and membrane vesicles over-expressing a specific 
transporter have provided most of the available knowledge on renal immunosuppressant 
transport mechanisms. Pharmaceutical companies designing and developing novel 
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immunosuppressants can make use of these assays as a powerful tool in preclinical 
prediction of immunosuppressant drug-drug interactions and toxicity. Indeed, direct 
transport using membrane vesicles is the most solid proof of substrate translocation via a 
transporter across biological membranes. Moreover, detailed information on the transport 
mechanisms and interactions can be provided under controlled conditions (chapter 3 and 8). 
However, intracellular events like accumulation and metabolism are beyond the scope of 
the artificial vesicle environment. Cellular transport assays are more appropriate for 
characterizing uptake transport in conjunction with metabolism and cellular efflux, and are 
suitable for prediction of nephrotoxicity as a result of drug accumulation (chapters 4, 5, 7 
and 8). Animal studies in vivo may allow to determine the overall pharmacokinetics and 
drug interactions, however, due to species differences, animal studies cannot always 
accurately predict the human situation (chapter 5). To overcome this, the ideal system 
would be to create an in vitro model that highly resembles in vivo conditions. Cellular 
multi-transduction, as shown in chapter 8, may aid in achieving a comparative expression 
system, which should include all relevant human transporters and metabolic enzymes. 
Using polarized cells, the myriad of effects exerted during basolateral-to-apical renal 
secretion, apical-to-basolateral renal reabsorption, as well as intracellular metabolism and 
accumulation can be defined. Moreover, the effects of relevant polymorphisms identified 
for transporters and metabolic enzymes can be investigated.  These in vitro studies should 
allow for more reliable predictions of the influence of transporters and metabolic enzymes 
in the efficacy and safety of immunosuppressant drugs.  
References 
Aherne GW, Piall E, Marks V, Mould G, White WF (1978). Prolongation and enhancement of serum methotrexate 
concentrations by probenecid. Br Med J 1: 1097-1099. 
Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV (2006). Pharmacogenetic characteristics of 
indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic 
Syndr 42: 441-449. 
Bahn A, Hagos Y, Reuter S, Balen D, Brzica H, Krick W et al (2008). Identification of a new urate and high 
affinity nicotinate transporter - human organic anion transporter 10 (hOAT10, SLC22A13. J Biol Chem 283: 
16332-16341.  
Bandler PE, Westlake CJ, Grant CE, Cole SP, Deeley RG (2008). Identification of regions required for apical 
membrane localization of human multidrug resistance protein 2. Mol Pharmacol 74: 9-19. 
Betonico GN, bbud-Filho M, Goloni-Bertollo EM, Alvarenga MP, Guillemette C, Villeneuve L et al (2008). 
Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in 
kidney transplant patients. Transplant Proc 40: 708-710. 
Cattaneo D, Baldelli S, Perico N (2008). Pharmacogenetics of Immunosuppressants: Progress, Pitfalls and 
Promises. Am J Transplant 8: 1374-1383. 
Chen VY and Rosania GR (2006). The great multidrug-resistance paradox. ACS Chem Biol 1: 271-273. 
Christians U, Schmitz V, Schoning W, drick-Peart J, Klawitter J, Haschke M et al (2008). Toxicodynamic 
therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges. Ther Drug Monit 30: 
151-158. 
Christians U, Strom T, Zhang YL, Steudel W, Schmitz V, Trump S et al (2006). Active drug transport of 
immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 28: 39-44. 
Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y (2007). Involvement of MRP4 (ABCC4) in 
the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol 71: 1591-1597. 
  
 
 
 
Chapter 9 
 
 
 
156 
 
Cox PG, Moons WM, Russel FG, van Ginneken CA (1989). Renal handling of salicyluric acid in the isolated 
perfused rat kidney: evidence for accumulation in tubular cells. J Pharmacol Exp Ther 251: 750-755. 
Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M (2005). Effect on serum uric acid levels of drugs 
prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 11: 4161-4175. 
de Groot DJ, de Vries EG, Groen HJ, de Jong S (2007). Non-steroidal anti-inflammatory drugs to potentiate 
chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 61: 52-69. 
Endres CJ, Hsiao P, Chung FS, Unadkat JD (2006). The role of transporters in drug interactions. Eur J Pharm Sci 
27: 501-517. 
Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH et al (2002). Molecular identification of a 
renal urate anion exchanger that regulates blood urate levels. Nature 417: 447-452. 
Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, Siuzdak G et al (2008). Multiple organic anion transporters 
contribute to net renal excretion of uric acid. Physiol Genomics 33: 180-192. 
Faber KN, Muller M, Jansen PL (2003). Drug transport proteins in the liver. Adv Drug Deliv Rev 55: 107-124. 
Filler G, Lepage N, Delisle B, Mai I (2001). Effect of cyclosporine on mycophenolic acid area under the 
concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 23: 514-519. 
Flippin MS, Canter CE, Balzer DT (2000). Increased morbidity and high variability of cyclosporine levels in 
pediatric heart transplant recipients. J Heart Lung Transplant 19: 343-349. 
Frenia ML and Long KS (1992). Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann 
Pharmacother 26: 234-237. 
Ghibellini G, Vasist LS, Leslie EM, Heizer WD, Kowalsky RJ, Calvo BF et al (2007). In vitro-in vivo correlation 
of hepatobiliary drug clearance in humans. Clin Pharmacol Ther 81: 406-413. 
Gilissen LP, Bierau J, Derijks LJ, Bos LP, Hooymans PM, van Gennip A et al (2005). The pharmacokinetic effect 
of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. 
Aliment Pharmacol Ther 22: 605-611. 
Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, Klein K et al (2008). Variability in human hepatic 
MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J 8: 42-52. 
Griffin D and Said HM (1987). The enterohepatic circulation of methotrexate in vivo: inhibition by bile salt. 
Cancer Chemother Pharmacol 19: 40-41. 
Guba M, Graeb C, Jauch KW, Geissler EK (2004). Pro- and anti-cancer effects of immunosuppressive agents used 
in organ transplantation. Transplantation 77: 1777-1782. 
Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A (2007). Human renal organic anion transporter 4 operates as an 
asymmetric urate transporter. J Am Soc Nephrol 18: 430-439. 
Hait WN and Yang JM (2005). Clinical management of recurrent breast cancer: development of multidrug 
resistance (MDR) and strategies to circumvent it. Semin Oncol 32: S16-S21. 
Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y (2007). Multidrug resistance-
associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc 
Nephrol 18: 37-45. 
Heemskerk S, van Koppen A, van den Broek L, Poelen GJ, Wouterse AC, Dijkman HB et al (2007). Nitric oxide 
differentially regulates renal ATP-binding cassette transporters during endotoxemia. Pflugers Arch 454: 321-334. 
Hohage H, Zeh M, Heck M, Gerhardt UW, Welling U, Suwelack BM (2005). Differential effects of cyclosporine 
and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. Transplant 
Proc 37: 1748-1750. 
Huen SC and Goldfarb DS (2007). Adverse metabolic side effects of thiazides: implications for patients with 
calcium nephrolithiasis. J Urol 177: 1238-1243. 
Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S et al (2008). The breast cancer 
resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. 
Kidney Int 73: 220-225. 
Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y (2007). Functional involvement of 
multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs 
adefovir and tenofovir. Mol Pharmacol 71: 619-627. 
Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M et al (1996). Clinical and experimental 
pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol 37: 
409-414. 
Ito S and Alcorn J (2003). Xenobiotic transporter expression and function in the human mammary gland. Adv 
Drug Deliv Rev 55: 653-665. 
Kagaya H, Miura M, Satoh S, Inoue K, Saito M, Inoue T et al (2008). No pharmacokinetic interactions between 
mycophenolic acid and tacrolimus in renal transplant recipients. J Clin Pharm Ther 33: 193-201. 
  
 
 
 
Chapter 9 
 
 
 
157 
 
Kennedy DT, Hayney MS, Lake KD (1996). Azathioprine and allopurinol: the price of an avoidable drug 
interaction. Ann Pharmacother 30: 951-954. 
Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T (2004). Renal transport of organic 
compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. 
Drug Metab Dispos 32: 479-483. 
Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M et al (2008). Transporter-mediated 
protection against thiopurine-induced hematopoietic toxicity. Cancer Res 68: 4983-4989. 
Kruh GD, Belinsky MG, Gallo JM, Lee K (2007). Physiological and pharmacological functions of Mrp2, Mrp3 
and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev 26: 5-14. 
Lin JH (2007). Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin 
Drug Metab Toxicol 3: 81-92. 
Louthrenoo W, Kasitanon N, Wichainun R, Sukitawut W (2002). Effect of minidose aspirin on renal function and 
renal uric acid handling in healthy young adults. J Clin Rheumatol 8: 299-304. 
Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV et al (2001). Leucopenia resulting 
from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or 
balsalazide. Gut 49: 656-664. 
Lu H and Klaassen C (2008). Gender differences in mRNA expression of ATP-binding cassette efflux and bile 
acid transporters in kidney, liver, and intestine of 5/6 nephrectomized rats. Drug Metab Dispos 36: 16-23. 
MacPhee IA, Spreafico S, Bewick M, Davis C, Eastwood JB, Johnston A et al (2000). Pharmacokinetics of 
mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 57: 1164-1168. 
Maher JM, Slitt AL, Cherrington NJ, Cheng X, Klaassen CD (2005). Tissue distribution and hepatic and renal 
ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab Dispos 33: 947-
955. 
Masereeuw R, Moons WM, Russel FG (1997). Saturable accumulation and diuretic activity of hydrochlorothiazide 
in the isolated perfused rat kidney. Pharmacology 54: 33-42. 
Mazzali M (2005). Uric acid and transplantation. Semin Nephrol 25: 50-55. 
Mori S, Ohtsuki S, Takanaga H, Kikkawa T, Kang YS, Terasaki T (2004). Organic anion transporter 3 is involved 
in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem 90: 931-941. 
Mourad M, Wallemacq P, De Meyer M, Malaise J, De Pauw L, Eddour DC et al (2008). Biotransformation 
enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on 
pharmacokinetics and clinical outcome. Transplantation 85: S19-S24. 
Nigam SK, Bush KT, Bhatnagar V (2007). Drug and toxicant handling by the OAT organic anion transporters in 
the kidney and other tissues. Nat Clin Pract Nephrol 3: 443-448. 
Nolin TD, Naud J, Leblond FA, Pichette V (2008). Emerging evidence of the impact of kidney disease on drug 
metabolism and transport. Clin Pharmacol Ther 83: 898-903. 
Ohtsuki S and Terasaki T (2007). Contribution of carrier-mediated transport systems to the blood-brain barrier as a 
supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm 
Res 24: 1745-1758. 
Oselin K and Anier K (2007). Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-
inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metab Dispos 35: 1452-1454. 
Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC et al (2008). Up-regulation of MRP4 and down-
regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk 
Res 32: 799-809. 
Picard N, Premaud A, Rousseau A, Le Meur Y, Marquet P (2006). A comparison of the effect of ciclosporin and 
sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol 62: 477-
484. 
Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P (2005). Identification of the UDP-
glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33: 
139-146. 
Pumo V, Sciacca D, Malaguarnera M (2007). Tumor lysis syndrome in elderly. Crit Rev Oncol Hematol 64: 31-
42. 
Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H et al (2005). Cyclosporin A is a 
broad-spectrum multidrug resistance modulator. Clin Cancer Res 11: 2320-2326. 
Rahman A and White RM (2006). Cytotoxic anticancer agents and renal impairment study: the challenge remains. 
J Clin Oncol 24: 533-536. 
Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D (2003). Cotransport of reduced glutathione 
with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38: 374-384. 
  
 
 
 
Chapter 9 
 
 
 
158 
 
Russel FG, Koenderink JB, Masereeuw R (2008). Multidrug resistance protein 4 (MRP4/ABCC4): a versatile 
efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29: 200-207. 
Sahasranaman S, Howard D, Roy S (2008). Clinical pharmacology and pharmacogenetics of thiopurines. Eur J 
Clin Pharmacol 64: 753-767. 
Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S et al (2002). Identification of 779 genetic variations in 
eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J Hum Genet 
47: 147-171. 
Schwenk M (1987). Drug transport in intestine, liver and kidney. Arch Toxicol 60: 37-42. 
Shibayama Y, Ushinohama K, Ikeda R, Yoshikawa Y, Motoya T, Takeda Y et al (2006). Effect of methotrexate 
treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic 
anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci 97: 1260-1266. 
Singh RR, Malaviya AN, Pandey JN, Guleria JS (1986). Fatal interaction between methotrexate and naproxen. 
Lancet 1: 1390. 
Skarby T, Jonsson P, Hjorth L, Behrentz M, Bjork O, Forestier E et al (2003). High-dose methotrexate: on the 
relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses 
in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol 51: 311-
320. 
Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D et al (2005). Allopurinol safely and effectively 
optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and 
mercaptopurine. Aliment Pharmacol Ther 22: 441-446. 
Staatz CE and Tett SE (2007). Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ 
transplant recipients. Clin Pharmacokinet 46: 13-58. 
Strang A and Pullar T (2004). Methotrexate toxicity induced by acute renal failure. J R Soc Med 97: 536-537. 
Sweet DH (2005). Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl 
Pharmacol 204: 198-215. 
Takano M, Yumoto R, Murakami T (2006). Expression and function of efflux drug transporters in the intestine. 
Pharmacol Ther 109: 137-161. 
Tanaka Y, Chen C, Maher JM, Klaassen CD (2008). Ischemia-reperfusion of rat livers decreases liver and 
increases kidney multidrug resistance associated protein 2 (Mrp2). Toxicol Sci 101: 171-178. 
Thervet E, Anglicheau D, Legendre C, Beaune P (2008). Role of pharmacogenetics of immunosuppressive drugs 
in organ transplantation. Ther Drug Monit 30: 143-150. 
Uchida Y, Kamiie J, Ohtsuki S, Terasaki T (2007). Multichannel liquid chromatography-tandem mass 
spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated 
protein 4 transporter. Pharm Res 24: 2281-2296. 
van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG (2002). The MRP4/ABCC4 gene encodes a novel 
apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP 
and cGMP. J Am Soc Nephrol 13: 595-603. 
van Aubel RA, Smeets PH, van den Heuvel JJ, Russel FG (2005). Human organic anion transporter MRP4 
(ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. 
Am J Physiol Renal Physiol 288: F327-F333. 
van de Water FM, Boleij JM, Peters JG, Russel FG, Masereeuw R (2007). Characterization of P-glycoprotein and 
multidrug resistance proteins in rat kidney and intestinal cell lines. Eur J Pharm Sci 30: 36-44. 
Wang L and Weinshilboum R (2006). Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and 
future directions. Oncogene 25: 1629-1638. 
Weier N, He SM, Li XT, Wang LL, Zhou SF (2008). Placental drug disposition and its clinical implications. Curr 
Drug Metab 9: 106-121. 
Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N et al (2005). The human multidrug 
resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 
65: 4425-4430. 
Wielinga PR, Reid G, Challa EE, van der Heijden, I, van Deeter L, de  Haas M et al (2002). Thiopurine 
metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in 
human embryonic kidney cells. Mol Pharmacol 62: 1321-1331. 
Xia CQ, Liu N, Miwa GT, Gan LS (2007). Interactions of cyclosporin a with breast cancer resistance protein. 
Drug Metab Dispos 35: 576-582. 
Yu TF and Gutman AB (1955). Paradoxical Retention of Uric Acid by Uricosuric Drugs in Low Dosage. 
Proceedings of the Society for Experimental Biology and Medicine 90: 542-547. 
  
 
 
 
 
159 
 
Summary 
This thesis provides evidence for the important role that specific renal transporters can 
play in the elimination and drug-drug interactions of immunosuppressants. Furthermore, it 
emphasizes the participation of renal transporters in hyperuricemic immunosuppressant 
side effects. Despite extensive studies on the therapeutic activity of immunosuppressants, 
little is known about the mechanisms of their renal handling. Renal excretion of a wide 
variety of drugs, including many immunosuppressants and their metabolites, depends 
mainly on the concerted action of basolateral and apical organic anion transport systems in 
the proximal tubule. Scientific interest in renal transporters led to considerable progress in 
their identification and characterization. A brief overview of the most prominent 
transporters involved in renal anionic drug excretion, which mainly belong to the ATP-
binding cassette (ABC) or the solute carrier (SLC) transporter families, was presented in 
chapter 2. The aim of this thesis was to contribute to the understanding of the mechanisms 
of renal immunosuppressant transport, their drug interactions, and their hyperuricemic 
complications. To achieve that, cells and membrane vesicles over-expressing renal 
transporters were used. Transport activities were measured via radio-labelled liquid 
scintillation counting or by high performance liquid chromatography. Kinetic analysis of 
transporter-mediated substrate/inhibitor interactions was performed, and 
immunosuppressant drug interactions at the organ level were investigated using isolated 
perfused rat kidneys. 
Chapter 3 described the role of the renal apical ABC transporters, multidrug resistance 
protein (MRP) 2 and 4, in the clinically reported severe and sometimes fatal drug-drug 
interaction between methotrexate (MTX) and nonsteroidal anti-inflammatory drugs 
(NSAIDs). Especially at high MTX dosages, severe adverse effects with this combination 
may occur usually resulting from an impaired renal elimination. Experiments were 
conducted using membrane vesicles isolated from HEK293 cells over-expressing MRP2 
and MRP4. MTX was transported by MRP2 and MRP4 with Km values of 480 ± 90 and 
220 ± 70 μM, respectively.  The inhibitory potency of the NSAIDs was generally higher 
against MRP4- than MRP2-mediated MTX transport, with therapeutically relevant IC50 
values, ranging from approximately 2 μM to 1.8 mM. Sulindac exhibited the highest, and 
salicylate the lowest inhibitory potency. It is likely that MRP2 and MRP4 possess multiple 
allosteric binding sites, as inhibition of MRP4 by diclofenac, and MRP2 by indomethacin 
and
 
ketoprofen followed a two-site competition model. In addition, phenylbutazone
 
stimulated MRP2 and celecoxib MRP4 transport at low concentrations,
 
but both drugs 
inhibited respective transporters at higher concentrations. The conclusion of this chapter 
was that the inhibition by NSAIDs of renal MTX efflux via MRP2 and MRP4 is a potential 
new site and mechanism contributing to the over-all interaction between these drugs. 
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In chapter 4, a number of immunosuppressants were investigated for their interaction 
with the basolateral SLC transporter, organic anion transporter (OAT) 1 and the apical 
MRP2 and MRP4 transporters, using MTX as a common substrate. The interaction of 
different immunosuppressants was measured with [
3
H]MTX uptake in HEK293 cells 
overexpressing OAT1, and ATP-dependent transport in membrane vesicles isolated from 
MRP2- and MRP4-overexpressing HEK293 cells. Our results showed that various 
immunosuppressants can significantly inhibit OAT1-mediated MTX uptake, including 
mycophenolic acid (MPA), mitoxantrone, cytarabine, hydrocortisone, vinblastine and 
vincristine. We found that 6-mercaptopurine inhibited MRP4-mediated transport, while its 
prodrug azathioprine, which possesses an additional imidazole side chain, did not, 
illustrating the importance of structure variations in substrate/inhibitor specificities of these 
transporters. Furthermore, cyclophosphamide, usually given concomitantly with MTX 
during chemotherapy of breast cancer, significantly stimulated MTX transport via the 
basolateral uptake transporter OAT1, but inhibited MTX efflux via both apical efflux 
transporters. This may result in intra-renal MTX accumulation. MPA and cyclosporine A 
(CsA), the immunosuppressants of choice for therapy of solid organ transplant rejection, 
inhibited MRP2-mediated transport. Vincristine and vinblastine inhibited MRP2, and had 
no effect on MRP4. Dexamethasone and mitoxantrone stimulated, while azathioprine and 
cytarabine had no effect on both transporters. It was concluded from this chapter that 
alteration of OAT1-, MRP2-, and MRP4-mediated transport contribute to unwanted renal 
immunosuppressant drug interactions, which, on the other hand, could be also exploited 
beneficially to increase drug efficiency in patients resistant to immunosuppressant 
chemotherapy. 
The role of MRP2 in the drug interaction between MPA and CsA has been previously 
suggested using rat liver, and via correlating MRP2 polymorphisms with MPA 
pharmacokinetics. Interaction of MPA and its inactive 7-hydroxy glucuronide (MPAG) 
metabolite with renal transporters has also been partially addressed at the level of OATs in 
the basolateral membrane. Chapter 5 dealt with the role of the apical efflux transporters, 
MRP2 and MRP4, in renal MPA excretion by using isolated perfused kidneys from TR- 
rats,  deficient in multidrug resistance protein (Mrp) 2, and HEK293 cells over-expressing 
human MRP2 and MRP4. In rat kidney, MPA was conjugated completely to MPAG, which 
was excreted significantly less in TR- compared to wild-type rats. We also identified MPA 
as a substrate of both human MRP2 and MRP4, whereas MPAG appeared to be only a 
substrate of MRP2. Furthermore, the interaction between MPA and the calcineurin 
inhibitors CsA and tacrolimus was studied. CsA reduced renal MPAG formation and 
excretion via inhibition of uridine diphospho-glucuronosyl transferase (UGT) 1A9 and 
MRP2, respectively. Tacrolimus did not interfere with either the formation or the excretion 
of MPAG. In conclusion, MRP2 is the main renal efflux transporter involved in MPA 
glucuronide renal secretion. CsA, but not tacrolimus, inhibited renal MPA glucuronidation 
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and MRP2-mediated glucuronide secretion. These findings add a novel mechanism to the 
clinical interaction between CsA and MPA. 
MRP4 is involved in the renal handling of many drugs, including immunosuppressants, 
and possesses multiple allosteric binding sites, as could be concluded from chapter 3. To 
understand how a transporter translocates its substrates, molecular information is needed 
about the amino acid residues that are involved in recognition, association and dissociation 
of the substrate. By mutating specific amino acids, information can be obtained about their 
contribution in substrate binding and protein transport activity. In chapter 6, several MRP4 
mutants were designed and tested for functionality. To characterize the MRP4 substrate-
binding site, the amino acids Phe368, Phe369, Glu374, Arg375, and Glu378 of 
transmembrane helix 6, and Arg998 of helix 12, localized in the intracellular half of the 
central pore, were mutated into the corresponding amino acids of MRP1 and MRP2. 
Membrane vesicles isolated from HEK293 cells over-expressing these mutants showed 
significantly reduced MTX and cyclic guanosine monophosphate (cGMP) transport 
activity. The only exception was substitution of Arg375 with serine, which had no effect on 
cGMP transport, but significantly decreased the affinity of MTX. Furthermore, MTX 
inhibition of MRP4-mediated cGMP transport was non-competitive, indicative of different 
allosteric binding sites. Inhibition was further increased by introduction of the R375S 
mutation. To link the mutations back to their structural basis, a homology model for MRP4 
was built, which revealed that Arg375 and Arg998 face right into the central aqueous pore 
of the transporter. We concluded that positively charged amino acids in transmembrane 
helices 6 and 12 contribute to the MRP4 substrate-binding pocket. 
One of the complications of immunosuppressant treatment is hyperuricemia. Several 
transporters participate in maintaining renal urate homeostasis, including MRP4 and urate 
transporter (URAT) 1. Chapters 7 and 8 describe the interaction of various drugs affecting 
serum urate levels with MRP4- and URAT1-mediated urate transport, respectively. In 
Chapter 7 the effect of these drugs was studied on [
14
C]urate transport using HEK293 cells 
over-expressing human MRP4 and in membrane vesicles isolated from these cells. The 
xanthine oxidase inhibitor, allopurinol, stimulated MRP4-mediated cellular urate efflux, 
and both allopurinol and its active metabolite, oxypurinol, stimulated urate transport by 
MRP4 in membrane vesicles up to 190  50% and 136  17%, respectively, which could 
add to their hypouricemic action. The diuretics, bumetanide and torasemide, had no effect, 
while furosemide, chlorothiazide and hydrochlorothiazide inhibited urate transport at 
concentrations that can be expected in the renal proximal tubule after therapeutic dosages. 
This could be an additional mechanism in their clinically observed hyperuricemic side 
effects. The uricosurics salicylate, benzbromarone, and sulfinpyrazone were also inhibitors, 
whereas probenecid stimulated urate transport at 0.1 μM and inhibited transport at higher 
concentrations. The conclusion from this chapter was that MRP4 may provide a potential 
target for drugs affecting urate homeostasis, which needs to be evaluated further in vivo. 
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Chapter 8 addresses drug interactions with URAT1-mediated urate transport. The 
effects of hyper- and hypouricemic drugs were studied on URAT1-mediated [
14
C]urate 
transport in HEK293 cells. Our results showed that the Km value of [
14
C]urate transport 
was 270 ± 40 µM. Hydrochlorothiazide cis-stimulated, while chlorothiazide, 
benzbromarone, probenecid, sulfinpyrazone, salicylate, oxypurinol, and penicillin cis-
inhibited URAT1-mediated transport in cells. We also double-transduced HEK293 cells to 
simultaneously over-express URAT1 and MRP4. To gain further insight in the mechanism 
of urate exchange, we employed membrane vesicles isolated from HEK293 cells over-
expressing URAT1. We showed that benzbromarone competitively, while chlorothiazide 
non-competitively cis-inhibited URAT1-mediated urate transport. In addition, 
chlorothiazide, but not benzbromarone, trans-stimulated urate transport. Membrane 
vesicles over-expressing URAT1 transported [
14
C]urate bidirectionally and uptake was 
increased by an outward directed chloride gradient, which was further trans-stimulated by 
urate. In conclusion, URAT1 is a gradient-sensitive bi-directional exchanger that could play 
a role in drug-induced hyperuricemic effects originating from the kidney. 
Finally, chapter 9 discussed all results presented in this thesis, focusing on the role of in 
vitro studies in predicting possible renal immunosuppressant drug interactions pre-
clinically, and the factors affecting these predictions. This chapter also discussed the 
contribution of renal transporters in immunosuppressant drug elimination compared to that 
of the liver, as well as the possible interplay between immunosuppressant transport and 
metabolism. In addition, the role of renal transporters in mediating drug-induced 
hyperuricemia was addressed. The gained knowledge from MRP4 binding side modeling 
was put into perspective of its possible clinical implications. Future perspectives 
highlighting the need to gain more insight into the role of other renal transporters like 
breast cancer resistance protein (BCRP) and MRP5, as well as other metabolic and genetics 
factors influencing renal immunosuppressant interactions were presented. This chapter was 
concluded by describing the possible improvements that are required to develop in vitro test 
systems that allow for more reliable predictions of the influence of transporters and 
metabolic enzymes in the efficacy and safety of immunosuppressant drugs. 
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Samenvatting 
De resultaten beschreven in dit proefschrift tonen aan dat transporteiwitten in de nier 
een belangrijke rol spelen in de eliminatie en geneesmiddelinteracties van 
immunosuppressiva. Tevens is gebleken dat deze transporteiwitten ook betrokken kunnen 
zijn bij het ontstaan van hyperuricemische bijwerkingen die door een aantal 
immunosuppressiva kan worden veroorzaakt. Hoewel er vele studies zijn gedaan naar de 
therapeutische activiteit van immunosuppressiva is er nog maar weinig bekend over de 
mechanismen waarmee deze middelen door de nieren worden uitgescheiden. De renale 
excretie van veel geneesmiddelen, waaronder ook de immunosuppressiva en hun 
metabolieten, wordt in belangrijke mate bepaald door het samenspel van de organisch-
aniontransportsystemen in de basolaterale en apicale membraan van de proximale tubulus. 
Onderzoek naar de identiteit en eigenschappen van verschillende niertransporteiwitten heeft 
in de afgelopen jaren een enorme vooruitgang geboekt. In hoofdstuk 2 wordt een overzicht 
gegeven van de belangrijkste transporteiwitten die betrokken zijn bij de renale excretie van 
geneesmiddelen. Deze eiwitten behoren tot de families van de „ATP binding cassette‟ 
(ABC)- en de „Solute Carrier‟ (SLC)-transporters. Het doel van dit proefschrift was om 
meer inzicht te krijgen in de mechanismen van het renale transport van immunosuppressiva, 
de geneesmiddelinteracties die daarbij kunnen optreden, alsmede de hyperuricemische 
complicaties. Om dat te bereiken zijn de belangrijkste renale transporteiwitten tot 
overexpressie gebracht in cellen en membraanblaasjes en is hun activiteit gemeten met 
behulp van radioactief-gemerkte stoffen en vloeistofscintillatietelling of met 
hogedrukvloeistofchromatografie. De interacties van de verschillende substraten en 
remmers met de transporteiwitten werden kinetisch geanalyseerd en de interacties van 
immunosuppressiva op orgaanniveau zijn onderzocht in de geïsoleerde geperfundeerde 
rattennier. 
In hoofdstuk 3 is de rol beschreven van de renale ABC-transporters, „multidrug 
resistance protein‟  (MRP) 2 en MRP4 bij de ernstige en soms fatale klinische interactie 
tussen methotrexaat (MTX) en „nonsteroidal antiinflammatory drugs‟ (NSAIDs). Vooral bij 
hoge MTX-doseringen kan deze combinatie leiden tot ernstige bijwerkingen, die meestal 
het gevolg zijn van een verminderde renale uitscheiding. De experimenten zijn uitgevoerd 
in membraanblaasjes geïsoleerd uit HEK293-cellen die MRP2 of MRP4 tot overexpressie 
brengen. De affiniteit (Km) van MTX-transport door MRP2 was 480 ± 90 μM en door 
MRP4 220 ± 70 μM. Remming door de NSAIDs was over het algemeen sterker tegen 
MTX-transport door MRP4 dan MRP2. De berekende IC50-waarden lagen in een 
therapeutisch relevant concentratiegebied variërend van circa 2 μM to 1,8 mM. Sulindac 
was de krachtigste en salicylzuur de zwakste remmer. Remming van MRP4 door 
diclofenac, en MRP2 door indomethacine en ketoprofen kon kinetisch het best worden 
beschreven volgens een competitiemodel met twee bindingsplaatsen. Daarnaast bleken 
fenylbutazon en celecoxib bij lage concentraties resp. MRP4 en MRP2 te stimuleren, 
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terwijl ze bij hogere concentraties het transport remden. Deze resultaten duidden op 
meerdere bindingsplaatsen op de transporteiwitten die elkaar allosteer kunnen beïnvloeden. 
De conclusie van dit hoofdstuk was dat remming door NSAIDs van de MTX-excretie door 
MRP2 en MRP4 in de nier een nieuw mechanisme is dat kan bijdragen aan de systemische 
interactie tussen deze geneesmiddelen in de patiënt. 
In hoofdstuk 4 is de interactie onderzocht van een aantal immunosuppressiva met 
MTX-transport door de basolaterale SLC-transporter, „organic anion transporter 1‟ (OAT1) 
en de apicale transporters, MRP2 en MRP4. Het effect van de immunosuppressiva werd 
gemeten op de opname van [
3
H]MTX in HEK293-cellen met OAT1-overexpressie en 
membraanblaasjes geïsoleerd van de cellen, maar dan met MRP2- of MRP4-overexpressie. 
De resultaten lieten zien dat mycofenolaat (MPA), mitoxantron, cytarabine, hydrocortison, 
vinblastine en vincristine de MTX-opname via OAT1 significant konden remmen. We 
vonden dat 6-marcaptopurine een remmer was van MRP4-transport, terwijl zijn prodrug, 
azathioprine, die een imidazol-zijketen heeft, geen remming gaf. Dit geeft aan hoe 
belangrijk variaties in de structuur van een verbinding voor de interactie met een 
transporteiwit kan zijn. Daarnaast bleek cyclofosfamide, dat vaak in combinatie met MTX 
wordt gegeven bij de chemotherapie van borstkanker, MTX-opname door de basolaterale 
OAT1 te stimuleren, maar MTX-transport via de apicale MRP-effluxtransporter te remmen. 
Dit zou kunnen leiden tot intrarenale accumulatie van MTX. MRP2-transport werd geremd 
door MPA en cyclosporine A (CsA), die samen worden gebruikt om afstotingsreacties bij 
orgaantransplantatie te bestrijden. Vincristine en vinblastine remden MRP2, maar hadden 
geen effect op MRP4. Dexamethason en mitoxantron stimuleerden beide effluxtransporters, 
terwijl azathioprine en cytarabine op geen invloed hadden. Geconcludeerd werd dat 
beïnvloeding van OAT1-, MRP2- en MRP4-gemedieerd transport kan bijdragen aan de 
ongewenste interacties met immunosuppressiva in de nier. Een dergelijke interactie kan ook 
in gunstige zin worden gebruikt om de therapeutische effectiviteit te verhogen bij patiënten 
die resistent zijn tegen chemotherapie met immunosuppressiva. 
Dat MRP2 mogelijk een rol speelt in de interactie tussen MPA en CsA blijkt uit eerder 
onderzoek in de lever van de rat en naar het verband tussen bepaalde polymorfismen in 
MRP2 en de farmacokinetiek van MPA. Transport van MPA en zijn inactieve metaboliet, 
7-hydroxyglucuronide (MPAG), door renale transporteiwitten is deels al beschreven voor 
de OATs in de basolaterale mebraan. In hoofdstuk 5 is de rol bestudeerd van de apicale 
effluxtransporters, MRP2 en MRP4, in de renal excretie van MPA met behulp van 
geïsoleerde geperfundeerde nieren van Mrp2-deficiënte TR
-
-
 
ratten en HEK293-cellen die 
MRP2 of MRP4 tot overexpressie brengen. In de rattennier werd MPA volledig 
geconjugeerd tot MPAG, dat significant minder werd uitgescheiden in TR
-
-ratten in 
vergelijking met normale ratten. We vonden ook dat MPA een substraat is van zowel 
MRP2 als MRP4, terwijl MPAG alleen door MRP2 werd getransporteerd. Vervolgens werd 
de interactie tussen MPA en de calcineurineremmers, CsA en tacrolimus, bestudeerd. CsA 
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verminderde de renale vorming en excretie van MPAG door resp. remming van 
uridinedifosfoglucuronosyltransferase (UGT) 1A9 en MRP2. Tacolimus had geen invloed 
op beide processen. Er kon worden geconcludeerd dat MRP2 de belangrijkste transporter is 
voor de renale uitscheiding van MPAG en dat CsA, maar niet tacrolimus, vorming en 
MRP2-gemedieerde excretie van MPAG remt. Dit is een nieuw mechanisme dat van belang 
kan zijn voor de klinische interactie tussen CsA en MPA. 
MRP4 is een ATP-afhankelijk transporteiwit dat betrokken is bij de renale uitscheiding 
van een groot aantal geneesmiddelen, waaronder immunosuppressiva. Uit hoofdstuk 3 kon 
geconcludeerd worden dat MRP4 over meerdere allostere bindingsplaatsen beschikt. Om te 
begrijpen hoe een transporteiwit verbindingen translokeert is moleculaire informatie nodig 
over de aminozuurresiduen die betrokken zijn bij de herkenning, associatie en dissociatie 
van het substraat. Door bepaalde aminozuren selectief te muteren kan hun bijdrage aan de 
substraatbinding en transportactiviteit worden onderzocht. In hoofdstuk 6 zijn 
verschillende mutanten van MRP4 gemaakt en is hun transportactiviteit getest. Om de 
substraatbindingsplaatsen van MRP4 te karakteriseren werden 6 aminozuren gemuteerd die 
in de centrale opening zijn glokaliseerd. Het betrof de aminozuren Phe368, Phe369, 
Glu374, Arg375, en Glu378 in transmembraanhelix 6, en Arg998 in helix 12, die werden 
gemuteerd in de corresponderende aminozuren van MRP1 en MRP2. Membraanblaasjes 
van HEK293-cellen waarin deze mutanten tot overexpressie waren gebracht vertoonden een 
significant lagere transportactiviteit van MTX en cyclisch-guanosinemonofosfaat (cGMP). 
De enige uitzondering was dat de substitutie van Arg375 met een serine geen effect had op 
cGMP-transport, terwijl de affiniteit voor MTX significant lager was. Bovendien bleek 
remming van MRP4-gemedieerd cGMP-transport door MTX noncompetitief te zijn, 
hetgeen ook een duidelijke aanwijzing is voor verschillende allostere bindingsplaatsen. 
Deze remming werd verder versterkt door introductie van de genoemde R375S-mutatie. 
Om deze mutaties te kunnen vertalen naar de volledige structuur van MRP4 werd een 
homologiemodel in de computer gebouwd, waaruit naar voren kwam dat Arg375 en 
Arg998 direct in de met water gevulde centrale opening van het transporteiwit. Uit de 
resultaten beschreven in dit hoofdstuk hebben we de conclusie getrokken dat de positief 
geladen aminozuren in transmembraanhelices 6 en 12 onderdeel uitmaken van de holte in 
MRP4 waarin substraten worden gebonden. 
Een van de complicaties van de behandeling met immunosuppressiva kan 
hyperuricemie zijn. Er zijn verschillende transporteiwitten in de nier betrokken bij de 
regulatie van de uraathomeostase, waaronder MRP4 en de uraattransporter 1 (URAT1). In 
hoofdstukken 7 en 8 is de interactie onderzocht tussen uraattransport door MRP4 en 
URAT1 met verschillende geneesmiddelen, waarvan bekend is dat ze de uraatconcentratie 
in sereum kunnen beïnvloeden. In hoofdstuk 7 is het effect van deze geneesmiddelen 
onderzocht op het transport van [
14
C]uraat in HEK293-cellen die MRP4 tot overexpressie 
brengen en membraanblaasjes geïsoleerd uit deze cellen. De xanthineoxidaseremmer 
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allopurinol stimuleerde de MRP4-gemedieerde efflux van uraat uit de cellen en zowel 
allopurinol, als zijn actieve metaboliet oxypurinol, stimuleerden uraattransport door MRP4 
in membraanblaasjes tot resp. 190  50% en 136  17%. Dit is een nieuw effect dat zou 
kunnen bijdragen aan de hypouricemische werking van deze middelen. De diuretica, 
bumetanide en torasemide, hadden geen effect, terwijl furosemide, chlorothiazide en 
hydrochloorthiazide het uraattransport remden bij concentraties die verwacht kunnen 
worden in proximale tubuluscellen na therapeutische doseringen. Dit zou een aanvullend 
mechanisme kunnen zijn in de hyperuricemische bijwerkingen van deze geneesmiddelen, 
die vaak wordt gezien in de klinische praktijk. The uricosurische middelen, salicylaat, 
benzbromaron en sulfinpyrazon bleken ook remmers te zijn, terwijl probenecide het 
uraattransport stimuleerde bij een concentratie van 0,1 μM en bij hogere concentraties 
remde. De conclusie van dit hoofdstuk was dat MRP4 een nieuw aangrijpingspunt kan zijn 
voor geneesmiddelen die de uraathomeostase in het lichaam beïnvloeden. Verder onderzoek 
is wel nodig om het klinische belang hiervan vast te stellen. 
In hoofdstuk 8 is aandacht besteed aan de interactie van geneesmiddelen met 
uraattransport door URAT1. De effecten werden onderzocht van hyper- en 
hypouricemische middelen op de URAT1-gemedieerde opname van [
14
C]urate in HEK293-
cellen. De Km van het [
14
C]uraattransport was 270 ± 40 µM. Hydrochloorthiazide cis-
stimuleerde URAT1-gemedieerd transport, terwijl chloorthiazide, benzbromaron, 
probenecide, sulfinpyrazon, salicylaat, oxypurinol en penicilline juist cis-inhibitie gaven. 
We hebben eveneens laten zien dat het mogelijk is om HEK293-cellen dubbel te 
transduceren en URAT1 en MRP4 gelijktijdig tot overexpressie te brengen. Om meer 
inzicht te krijgen in het mechanisme van carriergemedieerde uraatuitwisseling (antiport) 
hebben we membraanblaasjes van HEK293-cellen gebruikt, die URAT1 tot overexpressie 
brachten. We konden laten zien dat benzbromaron competitief cis-inhibitie gaf van 
uraattransport, terwijl chloorthiazide dit op noncompetitieve wijze deed. Daarnaast kon 
chloorthiazide het transport trans-stimuleren. Benzbromaron was daartoe niet in staat. 
Membraanblaasjes met URAT1-overexpressie transporteerden [
14
C]uraat bidirectioneel en 
de opname kon worden gestimuleerd door een uitwaartsgerichte chloridegradiënt, die 
verder met uraat trans-gestimuleerd kon worden. Uit dit hoofdstuk is geconcludeerd dat 
URAT1 een gradiëntgevoelige, bidirectionele antiporter is die een rol zou kunnen spelen bij 
de geneesmiddelgeïnduceerde hyperuricemische effecten in de nier. 
Tot slot zijn alle resultaten van het proefschrift in hoofdstuk 9 bediscussieerd, met 
bijzondere aandacht voor de rol van in vitro-experimenten bij de preklinische voorspelling 
van geneesmiddelinteracties met immunosuppressiva in de nier en de factoren die daarop 
van invloed zijn. In het hoofdstuk is ook een vergelijking gemaakt tussen de bijdrage van 
transporteiwitten in de nier en de lever aan de eliminatie van immunosuppressiva en het 
samenspel dat daarbij optreedt met metaboliserende enzymen. Daarnaast is de rol 
besproken die transporteiwitten in de nier spelen bij hyperuricemie veroorzaakt door 
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geneesmiddelen. Vervolgens is aandacht besteed aan de klinische relevantie van de kennis 
die is verkregen uit de modelleringsstudies aan de substraatbindingsplaatsen van MRP4. 
Als laatste zijn de toekomstperspectieven van het beschreven onderzoek besproken. Niet 
alle relevante niertransporteiwitten zijn in dit proefschrift bestudeerd. In de toekomst zal het 
belang van met name het „breast cancer resistance protein‟ (BCRP) en MRP5 onderzocht 
moeten worden. Hierbij zal ook de steeds verder toenemende kennis over de metabole en 
genetische factoren van renale immunosuppressiva-interacties betrokken moeten worden. 
Het hoofdstuk wordt afgesloten met een aanbeveling voor mogelijke verbeteringen die 
nodig zijn om in vitro-testsystemen te ontwikkelen die de invloed van transporteiwiten en 
metaboliserende enzymen op de effectiviteit en veiligheid van immunosuppressiva beter en 
betrouwbaarder kunnen voorspellen. 
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